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ABSTRACT 
Infection of herpes simplex virus type 1 (HSV-1) begins at the epidermis, a stratified layer 
composed primarily of keratinocytes.  The physiologically relevant cell type for the study of 
HSV-1 assembly is therefore the human keratinocyte.  Nonetheless, relatively little is known 
about the replication of HSV-1 in this natural host cell.   
Comparison of virus growth in monolayers of keratinocyte cells and Vero cells, a routinely 
used cell line for HSV-1 studies, revealed that these keratinocytes support a more productive 
virus replication than Vero cells.  Furthermore, newly assembled virus is produced more 
rapidly in keratinocytes and this enhancement occurs prior to, or upon the initiation of 
immediate early gene transcription.  This augmented replication in keratinocytes can be at 
least partially attributed to the method of entry of the virus.  We have found by penetration 
assays and electron microscopy that the virus is able to penetrate keratinocyte cells much 
more rapidly than Vero cells.  We have also shown that the virus entry mechanism is more 
efficient at lower temperatures in nTERT cells, with virus entering cells at temperatures as 
low as 7°C. Additionally preliminary work implies that depletion of one of the herpes virus 
entry receptors, Nectin-1, does not affect entry into nTERT cells, whereas entry is reduced 
up to 65% in HeLa cells.  Taken together, these results imply a role for other entry receptors, 
possibly as yet unidentified, in the entry of human keratinocyte cells. 
This work also identifies a role for cellular Rab proteins, GTPases essential for the regulation 
of vesicle trafficking, in HSV-1 infection of keratinocytes.  In particular Rab6, which was also 
found to play a role in infected HeLa cells (Elliott Group), appears to have a similar function 
in both these cells and together support a model for HSV-1 morphogenesis involving Rab-
regulated vesicle trafficking of viral glycoproteins to the cell surface.  Several other Rabs 
identified by this screen now provide interesting opportunities to elucidate further roles of 
Rab proteins in HSV-1 infection of keratinocyte cells. 
This project has broadly characterised the replication of HSV-1 in keratinocyte cells and 
explored the role of Rab GTPases in virus trafficking within keratinocytes - a cell type that is 
physiologically relevant to infection. 
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1.1 HERPES SIMPLEX VIRUSES  
The Herpesviridae family is a group of double-stranded DNA viruses, classified into three 
subfamilies; the Alphaherpesvirinae, the Betaherpesvirinae and the Gammaherpesvirinae.  
These viruses share four basic characteristics: a large number of viral genes are required for 
their own replication, viral DNA synthesis and capsid assembly occur in the nucleus, the 
infected cell is usually destroyed and the virus is able to maintain latency in the host cell.  
Alphaherpesviruses are neurotropic in behaviour, have a relatively short replication cycle, a 
variable host range, are fast-spreading in culture and establish latency in sensory ganglia.  
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are similar alphaherpesviruses 
which infect humans.  They share 82% amino acid homology, however HSV-1 is considered 
the prototypic example of the alphaherpesviruses and will be the focus of this thesis. 
1.1.1 EPIDEMIOLOGY AND DISEASE 
HSV-1 and HSV-2 can infect humans irrespective of ethnic group, age or geographical 
location.  Herpesviruses have been recognised as infectious agents since 1917 (reviewed in 
(197)) but the symptoms may even have been described by Hippocrates, suggesting these 
viruses have probably infected man for at least 2 millennia.  These viruses share similar 
epidemiology and clinical pathologies and it is estimated that 50% of adults in the UK are 
seropositive for HSV-1 (239), although rates have been reported to be as high as 84% in 
some countries (181).  HSV-1 and HSV-2 can infect a number of overlapping sites including 
the skin, oral and genital areas.  HSV-1 is most commonly associated with infections of the 
mouth and eye, however a rise in HSV-1 induced genital herpes has been documented more 
recently (132). 
The name Herpes is derived from the Greek word for “creeping” or “crawling”, due to the 
characteristics attributed to the movement of the symptoms across the skin.  Herpes labialis, 
better known as the common cold sore of the mouth or lips, is probably the best known form 
of disease caused by HSV-1.  These herpetic lesions are not exclusive to the mouth; before 
mandatory glove use by dentists, herpes whitlow (herpetic lesions on the fingers) used to be 
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more common.  Frequent reactivation of the lesions can lead to greatly reduced quality of life 
for the sufferer.  More serious infections are also seen in the eye where HSV-1 causes 
keratitis and is the second most common source of corneal blindness in the US (127).  
Severe complications of the infection can also give rise to encephalitis, especially in 
neonates (199, 233) and immunocompromised patients.  There has long been recognised a 
link between HIV and HSV infection, both at the cellular level (176, 202) and with regards to 
anti-viral treatments (167).  In fact, recent advances have led to findings that suggest that 
HSV-1/HSV-2 infected individuals may be more susceptible to HIV infection.  One possibility 
is that HSV-1/HSV-2 infection stimulates higher levels of circulating CD4+ T cells, the target 
cells for HIV infection (18).  Further research has also highlighted that the epithelial damage 
and inflammation caused by HSV infection produces a susceptible environment for HIV 
infection and therefore that pre-existing infection with HSV at mucosal surfaces is a major 
risk factor for HIV transmission (108). 
1.1.2 TREATMENTS AND VACCINES 
Although antiviral agents such as acyclovir (ACV) can be effective at treating HSV-1 
infections, they cannot remove the underlying latent infection, which will persist with the 
individual for life, reviewed in (68).  ACV, a nucleoside analogue of guanosine, must first be 
phosphorylated by the viral thymidine kinase, which allows for the specificity of action in 
infected cells only.  It is then phosphorylated by cellular factors, leading to the competitive 
inhibition of the viral DNA polymerase and ultimately viral DNA chain termination (68).   
Widespread use of this anti-viral since 1982 has led to reports of anti-viral resistance from as 
early as the same year and although the incidents in immunocompetent patients is only up to 
0.6%, this is increased ten-fold in immunocompromised patients and therefore presents a 
major problem for treatment of these patients, supporting the development of new anti-virals 
(39, 53, 125, 211, 231). 
To date, no vaccine for HSV-1 is available, however work is being undertaken to find novel 
methods to develop new vaccines for both HSV-1 and the closely related HSV-2 (116, 121), 
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as these infections share such similar epidemiology and disease.  It is thought that any 
vaccine development strategies would be relevant to both viruses, and it has been shown 
that cross-reactive protection from such a vaccine is possible in a mouse model (47).  
Herpes viruses are notoriously difficult to develop vaccines for due to their large genome and 
the long periods of latency in the host.  Currently there is only one successful vaccine in use; 
a live attenuated vaccine for varicella zoster virus (reviewed in (76)).  Despite early 
successes, one of the most recent HSV-2 vaccine trials, using glycoprotein D-2 as the 
antigen, failed to protect from HSV-2 infection but did provide a level of protection from HSV-
1 infection and disease in women (23).  The authors of this study speculated that the choice 
of populations played an important role in this failure of protection from HSV-2.  The 
protection conferred by this vaccine to HSV-1, however, is not as surprising, especially given 
the similarity in the antigen gD-2 (89%), the lower overall inoculum of HSV-1 in general and 
the genital tract being a less suitable environment for HSV-1 than HSV-2 infection (23). 
1.2 INFECTIOUS CYCLE 
HSV-1 is spread in salivary and other mucosal secretions, initially and commonly entering 
epithelial cells of the oral mucosa.  HSV-1 and the closely related alphaherpesvirus, HSV-2, 
are also able to infect the skin, genital mucosa and corneal mucosa.  However, as HSV-2 
causes the majority of genital-related infections, whilst HSV-1 is primarily responsible for oral 
and ocular infections, this description of the infectious cycle will focus on infection of the oral 
mucosa and skin (2).  
Once access to the epithelium is gained, infection leads to colonisation of the sensory nerve 
endings.  Subsequent retrograde transport of the virus delivers it to dorsal root ganglia where 
it maintains itself in a latent state in cell bodies of the trigeminal ganglia (127).  The 
elongated nature of neurones allows for efficient spread of the virus while their long-lived, 
post-mitotic status provides a long-term host for latency, at the same time allowing a certain 
degree of masking from the immune system due to their lack of Major Histocompatibility 
Complex class II (MHC-II) and low levels of MHC-I (reviewed in (86)).  Latent virus can be 
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reactivated and transported via anterograde transport to the axonal termini, where virus is 
released once more within the epithelial cells of the mucosal tissue, causing a secondary 
lytic infection at the primary site of infection.  This sporadic reactivation can occur 
intermittently at any time during the life of the host when induced by stimuli, such as stress 
and UV light exposure, and can result in recurrent mucocutaneous lesions as well as 
asymptomatic infection (197, 240).  Transmission of progeny virus is then able to spread via 
secretions, to a new host (2, 127). 
1.2.1 THE EPIDERMIS AS THE SITE OF INFECTION 
HSV-1 gains access to its host at the oral mucosa, skin or occasionally the cornea, via direct 
transmission from a seropositive individual secreting virus.  Although HSV-1 also infects 
neuronal cells, where it can become latent, for the study of the lytic phase of infection the 
skin is the target.  One of the skin’s main functions is to act as a barrier to the outside world, 
protecting the body from exposure to harmful agents such as toxins, microorganisms, 
mechanical trauma and carcinogens and also to prevent fluid loss.  It is highly adapted to this 
purpose and as such the exact composition of each type varies depending on its location and 
specific role in the body.  For example, the gastrointestinal lining is a simple, polarised, 
unstratified epithelium (one cell layer thick) to allow for adsorption, whereas the oral mucosa 
and skin are both highly stratified, composed of many layers of cells and more similar to each 
other than other body mucosa.  To understand how HSV-1 is able to infect an organ that has 
evolved to form a protective barrier, it is important to understand its structure in more detail. 
1.2.2 KERATINOCYTE CELLS 
The skin, or epithelium, consists of two layers; the dermis (primarily fibrous connective tissue 
to provide mechanical support) and the epidermis, in itself a collection of layers of cells with 
different properties.  Fibroblasts, melanocytes, Langerhans (dendritic) cells, Merkel cells 
(sensory cells), inflammatory cells and keratinocytes are all found in the epidermis, however 
in mice, 95% of the population are made up of keratinocytes (196).  The stratum basale 
(figure 1.1) rests upon the apical side of the dermis and supports a single layer of basal cells.  
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Figure 1.1: Diagram of the structure of the epidermis adapted from (163). 
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Figure 1.1
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A small proportion of these basal cells are slow dividing stem cells that produce a population 
of transit amplifying cells, which themselves divide a few times, more rapidly, before 
beginning their switch to differentiation (reviewed in (129)).  The basal keratinocytes are 
cuboidal in morphology and polarised, however after the terminal differentiation programme 
is initiated in the progenitor cells, they begin to migrate upwards and are no longer polarised 
in the same way.  At this stage a series of morphological and biochemical changes begin to 
occur (reviewed in (82, 128).  The keratinocytes of the stratum spinosum (figure 1.1) are 
larger than other cells in the epidermis as they are still metabolically active (250), and 
produce abundant keratins, which form bundles within the cell (34).  Upon reaching the 
granular layer keratinocytes begin to lose their organelles, DNA replication is shut off (80, 
134) and they produce profilaggrin granules, which contribute to bundling keratin further.  
Cornified envelope proteins, such as involucrin, are made and traffic to the underside of the 
plasma membrane, which forms a second barrier to contain the keratin bundles.  Lipid-
enriched lamellar granules begin to form, which are ultimately pushed out of the cells to form 
an external lipid-rich matrix.  This results in the population of cells known as squamous 
corneocytes, which make up the stratum corneum or the cornified (meaning keratinosised) 
layer.  These cells are more like flattened sacks, and have large aggregates of bundled 
keratin, no internal organelles (including nuclei) and a lamellar lipid layer to provide a 
hydrophobic barrier.  The stratum corneum is constantly being replenished by newly 
differentiating keratinocytes as the apical corneocytes are sloughed off from the surface of 
the epidermis. 
1.2.3 KERATINS 
There are approximately thirty different keratins that vary in size; the smallest generally found 
in the simple epithelium, and the largest in stratified epithelium, their distribution is also 
determined by the differentiation state of the keratinocyte.  Keratin 5 and 14 are found solely 
in basal cells, whilst expression of keratin 1 and 10 is switched on in differentiating cells (81).  
Other keratins, such as keratin 6, 16 and 17 are not normally expressed, but are associated 
with wound healing.  The morphology of the cells, the keratin type and localisation, and also 
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the expression of other differentiation specific proteins such as involucrin, help to distinguish 
layers of the epidermis. 
1.3 SKIN MODELS 
Cell lines such as Vero (African green monkey kidney epithelial), BHK (baby hamster kidney) 
and HeLa (human cervical cancer) are routinely used in the study of HSV-1 as they are often 
more easily manipulated, highly permissive to infection and more robust than primary cell 
lines, however are not necessarily as physiologically relevant as keratinocytes for the study 
of a human epitheliatropic virus.  MDCK cells (Madine Derby canine cells) have also been 
used and are the most extensively studied polarised epithelial cell line.  Studies using these 
cells have found that HSV-1 requires access to the basolateral membrane and intact 
microtubule networks to initiate a productive infection (145, 203). MDCKs have also been 
used in the study of the role of the gE/gI complex in cell-to-cell spread (119) reportedly 
because they are polarised and therefore relevant to the study of HSV-1 infection.  
Nevertheless, only the single layer of basal cells are polarised, the rest of the epithelium is 
not polarised in this way.  This means that although MDCK cells are a good model for the 
study of a single cell layer of the epithelium, they are not a good model for the skin as a 
whole complex organ. 
The stratified epithelium is therefore a complex target for infection and tissue culture 
monolayers do not accurately represent this.  Efforts to develop a more representative model 
for infection studies have produced a three-dimensional epithelial culture model, known also 
as an organotypic skin raft.  This is a cell culture model that replicates the characteristics of 
the epithelium in vivo as faithfully as possible.  The model involves growing a feeder 
fibroblast layer in a three-dimensional collagen matrix within a dish, then seeding 
keratinocytes on top.  This is submerged under media until the keratinocytes are confluent 
and then the whole structure is lifted onto a metal grid and allowed to sit at the air-liquid 
interface, during which time the keratinocytes stratify and differentiate (14, 128).  The 
resulting epidermis is of a similar thickness to skin in vivo and expresses the differentiation 
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specific keratins 1 and 10 (128, 150). Whilst the level of expression of these keratins is not 
identical to that in the skin and keratins associated with wound repair, not normally seen in 
healthy skin, are also detectable in the rafts and in cultured cells, it is generally accepted that 
they are still a relevant model to use based on their extensive similarities to the skin (177).  
As testament to their suitability as a skin model, they have been used for pharmacological, 
dermatological, toxicological and wound studies, as well as the study of virus infection.  The 
first virus to be applied to this model was the epitheliatropic human papilloma virus, studies 
of which found infection was stratum-limited and appeared to require basal layers for 
infection, after initiation of which the cells were no longer able to differentiate (150, 156).   
1.3.1 HSV-1 SKIN MODELS 
Studies on HSV-1 have shown skin rafts to develop similar cytopathic effects, when infected 
with the virus, as in vivo skin.  For example, when infected with HSV-1, both skin rafts and 
squamous epithelium in vivo demonstrate ballooning of the cells, reticular degeneration, 
intracellular nuclear eosinophilic inclusion body formation and large multinucleate cell 
formation (8, 229).  These same studies have also resulted in conflicting results on the 
nature of the infection in the rafts, and the site of initial infection.  The first study of HSV-1 
infection in a three-dimensional organotypic tissue culture system was by Syrjänen et al.  
HaCaT cells (immortalised human keratinocyte cells) were seeded on a fibroblast-collagen 
gel and infected either before or after lifting to the air-liquid interface (229). Active HSV-1 
infection spanned throughout the whole epithelium and was confirmed by DNA and RNA in 
situ hybridization in the rafts infected before lifting, but not after.  In the rafts infected after 
lifting to the air-liquid interface, no morphological changes were found and no infectious virus 
was recovered, however latency associated transcripts (LAT) expression was detected in 
both cell cultures.  The authors concluded that restricted HSV-1 gene expression took place 
in the cultures which did not produce subsequent infectious virus and that these represented 
a non-productive infection when HSV-1 was introduced after lifting to the air-liquid interface. 
These results indicated that both non-productive and lytic infections could be induced upon 
initial HSV-1 infection, and that the outcome was dependant on the time of inoculation, and 
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by extension, the differentiation state of the cells. A further investigation by the Syrjänen 
group went on to show that a full thickness infection of the epithelium could be seen at higher 
input levels of virus after lifting but only when infection was initiated after a more extended 
period of time. The authors explained that the full-thickness infection after lifting to the air-
liquid interface was likely the result of keratinocytes coming into contact with the infected 
media due to the overgrowth of these cells at the margins of the rafts. The non-productive 
infection was seen again when rafts were infected early after lifting from the air-liquid 
interface (111).  Full-thickness infection of differentiated skin rafts after lifting to the air-liquid 
interface has been noted by another group, however they identified productive HSV-1 
infection when inoculation was initiated directly after lifting from the air-liquid interface, as 
well as when left very late.  Additionally, after cells were infected they showed no further 
differentiation (8).  In a separate study, it was also concluded that a productive HSV-1 
infection could be initiated in a full thickness epithelium, by inoculation of the top cornified 
layer of a raft lifted to the air-liquid interface (238).  However, in contrast to the previously 
discussed studies, by immunostaining thin sections of these infected rafts HSV-1 infection 
appeared to be limited to the basal and parabasal layers, implying that virus was able to pass 
through the cornified layer to the basal layers without infecting the superficial layers (235).  
These variations could stem from multiple experimental differences, for example Syrjanen et 
al. and Hukkanen et al. both used keratinocyte cell lines to form their epidermis, which do not 
form the upper-most cornified layer, while the other two used primary keratinocytes, which do 
form a full-thickness epidermal layer (8, 111, 229, 238).  Different feeder fibroblast cell types 
were also used, while differing multiplicities of infection and infection at different stages in the 
raft formation could all contribute to the disparities of these results.  To date, these studies 
have shown that HSV-1 has the ability to infect all layers and differentiation states of 
keratinoyctes in raft models, depending on the infection conditions. However which of these 
systems most closely resembles in vivo infection is still unknown. The questions of which cell 
layers are the first to be infected, and where the virus spreads after initial infection, are 
therefore an area with further potential for study. 
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1.3.2 KERATINOCYTE CELL LINES 
Keratinocytes are therefore a biologically relevant system for the modelling of the lytic stage 
of infection of HSV-1.  There are a number of different epithelial cell types available, for 
example HFFF2 cells, however these are not keratinocytes but primary fibroblasts, which 
make up a much smaller contribution of the epithelium and we therefore consider them not 
as relevant for infection.  Primary keratinocytes can be sourced, however they are less 
frequently available and difficult to culture for any large-scale experiments or screens.  If they 
have not become malignant or lost their differentiation potential, keratinocyte cell lines could 
therefore represent a more tractable system for the study of HSV-1.  HaCaT cells (30), which 
are available for culture, are human keratinocytes which have been immortalised by 
continuous culture at high temperatures and low calcium.  They were found to maintain a 
skin-like differentiation pattern, however were slightly slower to form a stratified epithelium 
(30).  This cell type has been used for multiple HSV-1 studies (154, 184) and so represents a 
useful tool.  However, we chose to work primarily in nTERT cells as they are very similar to 
primary cells in their behaviour.  nTERT cells are primary keratinocytes which have been 
retrovirally induced to express hTERT (the catalytic subunit of the telomerase holoenzyme) 
and subsequently have spontaneously lost the function of p16INK4a (a tumour suppressor 
gene which usually inhibits the transition from G1 to S phase).  This allows the maintenance 
of growth for much longer than normal primary cell types (61).  They are more readily 
cultured than primary cells and are permissive to transfection (146).  Crucially, they have 
been shown to retain most of the ‘normal’ characteristics of primary cells, including a 
dependence on epidermal growth factor, their ability to differentiate and the fact that they 
remain non-invasive upon transplantation (61).  For cell culture they require the same media 
as primary cells, which includes insulin and cholera toxin - an additional confirmation that 
they are still similar in behaviour. 
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1.4 THE HERPESVIRUS PARTICLE  
The large HSV-1 genome encodes approximately 80 open reading frames across one unique 
long (UL) and one unique short (US) component.  Initially, the gene products of HSV-1 were 
designated as virion polypeptides (VP) according to their relative size on a polyalcrylamide 
gel (e.g. VP22, VP26), however some are named after their position on the open reading 
frame (UL36), or as arbitrarily numbered infectious cell proteins (e.g. ICP0, ICP27), while viral 
glycoproteins are usually referred to by letters (e.g. gD, gE).  The infectious HSV-1 virion is 
approximately 120-200 nm in diameter and is composed of an outer lipid envelope derived 
from the host membrane, studded with a mixed population of viral glycoproteins and some 
cellular proteins (figure 1.2).  A complex proteinaceous tegument layer lies beneath the 
envelope, and is thought to connect it to the icosahedral capsid, inside which the linear 
double-stranded 152 kb DNA genome is contained (127). 
1.4.1 THE TEGUMENT 
The tegument is the largest virion compartment, with 23 viral constituents identified to date 
(141, 219), and contains proteins such as VP1/2, VP16, VP22 and VP13/14.  Although often 
described as amorphous the tegument is formed of an inner and outer layer of proteins, 
dependent on the strength of interaction with the capsid (247).  Many tegument-glycoprotein 
and tegument-tegument interactions have been identified by our group and others (46, 70, 
74, 144, 225), which suggest that these interactions facilitate tegument assembly and 
association of the viral capsid to the envelope. 
1.4.2 GLYCOPROTEIN FUNCTIONS 
There are eleven known HSV-1 glycoproteins, with some being conserved members among 
the herpes viruses, for example gB.  Glycoproteins are involved in forming the association of 
the viral capsid with the cellular membrane for secondary envelopment, most likely through 
their interactions with the outer tegument proteins, for example gD and VP22 (46).  However, 
many of these transmembrane proteins play other roles in infection, for example gM and the 
gE-gI complex are required for efficient cell-cell spread in vivo (62) while the gE-gI complex 
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is involved in immune evasion by blocking of immunoglobulin G (63, 79, 118).  Work from our 
lab also indicates a role for gE and gM in recruiting ICP0 into the virion (144).  The viral 
glycoproteins gB, gC, gD and the complex gH-gL are involved in virus entry (section 1.5.1).  
Viruses lacking gK or UL20 are impaired in virion envelopment and therefore defective in 
egress and spread (78, 113, 114) and are also thought to play a role in virus-induced cell 
fusion (29, 56, 139, 186).   
1.5 LIFE CYCLE 
1.5.1 ATTACHMENT AND ENTRY 
The mature virus attaches initially and reversibly to heparan sulphate proteoglycans or 
glycosaminoglycans (GAG) on the plasma membrane of the target cell, the evidence for this 
being an inhibition of virus uptake upon addition of heparin in Hep-2 cells (248).  The 
interaction with GAG is mediated by the viral glycoprotein gC, however in the absence of gC, 
gD or gB seem to be sufficient for entry (102, 208).  Binding of gD to its receptor is thought to 
lead to a conformational change allowing contact of gB to gH/gL and entry to the cell (50, 99, 
101).  Experiments utilising a cDNA library derived from HeLa cells to screen for entry of 
HSV-1 into non-permissive CHO cells, identified herpes virus entry mediator (HVEM) or 
HveA as an entry receptor, or co-receptor, for gD (164).  However, there are still a number of 
human cells which HSV-1 is able to enter despite the use of anti-HVEM antibodies to block 
entry (164), indicating that this molecule is not absolutely necessary for entry.  An alternative 
receptor, nectin-1 or HveB, has been identified as an entry receptor through a similar screen, 
using a mutant virus expressing an altered form of gD which cannot bind to HVEM (242).  
Nectin-1 levels were found to be ten times higher in a keratinocyte cell line, than in HeLa 
cells, however blocking of nectin-1 with anti-nectin antibodies did not reduce entry of HSV-1 
efficiently (110).  Further to this, the distribution of nectin-1 in keratinocytes did not correlate 
with sites of cell wounding, which were shown to be preferred HSV-1 entry sites (203).  This 
suggests that other entry receptors may still be involved in keratinocyte cell entry, and indeed 
yet another entry receptor has been identified for gD: 3-O-sulfated heparan sulphate (3-OS 
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HS) (210).  It also seems that entry receptors are not restricted to an interaction with gD.  
Paired immunoglobulin-like receptor alpha (PILRα) has also been proposed as an entry 
receptor through an interaction with gB (201), as has non-muscle myosin heavy chain IIA 
(12).   
The question arises as to why HSV-1 appears to be able to utilise so many different entry 
receptors.  One possibility is that it enables a wide cell tropism for the virus, with different 
receptors used for entering different cells, for example neuronal cells express nectin-1 but 
not HVEM (164) and PILRα is expressed largely in cells of the immune system (201).  
Another possibility is that the choice of receptor used depends upon the state of the cell.  
Nectin-1 is expressed on epithelial cells at cell junctions and so may be inaccessible to the 
virus unless cell-cell contacts are disrupted (252).  The virus may require multiple 
interactions with receptors to modulate the immune response, or alternatively, may require 
specific receptors for primary entry as opposed to cell-to-cell spread.   
The well-characterised cellular route of endocytosis was first thought to be the mode of 
HSV1 entry as virus particles were often identified in envelopes or vesicles in the cell 
cytoplasm (112).  However, since then it has become clear that the virus is able to utilise 
both endocytosis, (through neutral or acidic compartments) and plasma membrane fusion 
(PM fusion) pathways of entry, and that some cells can facilitate entry via either of these 
pathways (reviewed in(86)).  Early studies employing a variety of agents to inhibit 
endocytosis or alter the pH of endosomes, demonstrated that low pH-dependent endocytosis 
was not the method of entry of HSV-1 in Vero or HEp-2 cells (245).  Electron microscopy 
studies and reporter system experiments support endocytosis in HeLa and CHO cells 
expressing an HSV-1 receptor, as enveloped virus particles were observed in plasma 
membrane invaginations 20 minutes after infection, and no naked capsids were identified 
close to the plasma membrane (170).  The same study found that entry into Vero cells was 
not affected by blocking ATP synthesis or receptor-mediated endocytosis, thereby lending 
support to the role of PM fusion in the entry of Veros.   
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Figure 1.2: HSV-1 Particle, adapted from (77). 
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Figure 1.2
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Crucially, a study in primary cells found that virions entering primary human keratinocytes co-
localised with markers of endocytic uptake, whereas in human neurones the virions did not 
(169).  This may suggest that at the initial site of infection, HSV-1 might enter cells via an 
endocytic pathway, but later in infection may employ a fusion-like mechanism.  However, 
more recent work on primary keratinocytes has studied virus entry in greater detail using 
dynasore (an inhibitor of endocytosis) and a cholesterol-sequestering drug in combination 
with electron microscopy techniques to show that the virus seems able to use alternative 
entry pathways; both endocytosis and PM fusion, in keratinocytes (191). 
There have been multiple studies in support of both methods of entry.  However, it has not 
been fully determined whether the entry method is cell-type dependent, or what causes a 
switch from one pathway to another.  In non-permissive CHO cells transfected with HVEM or 
nectin-1, HSV-1 enters through acidic endosomes, whereas in a different non-permissive cell 
line (J cells) transfected with the same receptors, entry is via a neutral compartment (87, 
170).  This suggests that cell-specific factors have a role in the entry pathway or route.  The 
cell surface glycoprotein αβvβ3-integrin has been identified as such a factor, as it can be 
transfected into the β3-integrin negative CHO-nectin-1 cells or J-nectin-1 cells, and facilitates 
a different mechanism of entry via a cholesterol-rich-raft and dynamin-2-dependent acidic 
pathway (88). 
1.5.2 TRANSLOCATION TO THE NUCLEUS 
After fusion-entry the virus must make its way to the nucleus and, as diffusion is not a 
possible candidate for translocation to the nucleus due to the viscosity of the cytoplasm 
(protein density can reach 300 mg/ml; equivalent to wet sand), it is thought that the virus 
utilises host processes for this translocation (217).  At this stage a proportion of the tegument 
layer is proposed to be phosphorylated and lost from the capsid (165), while the remaining 
inner tegument members are thought to recruit the microtubule motor dynein and its cofactor 
dynactin (190, 247).  In addition, microtubule depolymerising agents and dynamitin (which 
inhibits dynein-mediated transport processes) are able to prevent virus association with the 
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nucleus, therefore actin and microtubule networks are believed to be involved in the transport 
of the capsid to the nucleus (142).  In vitro studies have demonstrated that viral DNA is 
released upon capsid binding to the nuclear pore in the presence of an energy source and 
cytosol or Importin β (173). 
1.5.3 GENE EXPRESSION, GENOME REPLICATION AND CAPSID ASSEMBLY 
Transcription, virus replication and capsid assembly take place in the nucleus following a 
temporally regulated, three-stage cascade of gene initiation.  After successful virus entry into 
the cell, the viral transactivator VP16 is recruited to the nucleus with the cellular cofactors 
HCF and Oct-1, which act as a complex to activate the immediate early gene promoters (41, 
188, 244).  Expression of the immediate early genes ICP0, ICP4, ICP22, ICP27 and US1.5 
then initiate the early subset of genes, which are required for replication of viral DNA and 
nucleotide metabolism (127).  Concatameric molecules of viral DNA are produced via a 
rolling circle mechanism and accumulate in domains which eventually enlarge and cause the 
host cell DNA to be condensed and marginalised at the edges of the nucleus (reviewed in 
(28)).  Subsequently, this leads to the activation of late structural genes, which are classified 
as either ‘leaky’ late or ‘true’ late, with the latter requiring viral DNA synthesis to occur (127).  
The autocatalytic formation of capsids in the nucleus is then followed by encapsidation of the 
viral genome with the aid of scaffolding proteins.  These DNA-containing capsids are thought 
to acquire their primary envelope through budding at the inner nuclear membrane with the 
action of membrane proteins UL31 and UL34 (figure 1.3, reviewed in (155)). 
1.5.4 ENVELOPMENT AND EGRESS 
As the viral capsid is assembled in the nucleus, there are a number of potential routes by 
which the mature virion could form and exit the cell.  It was proposed initially that virus 
capsids acquired their final envelope by budding into the inner nuclear membrane (INM) with 
subsequent maturation steps occurring entirely within the lumen of the secretory pathway 
(54, 206).  HSV-1 capsids have also been seen to exit the nucleus via enlarged nuclear pore 
complexes (136), however this has been challenged by Hofemeister and O’Hare, 2008 and is 
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not widely accepted (106).  In more recent years a model for assembly, known as the 
envelopment-deenvelopment-reenvelopment model, has gained support from a wide range 
of biochemical, genetic and ultrastructural studies (figure 1.3).  Here, the initial envelope 
obtained from the INM would be lost by fusion with the outer nuclear membrane, with final 
envelopment occurring at a stage further downstream in the secretory pathway (35, 92, 220).  
It should be noted that this model is not yet universally accepted and the precise location of 
the HSV-1 envelopment site(s) within the cellular secretory pathway remains controversial.  
Some studies implicate multivesicular bodies as the site of final envelopment (40, 52, 178) 
however the trans-Golgi network (TGN) is often cited as the ultimate site of wrapping (120).  
This is based on evidence showing capsids in close proximity to a marker for the TGN by 
light microscopy (193, 226).  Our recent publication, involving ultrastructural and cellular 
factor depletion, has provided evidence for the final wrapping of capsids to occur at tubular 
vesicles, from membrane derived from the recycling endosomal network, and not at the TGN 
or multivesicular bodies (107).  This was shown by using interfering RNA to target the cellular 
protein, Rab5, which regulates endocytosis, and dynasore which inhibits dynamin activity 
(107).  Crucially, when infected cells were incubated with horseradish peroxidase (HRP), a 
fluid phase marker, vesicles labelled with HRP were seen to wrap capsids as early as 2 
minutes post-treatment, providing proof that the sites of secondary envelopment are vesicles 
that have recently originated from the plasma membrane (107).  Knowledge of the 
maturation and egress of the virus, although still contentious, has therefore been greatly 
enhanced through this study.  
 1.5.6 LATENCY 
Latently infected individuals will suffer no disease, do not produce infectious virus and are 
therefore unable to transmit HSV-1 during this time.  Latency and periodic reactivation, 
where the virus becomes lytic once more, is therefore a strategy of the virus to remain with 
the host for life.  The virus follows a program of lytic infection at the primary site of infection 
(usually the skin) and later establishes latency in neurones, where it can become reactivated 
and travel back to the original site of infection and follow a lytic cycle once more.  Appropriate 
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models of the lytic and latent stages of infection therefore differ, the former being sensory 
ganglia and the latter being epithelial cells.   
Latent infection is the result of a failure to initiate immediate early gene expression.  For 
example, if the transactivator VP16 is defective, unable to complex with its cofactors Oct-1 
and HCF, or if it does not reach the nucleus in sufficient quantities (127) then a latent 
infection can be established.  During this time the HSV-1 genome is circularised and remains 
un-integrated in sensory neurones and lytic gene expression is repressed.  It is thought that 
the LATs, which are transcribed but not translated during latency, may contribute to the 
maintenance of latency through interference with ICP0 synthesis; LAT mRNA is the anti-
sense of ICP0 (reviewed in (66)). 
1.6 THE ROLE OF RAB GTPases IN CELLULAR TRAFFICKING 
In an attempt to identify steps in vesicle movement that are important for HSV-1 maturation, 
our lab has been investigating the role of Rab proteins (Rabs) in virus replication.  Rabs are 
a family of small, monomeric Ras-like GTPases found in all eukaryotes, either ubiquitously or 
expressed in a tissue specific manner.  They are essential for the regulation of vesicle 
trafficking through their action as ‘molecular switches’ cycling between the GTP- and GDP-
bound states and are often used as markers for membrane identity.  They are involved in 
coat assembly, vesicle formation, motility, docking, and fusion (figure 1.4), reviewed in (96, 
122, 222).  Rab Escort Proteins (REPs) chaperone nascent Rabs through their initial post 
translational modifications and deliver them to their target membrane, whilst keeping their 
hydrophobic regions soluble (4, 7).  GTP is at a higher abundance in the cytosol than GDP 
and with the aid of a GTP Exchange Factor (GEF), takes the place of the GDP bound to the 
Rab, resulting in an active GTP-bound form of the Rab (223).  The switch back to the GDP-
bound form is catalysed by a GTPase activating protein (GAP), which causes the hydrolysis 
of the GTP and the subsequent release of the Rab from the membrane (235).  GDP 
dissociation inhibitor proteins (GDIs) bind to the Rab in its GDP- bound form in order to 
facilitate the trafficking of the Rab to the next target membrane, where a GDI displacement
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Figure 1.3: Illustration of the most recent envelopment-deenvelopment-reenvelopment 
model, adapted from (120).  Nucleocapsids acquire their primary envelope and gain access 
to the perinuclear space through budding at the inner nuclear membrane.  This initial 
envelope is lost upon fusion with the outer nuclear membrane, resulting in free capsids in the 
cytosol.  Tubular vesicles containing viral glycoproteins, most likely of recycling endocytic-
origin, wrap capsids to produce double membrane-bound mature virions (107).  Fusion of the 
double-bound virions with the plasma membrane releases infectious virus particles from the 
cell. 
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Figure 1.3
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factor (GDF) releases the Rab from the GDI (148, 213, 234). 
The role of Rab proteins in membrane trafficking means that they are continuously moving 
on membranes within the cell and the composition of Rab proteins found on any particular 
organelle is dynamic.  Their ability to change between GTP- and GDP-bound states, and 
their localisation to a particular membrane and within that membrane (for example within 
microdomains), allows the spatiotemporal control of trafficking fundamental to these 
GTPases (218). 
1.6.1 RAB EFFECTOR PROTEINS 
Rab proteins work with other cellular proteins such as numerous Rab effector proteins, 
SNAREs, the GAPs, GEFs, GDFs and GDIs and coat proteins, to regulate membrane 
trafficking.  Almost all Rab effectors interact with Rabs in the GTP-bound state (reviewed in 
(96).  These effectors can mediate different pathways and often one Rab will interact with 
many effector proteins; Rab5 was found to interact (directly or indirectly) with more than 
twenty proteins including Rabadaptin-5 and Rabex-5 (reviewed in (255)).  Effector proteins 
can play a role in organelle movement, for example Rabkinesin-6 is a microtubule motor 
protein which interacts with Rab6 and functions to transport vesicles from the Golgi to the 
ER, while the effector protein melanophilin acts as an intermediary between Rab27A and the 
actin motor protein myosin-Va, facilitating targeting to the cell periphery (64, 83).  They can 
also be involved in vesicle fusion via SNAREs, such as Rab5’s indirect interaction with the 
SNARE vacuolar protein sortin-associated protein 45 via the Rab5 effectors early endosome 
antigen 1 (EEA1) and rabenisyn 5 (reviewed in (224)). 
The Rab family numbers eleven in yeast but is in excess of sixty proteins in humans and this 
is thought to reflect the increased need for complex control of intracellular transport in higher 
eukaryotes (27, 205).  Rab proteins often share up to 95% sequence similarity, with the 
guanine-nucleotide binding site being the most conserved region and a highly variable region 
at the carboxyl termini thought to account for the Rabs specificity (43).  Rabs can interact 
with multiple different effector proteins, and different effector proteins can interact with 
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multiple different Rab proteins.  Multiple Rabs can control one pathway, or a single Rab can 
be involved in different pathways and this, coupled with their high sequence similarity, means 
that they display redundancy in their functions. 
1.6.2 RABS AND VIRUS INFECTION 
Rabs have been implicated in the infectious processes of many viruses including HIV and 
foot-and-mouth disease virus (FMDV) entry (Rab6 (33); Rab5 (117)), Influenza A budding 
(Rab11 (36)), human cytomegalovirus (HCMV) intracellular localisation (Rab6 (115)) and 
hepatitis C virus replication (Rab1, (215)).  Rab proteins have even been identified 
incorporated within mature HSV-1 virions (Rab2A and 2B, Rab4B, 5, 6, 7A, 10, 11, 15, 33B 
and 35 ((141) and unpublished data from the Elliott group).  Rab1 and Rab43 have both 
been shown to be important for HSV-1 secondary envelopment through infection studies of 
cells depleted for the relevant GAPs and also by depletion (107, 254).  Rab1 is involved in 
regulating endoplasmic reticulum (ER) to Golgi trafficking, which is required for the 
movement of viral glycoproteins from their site of production to the plasma membrane, and 
so it is not surprising that, when its activity is repressed, Rab1 would have an effect on HSV-
1 infection.  The mechanism for the role of Rab43 in HSV-1 infection is yet to be elucidated, 
but Rab43 is thought to have a role in regulating the interaction of pre-Golgi intermediates 
with microtubules (57).  We have also recently published on a role of Rab5 and Rab11 in 
HSV-1 infection of HeLa cells (107).  Rab5 regulates the fusion between endocytic vesicles 
and early endosomes (37, 137, 172), whilst Rab11 works downstream and regulates 
recycling endosomes (162, 189).  Our work suggests that when these Rab proteins are 
depleted in infected cells, the transport of viral glycoproteins from the plasma membrane to 
endocytic vesicles required for capsid envelopment is impaired, resulting in capsids being 
mis-localised and unable to wrap (107). 
Rab proteins therefore represent suitable targets for investigation with regards to their role in 
virion trafficking and infection.  More recently, work in the Elliott group has led to the 
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Figure 1.4: Diagram illustrating the complexity and localisation of known Rab GTPases in an 
epithelial cell (from (224)).  Rab1 regulates anterograde ER to Golgi trafficking and is 
localised to ER exit sites and pre-Golgi intermediate compartments.  Rab5 controls 
endocytosis and clathrin-dependent early endosome fusion, and with Rab34 
macropinocytosis.  Rab5 and Rab22 both associate with early endosomes and are thought to 
participate in similar pathways.  The Golgi-localised Rab6 GTPase mediates intra-Golgi 
trafficking, while Rab10 participates in GLUT4 vesicle translocation (with Rab8 and Rab14) 
and is found in the TGN, sorting endosomes and early endosomes.  Rab11 regulates the 
trafficking of slow recycling endosomes in cooperation with Rab35. 
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identification of further Rab GTPases, including Rab6, important in HSV-1 infection by the 
use of RNA interference (RNAi) (unpublished data, Elliott Group, Imperial College, London).  
RNAi describes the process in which double-stranded RNA (dsRNA) is able to silence gene 
expression selectively by inducing the degradation of complementary mRNA or by inhibiting 
translation (19, 20, 48, 75, 97).  RNAi was demonstrated in mammalian cells in 2001 and 
since then has become a widely used means of inhibiting target gene expression (42, 67).  
Interestingly, the deletion of several different Rabs by this method reduced virus yield by up 
to 100-fold, with depletion of Rab6 producing the most prominent effect on virus titre 
(unpublished data, Elliott Group, Imperial College, London).  This Rab has recently been 
shown to regulate vesicle trafficking from the Golgi to the plasma membrane (94, 95, 159) 
and this role appears to be utilised by HSV-1 for the transport of at least two glycoproteins, 
gD and gE, from the TGN to the plasma membrane (unpublished data, Elliott Group, Imperial 
College, London).  These results indicate that a specific set of Rabs are involved in HSV-1 
infection of HeLa cells. 
1.7 HYPOTHESES AND AIMS 
Literature on HSV-1 has been based on experiments in a number of different cell lines and 
types, many of which did not originate from the human nervous system or skin.  The study of 
HSV-1 infection of human keratinocytes for this thesis aims to elucidate processes in HSV-1 
replication and assembly that are currently contentious or as yet unknown.  It is hypothesised 
that keratinocytes will provide the optimal environment for infection and therefore provide a 
valuable model for infection, given their physiological relevance to HSV-1 infection. 
It is hoped to utilise Rab GTPases as a tool to further dissect viral processes reliant on the 
keratinocyte cellular trafficking system.  It is expected that a selection of Rab proteins will be 
necessary for proper virus replication and that these may be comparable to the previously 
identified group of Rabs identified from infected HeLa cells. 
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1.7.1 AIMS 
Part 1 
1) HSV-1 replicates in human keratinocytes in vivo, however its replication in these cells 
has not been fully characterised.  A potential model for HSV-1 replication in skin is 
the nTERT cell-line, in which HSV-1 has not been studied.  Therefore, to establish 
nTERTs as a suitable model for future studies of HSV-1 infection in the skin, HSV-1 
growth in this cell type will be examined in detail. 
2) It is unknown if the properties of HSV-1 infection of its natural host, the keratinocyte, 
is different to infection of standard cell-lines such as the Vero cell.  Hence, virus 
replication in both cell-types will be compared and stages where there are differences 
will be identified. 
3) Previous studies of HSV-1 infection in keratinocytes have been unable to agree upon 
the entry mechanism and subsequent spread of the virus, therefore the nTERT cell 
model will be used to investigate HSV-1 entry and spread in keratinocytes. 
Part 2 
1) To optimise nTERT cells for transfection and target protein depletion. 
2) Screen a selection of human Rab GTPases for their involvement in nTERT 
keratinocyte infection. 
3) Characterise any Rab hits identified by the screen with regard to their role in HSV-1 
replication. 
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2.1 MAMMALIAN CELL CULTURE 
Unless otherwise specified, deionised 18.2 MΩ water was used throughout as the solvent for 
all buffers and solutions, and where appropriate solutions were autoclaved before use. 
2.1.1 CELL TYPES 
Vero (African green monkey-derived kidney fibroblast-like cell line), HeLa (human epithelial 
carcinoma cell line), HFFF2 (primary human foreskin fibroblasts) and BSC1 (African green 
monkey kidney epithelial cell line) cells were acquired from the European Collection of Cell 
Cultures (ECACC) (Health Protection Agency, Porton Down, UK).  The human primary 
immortalised keratinocyte cell types nTERT (human telomerase reverse transcriptase) and 
HaCaT (Human adult low Calcium Temperature) were kind gifts from Professor Judith Breuer 
(University College London, UK).  All cells described were adherent cell types. 
2.1.2 CELL CULTURE MAINTENANCE 
All cell culture work was carried out using sterile technique in BioMAT2 class II 
microbiological safety cabinets (Medical Air Technology, Oldham, UK).  Cells were 
maintained in supplemented Gibco® Dulbecco’s modified eagle medium (DMEM, Invitrogen, 
Carlsbad, CA, USA).  Vero and HeLa cells were cultured in DMEM supplemented with 10% 
v/v newborn calf serum (NCS, Invitrogen), 50 U/ml penicillin (Sigma, St. Louis, MO USA) and 
50 pg/ml streptomycin (Sigma) (Pen-Strep).  BSC1, HaCaT and HFFF2 cells were grown in 
DMEM media supplemented as described above with the substitution of NCS with 10% v/v 
foetal calf serum (FCS, Invitrogen).  The nTERT cells were maintained in three-parts DMEM 
to one part Ham’s F-12 (PAA, Pasching, Austria) supplemented with 10% v/v FCS, Pen-
Strep, 10 ng/ml mouse epidermal growth factor (AbD Serotec, Oxford, UK), 1 ng/ml cholera 
toxin (Sigma), 400 ng/ml hydrocortisone (Sigma), 5 µg/ml insulin (Sigma), 5 µg/ml transferrin 
(Sigma) and 13 ng/ml liothyronine (Sigma).  Vero or BHK cells were cultured in 850 cm2 
CELLSTAR® tissue culture treated roller bottles with standard caps (Greiner Bio One) for 
extracellular virus purification (section 2.2.5).  Cell culture media in the roller bottles was CO2 
enriched by gently bubbling CO2 through it for approximately 2-3 seconds.  Roller bottles 
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were incubated in a Wheaton standard incubator (Fisher Scientific).  All other cells, cultured 
in tissue culture flasks, were incubated in Heraeus® HERA cell 240 incubators (Thermo 
Fisher Scientific Inc., Waltham, MA USA) at 37°C in a humidified, 10% CO2 atmosphere.   
Cells were sub cultured in 75 cm2 CELLSTAR® cell culture flasks (Greiner Bio One, Belgium) 
using reagents pre-warmed to 37°C in a W14 water bath (Grant Instruments, Shepreth, UK).  
HeLa and Vero cells were sub cultured at 1:10, BSc1 cells at 1:3 and HaCaT and nTERT 
cells at 1:6, every 3-4 days.  The previous culture medium was removed and cells were 
washed briefly with 0.5 g/L trypsin- ethylenediaminetetraacetic acid (EDTA) solution 
(Invitrogen) before incubating at 37°C in 1.5 ml of this solution for 3 mins (up to 20 mins for 
nTERT cells).  Once loose, cells were resuspended in 10 ml of fresh culture medium and 
diluted into new tissue culture flasks in a total volume of 20 ml.   
Vero, HeLa and BSC1 cells were passaged up to 20 times for use in experiments, while 
HFFF2 were only passaged up to 10 times.  HaCaT and nTERT cells were passaged 
continuously up to passage 40, however past reports suggest HaCaT are stable up to 
passage 140 (30).  New cell stocks were revived, when necessary, from aliquots of frozen, 
early-passage cells at -80°C.  Briefly, a frozen cell aliquot was thawed rapidly in a 37°C W14 
water bath before diluting to 10 ml with fresh, pre-warmed media.  This suspension was 
centrifuged for 5 mins at 1300 rpm at 4°C in a TX-750 swinging bucket rotor for the Hereaus 
Megafuge 40R (Thermo Fisher Scientific Inc., Waltham, MA, USA) to obtain a cell pellet.  
The pellet was resuspended in 10 ml fresh culture media and transferred to a 25 cm2 or a 75 
cm2 tissue culture flask and allowed to reach 100% confluency before passaging.  Cells were 
periodically frozen in aliquots at early-passage for later use.  Trypsinised cells were counted 
and 3x106 cells per aliquot were pelleted by centrifugation for 5 mins at 4000 rpm at 4°C.  
The cell pellet was resuspended in 1 ml of Gibco® Recovery™ cell culture freezing medium 
(Invitrogen) and was frozen at -80°C (Ultra Low Freezer, New Brunswick Scientific, NJ, US) 
using a 5100 Cryo 1˚C freezing container (Thermo Fisher Scientific Inc.) before transfer to 
liquid nitrogen for long term storage. 
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Table 2.1:  Cell numbers required to be seeded in various sized tissue culture plates in order 
to be 100% confluent 24 hours post-seeding.
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Table 2.1 
 Number of cells seeded per well in cell culture plate 
Cell Type 96 24 12 6 
Vero 5.0 x 104 1.5 x 105 3.0 x 105 6.0 x 105 
HeLa 5.0 x 104 1.5 x 105 3.0 x 105  
HFFF2 5.0 x 104 1.0 x 105 4.0 x 105 8.0 x 105 
BSC1 5.0 x 104 7.5 x 104  3.0 x 105 
nTERT 8.0 x 104 5.0 x 105 1.0 x 106 2.0 x 106 
BHK 5.0 x 104    
HaCaT 8.0 x 104 5.0 x 105 1.0 x 106 2.0 x 106 
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2.1.3 CELL COUNTING AND SEEDING 
For experiments using cells at specific densities, cells were counted prior to seeding.  A cell 
suspension of trypsinised cells was diluted in a known volume of culture media and 
transferred to the chamber of a haemocytometer (Fisher Scientific Inc.).  Cells were counted 
in four sets of 16- squares under an Olympus CKX31 light microscope (Tokyo, Japan) using 
a 10X objective and an average was used to calculate the number of cells per ml of culture 
media, after an adjustment for the dilution factor used.  To ascertain cell viability the 
trypsinised cell suspension was diluted in 0.4% v/v trypan blue (Sigma) before counting.  The 
number of cells stained blue was then counted as above, and was used to calculate the 
percentage of dead cells in the culture media. 
Cells were seeded in volumes of 100 µl/500 µl/ 1 ml/2 ml per CELLSTAR® 96/24/12/6-well 
culture plates (Greiner Bio One) at the densities indicated in table 2.1 to achieve 100% 
confluency 24 hours post-seeding.  For immunofluorescence studies cells were seeded at 
75% of the density indicated in table 2.1 to produce 75% sub-confluent monolayers at 24-
hours post-seeding.  These cells were seeded on 13 mm glass cover slips (VWR Int., PA, 
USA).  
2.1.4 MYCOPLASMA TREATMENT 
For the treatment of cultured cells infected with mycoplasma the removal agent Plasmocin™ 
(InvivoGen, CA, USA) was used as per manufacturers instructions.  Briefly, during the 
normal passaging of confluent cells in tissue culture flasks, cells were diluted in fresh media 
containing 25 µg/ml Plasmocin™.  This treatment was continued for two weeks (four 
passages) after which the elimination of mycoplasma infection was confirmed using the EZ-
PCR Mycoplasma test kit (GeneFlow, Staffordshire, UK) as indicated in the instruction 
manual. 
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2.2 VIROLOGY METHODS 
All virus work was carried out in BioMAT2 class II microbiological safety cabinets (Medical Air 
Technology) and cells used for virus work were cultured in Heraeus® HERA cell 150 
incubators (Thermo Fisher Scientific Inc.) at 37°C in a humidified, 5% CO2 atmosphere.  All 
virus samples and stocks were stored in 2 ml screw-top microtubes (Sarstedt, Nümbrecht, 
Germany) at -80°C and were not used for experiments past two freeze-thaw cycles.  Unless 
otherwise indicated, all cell culture media used for infections was pre-warmed using a 
SUBAqua 12 Plus water bath set to 37°C (Grant Instruments). 
2.2.1 VIRUSES 
Wild type HSV-1 strain sc16 (104) was a kind donation from Helena Browne (Cambridge 
University, UK) and wild type HSV-1 strain 17+ was originally isolated in Glasgow (100).  The 
recombinant virus expressing GFP-tagged VP22 was constructed in strain 17+, (GFP-22 
(72), constructed by Gill Elliott, Imperial College London, UK) and were used at the 
multiplicities indicated.  The 110lacZ virus was a kind gift from Stacey Efstathiou (Cambridge 
University, UK) (131).  The 110lacZ virus encodes a lacZ gene driven by an ICP0 promoter, 
inserted into the non-essential US5 locus of the wild type strain sc16, so that the virus 
produces a blue, β-galactosidase-positive, plaque and the infected cell appears blue.  
2.2.2 PRODUCTION OF VIRUS WORKING STOCKS 
New virus working stocks were prepared from Master or Sub-Master stocks of virus grown in 
Vero cells in five 225 cm2 tissue culture flasks (CORNING® Inc., NY, USA).  Confluent cells 
were infected at a multiplicity of infection (MOI) of 0.01-0.05 virus infectious units per cell 
(where cell number was presumed to be 3 x 107 cells per flask) in 50 ml of cell culture media 
containing a reduced percentage of serum (2% v/v NCS) known as infection media.  The 
infection was allowed to progress until extensive cytopathology was visible; yellow colour of 
media, cells appeared ‘round’ under the microscope and became readily non-adherent when 
the infected tissue culture flask was tapped.  Infected cells were then harvested along with 
the infected media and collected in a 500 ml centrifuge tube (CORNING® Inc.) which was 
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then centrifuged at 3000 rpm for 30 mins at 4°C, in an airtight swinging bucket rotor (7500 
6445) for the Sorvall® Legend RT centrifuge (both Thermo Fisher Scientific Inc.).  The 
supernatant was discarded and the cell pellet resuspended in 3 ml sterile phosphate-buffered 
saline (PBS, VWR) (appendix).  This virus-cell suspension was then subjected to three 
cycles of freeze/thawing to disrupt the cells and release intracellular virus using dry ice (BOC 
Group PLC, Guildford, UK)/ethanol (VWR) to freeze and a SUBAqua 12 Plus water bath set 
to 37°C to rapidly thaw the virus.  Cell debris was pelleted by centrifugation at 3000 rpm for 5 
mins at 4°C in an airtight swinging bucket rotor (7500 6445) for the Sorvall® Legend RT 
centrifuge.  The cleared supernatant was then aliquoted into 2 ml screw-top microtubes and 
stored at -80°C.  Before use in experiments the virus was titrated onto Vero cells to ascertain 
the number of plaque forming units (PFU) per ml of PBS. 
2.2.3 PLAQUE ASSAYS 
Virus samples or stocks were diluted in 10-fold steps for titrations, or diluted to produce 
PFU/well indicated in the text, in DMEM (2% v/v NCS, Pen-Strep) infection media.  The 
inoculum was used to infect one-day-old confluent monolayers of Vero, nTERT or HaCaT 
cells in 6- or 12-well plates, in 400 or 800 µl inoculum volume per well, respectively.  After 
incubation for one hour at 37°C, 5% CO2, the inoculum was removed and replaced with 1 or 
2 ml/well of cell culture media with 2% v/v NCS, 1% human serum (HS, Sera Laboratories 
Ltd., Haywards Heath, UK) and Pen-Strep for titrations.  For plaque assays, cells were over-
laid with 1 or 2 ml/well of reduced serum cell culture media with the percentage human 
serum or LP14 antibody indicated in the text.  For agarose plaque assays cells were overlaid 
with SeaPlaque agarose (2% w/v, Lonza, ME, USA) in reduced serum cell culture media pre-
warmed to 37°C.  The agarose was allowed to set at room temperature for 20 minutes.  The 
cells were further cultured at 37°C, 5% CO2 until plaques became visible by eye (usually 3 
days for titrations) or the times specified in the text.  Cells were fixed in 2X formal saline 
solution (see appendix) for 20 mins at room temperature, before staining with 0.1% crystal 
violet (appendix) and plaques were counted and considered representative of a single initial 
viral infection. 
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2.2.4 EXTRACELLULAR VIRUS PURIFICATION 
Roller bottles of confluent Vero or BHK cells were infected at a multiplicity of infection (MOI) 
of 0.01-0.05 virus particles per cell (where cell number was presumed to be 1.5 x 108 cells 
per roller bottle) in 100 ml of infection media.  Roller bottles were incubated in a Wheaton 
standard incubator (Fisher Scientific) at 37°C until extensive cytopathology was visible at 
which time the infected cells were harvested along with the infected media and collected in 
500 ml centrifuge tubes (CORNING® Inc.) which were then centrifuged at 3000 rpm for 30 
mins at 4°C, in an airtight swinging bucket rotor (7500 6445) for the Sorvall® Legend RT 
centrifuge.  The cleared supernatant was collected in an SLA-3000 centrifuge tube and 
centrifuged in an SLA-3000 Super-Lite rotor for the Sorvall® RC5C centrifuge (both Thermo 
Fisher Scientific Inc.) for 90 mins at 9000 rpm at 4°C.  A 10 ml 5% to 15% w/v Ficoll 400 
(Sigma-Aldrich, St. Louis, Mo, USA) gradient was prepared using a single channel peristaltic 
Pump P-1 and gradient maker (GE Healthcare, Little Chalfont, UK) in a 13.2 ml thin-wall 
polyallomer ultracentrifuge tube (Beckman Coulter, Brea, CA, USA).  The virion pellet was 
resuspended in 1 ml PBS and layered onto the gradient which was then centrifuged at 
12,000 rpm for 2 hours at 4°C in a SW41 Ti swinging bucket rotor (Beckman Coulter) for the 
Sorvall® Discovery™ SE centrifuge (Thermo Fisher Scientific Inc.).  Using a 19-guage 
Microlance™ hypodermic needle (Becton Dickinson, Drogheda, Ireland) the purified virions 
(visible as a slightly opaque band) were collected through the side of the tube and 
resuspended in 10 ml PBS.  The remaining Ficoll was washed from the purified virions by 
centrifuging in the same centrifuge for a further hour at 25,000 rpm, 4°C, after which time the 
virion pellet was suspended in 200 µl PBS ready for use. 
2.2.5 GROWTH CURVES 
Cells from a spare well were trypsinised and counted as described in section 2.1.3.  Virus 
working stock was diluted in the appropriate cell culture media with reduced serum (2%) to 
give the MOI indicated in the figure legend.  The cell culture medium was replaced with 200 
or 400 µl of inoculum for 24 or 12-well tissue culture plates respectively, and incubated for 1 
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hour at 37°C, 5% CO2.  The cells were then washed once with fresh cell culture media and 
incubated in the appropriate volume of infection media for the stated times.  Alternatively the 
inoculum was collected, with (intra- and extra-cellular virus) or without (extracellular virus 
only) scraping the cells into the media, and considered as the ‘virus input’.  At each stated 
time the supernatant (extracellular-), supernatant and cells (total-) or the cells scraped into 
fresh infection media (intracellular-virus) were collected and stored in 2 ml screw-top 
microtubes at -80°C.  Before subjecting total- or intra-cellular virus samples to titration, 
samples were freeze/thawed three times using dry ice /ethanol to freeze and a SUBAqua 12 
Plus water bath set to 37°C to rapidly thaw the virus suspension.  Cell debris was pelleted by 
centrifugation at 5000 rpm for 5 mins at room temperature in an airtight fixed angle FA-45-
24-11 rotor for the 5424 bench-top centrifuge (both Eppendorf, Hamburg, Germany) and the 
supernatant was collected for titration, as described in section 2.2.3. 
2.2.6 ADSORPTION ASSAY 
One-day-old confluent monolayers of cells in 6-well plates were pre-chilled on ice for 15 
mins.  Cell culture media was removed and replaced with 500 µl virus diluted in the 
appropriate ice-cold infection media to give the indicated number of PFU per well (usually 
100-200 PFU per well).  To allow virus to bind but not enter cells, the cells were incubated on 
ice for the times specified in the figure legends, then washed twice with ice-cold PBS.   Cells 
were then over-laid with 2 ml fresh, warm, reduced-serum cell culture media containing HS 
(1% for Vero and BSC1 and 2% for nTERT and HaCaT cells) and returned to 37°C for 2 
days until plaques were visible by eye, before fixing as described in section 2.2.3.  Images of 
fixed cells were captured using a Perfection V700 Photo scanner (Epson, Nagano, Japan). 
2.2.7 PENETRATION ASSAY 
One-day-old confluent monolayers of cells in 6-well plates were pre-chilled on ice for 15 
mins.  Cell culture media was removed and replaced with 500 µl virus diluted in the 
appropriate ice-cold infection media to give the indicated number of PFU per well (usually 
100-200 PFU per well).  To allow virus to bind but not enter cells, the cells were incubated for 
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1 hour on ice, before washing with pre-warmed/chilled (as specified in the text) reduced 
serum cell culture media (without virus) and incubating at the temperatures stated in the text. 
Room temperature was gauged to be 21°C, plates incubated in a Liebherr Premium 
refrigerator (Liebherr, Bulle, Switzerland) were at 7°C and plates incubated on ice were taken 
to be at 0°C.  After each indicated length of time, cells were retrieved from the incubator and 
placed on ice.  Cells were treated with 500 µl of ice-cold pH 3 citrate buffer (103) (see 
appendix) for 1 min to inactivate bound virus, before being washed twice with ice-cold PBS.   
Cells were then over-laid with 2 ml fresh, warm, reduced serum cell culture media containing 
HS (1% for Vero and BSC1 and 2% for nTERT and HaCaT cells) and returned to 37°C for 2 
days until plaques were visible by eye, before fixing as described in section 2.2.3.  Images of 
fixed cells were captured using a Perfection V700 Photo scanner (Epson, Nagano, Japan). 
2.2.8 β-GALACTOSIDASE STAINING 
Fixed cells infected with the sc16 110lacZ virus (referenced in section 2.2.1) were detected 
by 5-Bromo-4-chloro-3-indolyl β-D-galactosidase (X-gal) staining (modified from a previously 
described protocol (130) as follows.  Cells fixed using 4% w/v paraformaldehyde (PFA) 
(Sigma-Aldrich) (described in section 2.8.1) were washed using ice-cold 2 mM MgCl2 (VWR) 
in PBS for 3 x 2 min washes.  Cell monolayers were then covered with ice-cold detergent 
solution for 10 mins before removing and incubating in X-gal solution (see appendix for both 
solutions) at 37°C until blue staining was visible (usually at least 4 hours).  X-gal solution was 
then removed by aspiration and the cells rinsed first with 2 mM MgCl2 in PBS, then with H2O 
and allowed to dry. 
2.2.9 β-GALACTOSIDASE QUANTIFICATION ASSAY 
Confluent layers of cells, seeded in 96 well plates, were infected with 25 µl of the sc16 
110lacZ virus at the MOI indicated for one hour (either on ice, or at 37°C, as specified).  The 
inoculum was then removed and replaced with fresh, pre-warmed reduced serum cell culture 
media and the cells were incubated for 4 hours at 37°C.  The media was removed by
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Table 2.2:  Sense and anti-sense sequences of Ambion® Silencer® Select siRNA library 
directed against human Rab proteins (Applied Biosystems Inc.). 
Table 2.2 
RefSeq 
Accession 
Number 
Gene 
Symbol siRNA ID 
Sense siRNA 
Sequence 
Antisense siRNA 
Sequence 
NM_004161 RAB1A s11658 GGGAACAAAUGUGAUCUGAtt UCAGAUCACAUUUGUUCCCta 
s229381 CAAAGAAAGUAGUAGACUAtt UAGUCUACUACUUUCUUUGtg 
NM_030981 RAB1B s119 GCACCAGCCUUAACCCUCAtt UGAGGGUUAAGGCUGGUGCcc 
s117 GCUGAAAUCAAAAAGCGGAtt UCCGCUUUUUGAUUUCAGCag 
NM_002865 RAB2A s11660 GAAGGAGUCUUUGACAUUAtt UAAUGUCAAAGACUCCUUCtt 
s11661 GAGCUUUACUAGUUUACGAtt UCGUAAACUAGUAAAGCUCct 
NM_032846 RAB2B s39688 UCAUGCUCAUUGGGAAUAAtt UUAUUCCCAAUGAGCAUGAta 
s39689 GAAUCCUUCCGUUCUAUCAtt UGAUAGAACGGAAGGAUUCtt 
NM_002866 RAB3A s11667 CCAUCUAUCGCAACGACAAtt UUGUCGUUGCGAUAGAUGGtc 
s11666 CCAUCACCACCGCAUACUAtt UAGUAUGCGGUGGUGAUGGtc 
NM_002867 RAB3B s11671 GCUAUGCUGAUGACACGUUtt AACGUGUCAUCAGCAUAGCgg 
s11669 GCUUCAUUCUGAUGUAUGAtt UCAUACAUCAGAAUGAAGCcc 
NM_138453 RAB3C s41884 GCACAGUUGGGAUCGAUUUtt AAAUCGAUCCCAACUGUGCtg 
s41885 CAAGAUUGGUCAACUCAAAtt UUUGAGUUGACCAAUCUUGta 
NM_004283 RAB3D s18327 AACUGCUACUGAUAGGCAAtt UUGCCUAUCAGUAGCAGUUtg 
s18326 AGGAGAACAUCAAUGUGAAtt UUCACAUUGAUGUUCUCCUtg 
NM_004578 RAB4A s11676 GAACGAUUCAGGUCCGUGAtt UCACGGACCUGAAUCGUUCtt 
s11675 GGUCCGUGACGAGAAGUUAtt UAACUUCUCGUCACGGACCtg 
NM_016154 RAB4B s28801 AGAAUAAGUUCAAACAGGAtt UCCUGUUUGAACUUAUUCUca 
s28800 GGAAGACUGUGAAGCUACAtt UGUAGCUUCACAGUCUUCCca 
NM_004162 RAB5A s11679 CAAGCCUAGUGCUUCGUUUtt AAACGAAGCACUAGGCUUGat 
s11678 GGAAGAGGAGUAGACCUUAtt UAAGGUCUACUCCUCUUCCtc 
NM_002868 RAB5B s11681 CGACAUUACUAAUCAGGAAtt UUCCUGAUUAGUAAUGUCGta 
s11682 GGAGCGAUAUCACAGCUUAtt UAAGCUGUGAUAUCGCUCCtg 
NM_004583 RAB5C s11710 GCAAUGAACGUGAACGAAAtt UUUCGUUCACGUUCAUUGCag 
s11708 GGACAGGAGCGGUAUCACAtt UGUGAUACCGCUCCUGUCCag 
NM_002869 RAB6A s11686 AAUUCUUCACGGUAAGAAAtt UUUCUUACCGUGAAGAAUUaa 
s11685 GAGCUGAAUGUUAUGUUUAtt UAAACAUAACAUUCAGCUCtt 
NM_016577 RAB6B s28327 CCAUUGGGAUUGACUUCUUtt AAGAAGUCAAUCCCAAUGGtt 
s28326 AGGCAACCAUUGGGAUUGAtt UCAAUCCCAAUGGUUGCCUgg 
NM_032144 RAB6C s38489 GCACUGAUGUAAAUUACUUtt AAGUAAUUUACAUCAGUGCtc 
s38490 GCAUAUUCCGGUGAUAACUtt AGUUAUCACCGGAAUAUGCtg 
NM_004637 RAB7A s15443 GCUAGUCACAAUGCAGAUAtt UAUCUGCAUUGUGACUAGCct 
s15442 GCUGCGUUCUGGUAUUUGAtt UCAAAUACCAGAACGCAGCag 
NM_177403 RAB7B s50333 GCUCUGUCGAGGUACCAGAtt UCUGGUACCUCGACAGAGCcc 
s50334 AGAUUAUCAUAUUGGGUGAtt UCACCCAAUAUGAUAAUCUtg 
NM_005370 RAB8A s8680 GAGUCAAAAUCACACCGGAtt UCCGGUGUGAUUUUGACUCcc 
s8679 GCAAGAGAAUUAAACUGCAtt UGCAGUUUAAUUCUCUUGCca 
NM_016530 RAB8B s28634 CGAUAGAACUAGAUGGAAAtt UUUCCAUCUAGUUCUAUCGtt 
s28633 GAAAGAUUCCGAACAAUCAtt UGAUUGUUCGGAAUCUUUCct 
NM_004251 RAB9A s17917 GGUCAGAUCAUUUGAUUCAtt UGAAUCAAAUGAUCUGACCta 
s17916 CCAGCUCUUCCAUACAAUAtt UAUUGUAUGGAAGAGCUGGgt 
NM_016370 RAB9B s27691 GGGUAACAAGGUAGACAAAtt UUUGUCUACCUUGUUACCCag 
s27692 GCUUAUGAACCGUUACGUAtt UACGUAACGGUUCAUAAGCga 
NM_016131 RAB10 s21390 GGACGACAAAAGAGUUGUAtt UACAACUCUUUUGUCGUCCat 
s21391 GGAUGAUGCCUUCAAUACUtt AGUAUUGAAGGCAUCAUCCga 
NM_004663 RAB11A s16702 CAACAAUGUGGUUCCUAUUtt AAUAGGAACCACAUUGUUGct 
s16703 GAGAUUUACCGCAUUGUUUtt AAACAAUGCGGUAAAUCUCtg 
NM_004218 RAB11B s17648 GCAUUCAAGAACAUCCUCAtt UGAGGAUGUUCUUGAAUGCtt 
s17647 CUAACGUAGAGGAAGCAUUtt AAUGCUUCCUCUACGUUAGtg 
NM_001025300 RAB12 s47368 CUCUGGAUAUUUUAAGGAAtt UUCCUUAAAAUAUCCAGAGgc 
s47369 GAUGCCUCUGGAUAUUUUAtt UAAAAUAUCCAGAGGCAUCtt 
NM_002870 RAB13 s11690 GAGCGGUUCAAGACAAUAAtt UUAUUGUCUUGAACCGCUCtt 
s11691 GGAAUCCGAUUUUUCGAAAtt UUUCGAAAAAUCGGAUUCCat 
NM_016322 RAB14 s28312 GGUCUAUGAUAUCACUAGAtt UCUAGUGAUAUCAUAGACCat 
s28311 GAAAAUCUAUCAGAACAUUtt AAUGUUCUGAUAGAUUUUCtt 
NM_198686 RAB15 s51761 CCAUCGGUGUUGACUUUAAtt UUAAAGUCAACACCGAUGGtg 
s51762 GAGAGAUACCAGACCAUCAtt UGAUGGUCUGGUAUCUCUCct 
NM_022449 RAB17 s34608 GGAGGUGACCUUCCAGGAAtt UUCCUGGAAGGUCACCUCCcg 
s34609 GCGCUUCUGGUGUACGACAtt UGUCGUACACCAGAAGCGCag 
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Table 2.2 continued 
RefSeq 
Accession 
Number 
Gene 
Symbol siRNA ID 
Sense siRNA 
Sequence 
Antisense siRNA 
Sequence 
NM_021252 RAB18 s22703 GGAUGGAAAUAAGGCUAAAtt UUUAGCCUUAUUUCCAUCCac 
s22704 GGUUCACAGAUGAUACGUUtt AACGUAUCAUCUGUGAACCtc 
NM_001008749 RAB19 s53589 GGAUUCAUGAGAUAGAGAAtt UUCUCUAUCUCAUGAAUCCag 
s53588 GGACCAAGAGUUCCCAUUAtt UAAUGGGAACUCUUGGUCCag 
NM_017817 RAB20 s31159 CUCUCGACGUGUUCAUUUAtt UAAAUGAACACGUCGAGAGtc 
s31158 CAGUGGAUAUAUCCAGUCAtt UGACUGGAUAUAUCCACUGtg 
NM_014999 RAB21 s22824 GGGUCAAAGAAUUACGGAAtt UUCCGUAAUUCUUUGACCCag 
s22823 GGGUCCAAUUUACUACAGAtt UCUGUAGUAAAUUGGACCCaa 
NM_020673 RAB22A s32993 CAGCUAUAAUCGUUUAUGAtt UCAUAAACGAUUAUAGCUGca 
s32992 UGAGCUACAUAAAUUCCUAtt UAGGAAUUUAUGUAGCUCAtt 
NM_016277 RAB23 s28567 CAGUGAAAGAAGAUCUAAAtt UUUAGAUCUUCUUUCACUGat 
s28568 CAAUCUUAGACCCAACAAAtt UUUGUUGGGUCUAAGAUUGat 
NM_001031677 RAB24 s28803 CGAGCAAAGUUCUGGGUGAtt UCACCCAGAACUUUGCUCGct 
s28804 GCUUUGAGCGAGCAAAGUUtt AACUUUGCUCGCUCAAAGCtg 
NM_020387 RAB25 s32701 CAUGCUCGUGGGUAACAAAtt UUUGUUACCCACGAGCAUGac 
s32700 GCCCGAAUGUUCGCUGAAAtt UUUCAGCGAACAUUCGGGCct 
NM_014353 RAB26 s24591 CGGCUGCAUGAUUACGUUAtt UAACGUAAUCAUGCAGCCGga 
s24590 GUUCCGCAGUGUUACCCAUtt AUGGGUAACACUGCGGAACcg 
NM_004580 RAB27A s11694 GGAGAGGUUUCGUAGCUUAtt UAAGCUACGAAACCUCUCCtg 
s11693 GCCUCUACGGAUCAGUUAAtt UUAACUGAUCCGUAGAGGCat 
NM_004163 RAB27B s11696 GACUUAAUCAUGAAGCGAAtt UUCGCUUCAUGAUUAAGUCca 
s11697 GGAAUAGACUUUCGGGAAAtt UUUCCCGAAAGUCUAUUCCta 
NM_004249 RAB28 s17911 CUAUAGGACUGGAUUUCUUtt AAGAAAUCCAGUCCUAUAGtt 
s17910 GGAGCAUAUGCGAACAAUAtt UAUUGUUCGCAUAUGCUCCaa 
NM_014488 RAB30 s26136 GGAGUUGAUUUUAUGAUUAtt UAAUCAUAAAAUCAACUCCaa 
s26137 CAAUGUAUCCUCACCCUUAtt UAAGGGUGAGGAUACAUUGtt 
NM_006868 RAB31 s21732 CAAUGGAACAAUCAAAGUUtt AACUUUGAUUGUUCCAUUGtt 
s21731 GGAAUACGCUGAAUCCAUAtt UAUGGAUUCAGCGUAUUCCtt 
NM_006834 RAB32 s21618 ACAUGACCCGAGUAUACUAtt UAGUAUACUCGGGUCAUGUtg 
s21619 CCGAGUAUACUACAAGGAAtt UUCCUUGUAGUAUACUCGGgt 
NM_004794 RAB33A s17908 GAUUCGCAUCUUCAAAAUAtt UAUUUUGAAGAUGCGAAUCtg 
s17907 GCAUUACUACCGCAACGUAtt UACGUUGCGGUAGUAAUGCtc 
NM_031296 RAB33B s37938 GAACGAUUCAGAAAGAGCAtt UGCUCUUUCUGAAUCGUUCtt 
s37937 CCUACCAUCUUGGAUAGAAtt UUCUAUCCAAGAUGGUAGGct 
NM_031934 RAB34 s38245 ACACCUUUGAUAAGAAUUAtt UAAUUCUUAUCAAAGGUGUct 
s38244 GGAGAGGUUCAAAUGCAUUtt AAUGCAUUUGAACCUCUCCtg 
NM_006861 RAB35 s21707 GCAGUUUACUGUUGCGUUUtt AAACGCAACAGUAAACUGCtc 
s21708 GAAGAGAUGUUCAACUGCAtt UGCAGUUGAACAUCUCUUCca 
NM_004914 RAB36 s18461 AGAAUGUUUUUGAUCGAGAtt UCUCGAUCAAAAACAUUCUtg 
s18462 CCACAGGUUUUGCAAGAAUtt AUUCUUGCAAAACCUGUGGat 
NM_001006638 RAB37 s50263 CCAGCUUCCAGAUCCGAGAtt UCUCGGAUCUGGAAGCUGGgc 
s50262 CCAGAUCCGAGACUAUGUAtt UACAUAGUCUCGGAUCUGGaa 
NM_022337 RAB38 s24319 CCAGAUGCCUGGUGAAACAtt UGUUUCACCAGGCAUCUGGag 
s24320 GCAAAUGAGUGUGACCUAAtt UUAGGUCACACUCAUUUGCaa 
NM_017516 RAB39 s29359 GACUGUGGAAUGAAGUAUAtt UAUACUUCAUUCCACAGUCtg 
s29360 GGAGCGGUUCAGAUCAAUAtt UAUUGAUCUGAACCGCUCCtg 
NM_171998 RAB39B s42008 ACCUGACAAGAGACAUAUAtt UAUAUGUCUCUUGUCAGGUct 
s42009 AGAGUGGAUUUGUACCAAAtt UUUGGUACAAAUCCACUCUtc 
NM_080879 RAB40A s44481 AGAUGGAAGUCGCAUUGUAtt UACAAUGCGACUUCCAUCUtc 
s44480 GCAUUGUAGAUUCAAGAAAtt UUUCUUGAAUCUACAAUGCga 
NM_006822 RAB40B s21589 UCACAGAGUCGUUCACGGAtt UCCGUGAACGACUCUGUGAtg 
s21588 CGCUGGUCUUUUGACGGCAtt UGCCGUCAAAAGACCAGCGgt 
NM_021168 RAB40C s33730 ACAGUAACGGGAUCGACUAtt UAGUCGAUCCCGUUACUGUag 
s33729 CACCAACCGCUGGUCCUUUtt AAAGGACCAGCGGUUGGUGat 
NM_001032726 RAB41 s51269 GAAUUGACUUCUUGUCUAAtt UUAGACAAGAAGUCAAUUCca 
s51268 CGGUUGAAAUCGAACUGGAtt UCCAGUUCGAUUUCAACCGtc 
NM_152304 RAB42 s41782 CAGUUACUCCAGAGGCUAAtt UUAGCCUCUGGAGUAACUGgg 
s41781 UCGAGGCUUUCUACAGAAAtt UUUCUGUAGAAAGCCUCGAct 
NM_198490 RAB43 s50452 CCACAGACUUGGUGCCUGAtt UCAGGCACCAAGUCUGUGGgt 
s50453 GCUGAUCGGGAACAAGUCAtt UGACUUGUUCCCGAUCAGCag 
NM_002855.4 
Nectin-1 
s11603 GCCUCACUCUCAACGUGCAtt  
NM_203285.1 s11604 GCACAGACGUGGUUCUGCAtt  
NM_203286.1 s11605 CCUGCAAAGCUGAUGCUAAtt  
 Nectin-1 CAAACCCACCAAUUGGAUA UAUCCAAUUGGUGGGUUUG 
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aspiration and the cells were washed twice with ice cold PBS, before being lysed.  Lysis and 
subsequent β-galactosidase quantification was carried out using the Invitrogen β-Gal Assay 
Kit, as specified in the manufacturers protocol.  Briefly, cells were lysed with 10 µl β-Gal lysis 
buffer per well, before being subjected to three cycles of freeze/thawing to disrupt the cells 
and release intracellular β-galactosidase.  Standards were prepared with β-galactosidase 
enzyme (Sigma) and wells containing only assay reagents or uninfected cells were used as 
blanks.  A master stock of Cleavage Buffer (50 µl/well) and ONPG (17 µl/well) was prepared 
and 67 µl was added to each well of lysed cells for 30 mins at 37°C, until a yellow colour 
developed.  Stop Buffer (125 µl/well) was used to halt the reaction and the absorbance at 
420 nm was read on a FLUOstar Omega multimode microplate reader (BMG Labtech, 
Offenburg, Germany).  Blank absorbance readings were removed from absorbance readings 
of samples and β-galactosidase activity was calculated from the standard curve, as mU β-
galactosidase activity per well or per cell. 
2.3 TRANSFECTION TECHNIQUES 
2.3.1 siRNA TRANSIENT TRANSFECTION 
An Ambion® Silencer® Select siRNA library directed against human Rab mRNAs, and three 
separate sets pre-designed to target Nectin-1 were obtained from Applied Biosystems Inc. 
(CA, USA).  One siRNA duplex targeting Nectin-1 was taken from (237) (see table 2.2 for 
sequence details).  Two duplexes (the sense and the anti-sense) were used to knock down 
each target splice variant at a final concentration of 5 – 30 nM per isoform (as indicated in 
the figure legends) using Lipofectamine™ 2000 (Invitrogen) transfection reagent according to 
the manufacturer’s instructions.  Briefly, for ‘reverse transfection’ the indicated volume 
(usually 1 µl) of Lipofectamine™ 2000 reagent was mixed with 50 µl of Opti-MEM® reduced 
serum media (Invitrogen) per well and allowed to stand at room temperature for 5 mins.  
Separately, the required concentration of siRNA duplexes was prepared in 50 µl of Gibco® 
Opti-MEM reduced serum media per well, after which the Lipofectamine™ 2000 mix was 
added to the siRNA mix and incubated at room temperature for 20 mins.  Freshly trypsinised 
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HaCaT or nTERT cells were prepared, usually at a density of 2.5 x 104 cells per well to give 
~25% confluency after one-day (or as indicated in the text) as described in section 2.1.2 and 
2.1.3 without the use of antibiotics in the cell culture media.  The transfection solution was 
then combined with the cell suspension and seeded onto 24-well tissue culture plates, which 
were incubated at 37°C, 10% CO2 for at least 6 hours before replacing the cell supernatant 
with fresh cell culture media (again without antibiotics).  Cells were allowed to grow for 3 
days after seeding before being used for assays or infections.  For ‘forward transfection’ 
nTERT or HaCaT cells were seeded in 24-well tissue culture plates at a density of 2.5 x 104 
cells per well, in antibiotic-free cell culture media.  One-day post-seeding 100 µl of 
transfection solution (prepared as described above) was added to each well.  These were 
incubated at 37°C, 10% CO2 for a minimum of 6 hours before replacing the cell supernatant 
with fresh cell culture media (again without antibiotics).  Cells were allowed to grow for three 
days post-transfection before being used for assays or infections. 
2.3.2 TRANSIENT TRANSFECTION OF PLASMIDS 
Monolayers of cells seeded in 24-well plates at ~80% confluency were transfected with 
Lipofectamine™ 2000 reagent.  Briefly, the indicated volume (usually 1 µl per well) of 
Lipofectamine™ 2000 reagent was mixed with 50 µl of Opti-MEM® reduced serum media per 
well and allowed to stand at room temperature for 5 mins.  Separately, the required 
concentration of plasmid DNA (indicated in the figure legend, details given in table 2.3) was 
prepared in 50 µl of Opti-MEM® per well.  The Lipofectamine™ 2000 mix was added to the 
plasmid mix and incubated at room temperature for 20 mins before addition to the cell 
monolayers. 
2.4 ANTIBODIES  
All primary and secondary antibodies used for Western blotting (sections 2.5.2) and 
immunofluorescence staining (section 2.8.2) are detailed in tables 2.4 and 2.5. 
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2.5 PROTEIN ANALYSIS 
All protein samples were stored at -20°C, or -80°C for longer time periods. 
2.5.1 SDS-PAGE 
Cells were washed in PBS and lysed in 50-100 µl 2X SDS Sample Buffer (see appendix) 
before passing through a 23-gauge Microlance™ hypodermic needle (Becton Dickinson) and 
boiling for 5 mins.  Lysed samples were diluted 1:1 using 2X SDS-PAGE loading dye (see 
appendix) and incubated at 100°C for 3 mins prior to loading.  Samples were loaded onto 
Tris glycine polyacrylamide gels (see appendix) (10, 12 or 15% polyacrylamide, depending 
on the molecular weight of the target proteins) cast in 10 x 10 cm pre-formed mini cassettes 
(Invitrogen) and Novex® Sharp Pre-Stained Protein Standards (Invitrogen) were used for 
sizing proteins.  Each lysate was separated by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) using a Novex mini cell SureLock™ system (Invitrogen) with 
SDS-PAGE running buffer (see appendix), for 1 hour at 220 V as described in the 
manufacturers instructions.  
2.5.2 WESTERN BLOTTING  
Protein was transferred from the SDS-PAGE gels to a Whatman® Protran® nitrocellulose 
membrane (Whatman, GmbH, Dassel, Germany) using transfer buffer (see appendix), an X 
Cell II Blot module (Invitrogen) and the Novex mini cell SureLock™ system for 2 hours at 25 
V or overnight at 7 V, as per manufacturers guidelines.  Membranes were washed briefly in 
reverse-osmosis water before protein transfer was confirmed by submersion in 0.1% w/v 
Ponceau S solution in 5% v/v acetic acid (Sigma-Aldrich) for 2 mins.  Ponceau S solution 
was removed from the membrane by further washing in reverse-osmosis water.  Membranes 
were blocked for at least 1 hour at room temperature or 4°C overnight with blocking buffer 
consisting of 5% w/v Fluka Analytical skimmed milk powder (Sigma-Aldrich) and 0.1% v/v 
Tween-20® (Sigma-Aldrich) in PBS.  Blocking milk was removed by brief washes in wash 
buffer consisting of 0.1% v/v Triton® X-100 (Sigma-Aldrich) in PBS.  All antibodies were 
diluted at the concentrations indicated in tables 2.4 and 2.5 in 0.1% v/v Tween-20® in PBS, 
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with the exception of anti-Rab antibodies, which were diluted in blocking buffer.  All 
incubations and washes were carried out at room temperature with agitation on a Stuart® 
SSL3 gyro-rocker set to 30 rpm (Bibby Scientific Ltd., Staffordshire, UK).  Primary antibody 
was added to the membrane for a minimum of 1 hour followed by 3 x 10 min incubations in 
wash buffer.  Secondary antibody was also added for 1 hour and washed in the same 
manner as primary incubated membranes.  The membrane was incubated in Super Signal 
West Pico Chemiluminescent Substrate (Thermo Fisher Scientific Inc.) (usually 1 ml per 
membrane) for 2 mins before exposing to FujiFilm RX NIF X-ray film (Fisher Scientific).  
Developed films were scanned using a Perfection V700 Photo scanner (Epson).  Membranes 
were stored at 4°C in PBS or for long-term storage at -20°C in Chemiluminescent Substrate 
(which was removed with wash buffer before re-blocking).  Membranes were routinely re-
blocked and probed with additional antibodies as described above; membranes were not 
stripped. 
2.6 RNA ANALYSIS 
All mRNA was stored at -80°C and cDNA was stored in the short-term at 4°C or for longer-
term storage at -20°C.  Incubations at a specified temperature were usually carried out in a 
SUBAqua 12 Plus water bath, unless otherwise specified.  
2.6.1 mRNA EXTRACTION 
For extraction and purification of RNA from cells an Oligotex Direct mRNA Mini Kit was 
obtained (Qiagen, Venlo, Netherlands) and instructions followed as specified in the “Isolation 
of Poly A+ mRNA from Animal Cells” section of the manual.  All centrifugation steps were 
carried out at room temperature at 14,000 rpm in an airtight fixed angle FA-45-24-11 rotor for 
the 5424 bench-top centrifuge.  Briefly, trypsinised cells were pelleted by centrifugation for 5 
mins and lysed in 600 µl of room temperature Buffer OL1. Samples were then homogenised 
by passing through a 19-gauge Microlance™ hypodermic needle 5-10 times, and then mixed 
with 1.2 ml of Buffer ODB.  Samples were then centrifuged for 3 mins and the supernatant
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Table 2.3:  Plasmids used in this thesis.  Plasmids used were not constructed as a part of 
this thesis and so plasmid maps are not included. 
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Table 2.3 
Plasmid Name Promoter Protein Expressed Source 
pCMV-Gluc-1 HCMV Gaussia luciferase with 
secretion signal 
Nanolight (AZ, USA) 
GFP-Rab6A HCMV Rab6A fused to GFP Casper Hoogenraad, Universiteit 
Utrecht, The Netherlands (200) 
GFP-Rab5A HCMV Rab5A fused to GFP Stephen Ferguson, The University 
of Western Ontario, USA (207) 
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was collected and mixed with 30 µl of Oligotex Suspension per sample and incubated for 10 
mins at room temperature.  The Oligotex-mRNA complexes were then pelleted and washed 
by further centrifugation for 5 mins and resuspended in 100 µl Buffer OL1 and 400 µl Buffer 
ODB, before a first incubation at 70°C for 3 mins and a second incubation at room 
temperature for 10 mins.  The Oligotex-mRNA was then pelleted and washed a second time 
by centrifugation for 5 mins and resuspending the pellet in 350 µl Buffer OW1.  This 
suspension was transferred to a small spin column placed in a 1.5 ml microcentrifuge tube 
and centrifuged for 1 min.  The microcentrifuge tube was replaced with a fresh tube and 350 
µl of Buffer OW2 was applied to the small spin column, followed by centrifugation for 1 min.  
This wash step was repeated once more before applying 30 µl 70°C Buffer OEB to the spin 
column in a fresh microcentrifuge tube and centrifuging for 1 min to collect the eluted mRNA.  
The concentration of mRNA in each sample was then quantified on a Nanodrop ND-1000 
spectrophotometer (Thermo Scientific). 
2.6.2 cDNA PRODUCTION 
To make cDNA from mRNA extracted by the method of section 2.6.1, first excess DNA was 
removed by diluting 200 ng of mRNA in 8 µl nuclease-free water (Ambion) followed by the 
addition of 1 µl 10X DNase reaction buffer (Invitrogen) and 1 µl amplification grade DNase I 
(1 U/µl, Invitrogen) and incubating for 15 mins at room temperature.  Next, 25 nM of EDTA 
(Invitrogen) was added to each sample and incubated at 65°C for 10 mins to inactivate 
DNase.  Both 50 ng of Random Primers (Promega) and 10 nM of dNTPs (Promega) were 
added before an additional 5 min incubation at 65°C.  The samples were then chilled on ice 
briefly and 4 µl 5X First-Strand Buffer (Invitrogen), 1 µl 0.1M DTT (Invitrogen), 1 µl RNasIN™ 
(40U/ µl, Promega) and 1 µl SuperScript ™ III reverse transcriptase (200 U/µl, Invitrogen) 
were each added to the sample.  The sample-SuperScript™ III RT mix were then cycled on a 
Veriti 96 Well Thermal Cycler (Applied Biosystems) as follows; 5 mins at 25°C, 60 mins at 
50°C and 15 mins at 70°C.  
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2.6.3 QUANTITATIVE REAL TIME PCR 
All primers used for quantitative real time PCR (qRT-PCR) assays were obtained from 
Invitrogen are detailed in table 2.6. MESA GREEN qPCR MasterMix Plus for SYBR® Assay 
with dTTP (Eurogentec, Liège, Belgium) was used for all qRT-PCR assays as detailed in the 
manufacturer’s instructions.  Briefly, cDNA standards were prepared by diluting cDNA in 
nuclease-free water in ten-fold dilutions.  In a fast optical 96 well reaction plate (Applied 
Biosystems), 5 µM of sense and 5 µM of antisense primers and 5 µl of MESA GREEN qPCR 
MasterMix Plus for SYBR® Assay and 4 µl of cDNA or standards (cDNA samples were 
diluted 1:10 in nuclease-free water) were added to each well in triplicate.  Plates were sealed 
with a 96-well plate sealing mat (VWR), before carrying out qRT-PCR on an ABI7900HT 
qPCR machine (Applied Biosystems) with the following cycling parameters: 95°C for 15 
mins, (95°C for 10 sec, 60°C 15 sec, 72°C for 15 sec, repeated 40 times), 95°C for 15 sec, 
60°C for 15 sec.  Results were analysed using Sequencing Detection System software v2.3 
(Applied Biosystems). 
2.7 ASSAYS 
2.7.1 PROTEIN QUANTIFICATION 
Cells were washed in PBS and lysed in 50-100 µl lysis buffer (see appendix), chilled on ice 
for 5 mins then centrifuged at 12,000 rpm for 5 minutes in an airtight fixed angle FA-45-24-11 
rotor for the 5424 bench-top centrifuge.  Cell lysates were assayed for protein quantification 
in triplicate using the DC™ Protein Assay (Bio-Rad Laboratories, CA, USA) as described in 
the manufacturer’s instructions.  Briefly, protein standards were prepared between 0.2 mg/ml 
to 1.35 mg/ml, using bovine serum albumin (Bio-Rad Laboratories) in lysis buffer (see 
appendix).  Working solution A was prepared by adding 20 µl of Reagent S to 1 ml of 
Reagent A before adding 100 µl of this solution to each 20 µl volume of sample or protein 
standard.  Reagent B was then added; 800 µl per sample, and incubated for 15 mins at room 
temperature before the absorbance was read at 750 nm on a Heλios β v4.2 
spectrophotometer (Thermo Electron Corporation, MA, USA). 
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Table 2.4: Primary antibodies for western blotting (WB) and immunofluorescence staining 
(IF).  All mouse antibodies are monoclonal, all rabbit antibodies polyclonal.  Antibody names 
are as stated in the literature or a catalogue order number is given where antibody name was 
not available (accurate on 30/09/2012).  GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; PML, promyelocytic leukemia protein; EEA1 early endosome antigen 1. 
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Table 2.4 
Antigen Name/catalogue 
number 
Secondary Working dilution Source 
WB IF 
α-tubulin T-5168 rabbit 1:20,000  Sigma 
GAPDH 6C5 mouse 1:4000  Ambion 
gD LP14 mouse 1:5000 1:50 Tony Minson (University of 
Cambridge, UK) (158) 
gE 3114 mouse 1:1000  David Johnson (Oregon 
Health and Science 
University, OR, USA) (49) 
giantin Ab24586 rabbit  1:200 Abcam  
giantin Ab37266 mouse  1:200 Abcam 
ICP0 11060 mouse 1:200 1:50 Santa Cruz Biotechnology 
(CA, USA) 
ICP27 H1119 mouse 1:5000  Stephen Rice, (University 
of Minnesota, MN, USA) 
Importin β Ab2811 mouse 1:5000  Abcam 
PML DB75 rabbit  1:50 Peter O’Hare (Imperial 
College London, UK) (16) 
Rab1A FL-205 rabbit 1:200  Santa Cruz Biotechnology 
Rab5 610724 mouse 1:1000  Becton Dickinson 
Rab6 C19 rabbit 1:200  Santa Cruz Biotechnology 
Rab7 Ab50533 mouse 1:500  Abcam 
Rab10 D36C4 XP™ rabbit 1:1000  Cell Signaling Technology 
(MA, USA) 
Rab11 D4F XP™ rabbit 1:2000  Cell Signaling Technology 
Rab22A Ab67049 mouse 1:500  Abcam 
VP5 3B6 mouse 1:3000  Virusys (MD, USA) 
VP22 
Nterminus 
AGV031 rabbit 1:20,000  (71) 
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Table 2.5:  Secondary antibodies for western blotting (WB) and immunofluorescence 
staining (IF).  * Goat anti-mouse HRP antibody was used at 1:5000 for ICP0 antibodies. § 
Goat anti-rabbit HRP antibody was used at 1:20,000 for AGV031 antibody. (H+L), heavy and 
light immunoglobulin chains; HRP, horseradish peroxidase. 
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Table 2.5 
Reactivity Details Catalogue 
number 
Application Working 
Dilution 
Source 
mouse IgG 
(H+L) 
goat HRP TI-2000 WB 1:10,000* Bio-Rad 
Laboratories 
rabbit IgG 
(H+L) 
goat HRP 170-6515 WB 1:10,000§ Bio-Rad 
Laboratories 
rabbit IgG 
(H+L) 
goat Alexa Fluor® 488 A 11008 IF 1:200 Invitrogen 
mouse IgG 
(H+L) 
goat Alexa Flour® 568 A 11004 IF 1:200 Invitrogen 
rabbit IgG 
(H+L) 
goat Alexa Flour® 568 A 11011 IF 1:200 Invitrogen 
mouse IgG 
(H+L) 
goat Alexa Flour® 488 A 11001 IF 1:200 Invitrogen 
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2.7.2 GAUSSIA LUCIFERASE SECRETION ASSAY 
Four-day-old monolayers of nTERT cells, which had already been ‘reverse transfected’ with 
siRNA as described in section 2.3.1 were transfected with 400 ng/well of plasmid pCMV-
Gluc-1 as described in section 2.3.2.  At 24-hours post-plasmid-transfection, control cells 
were incubated with 500 µl cell culture media containing 5 µg/ml Brefeldin A (BFA) (Sigma) 
for 4 hours at 37°C.  One hour prior to harvesting the extracellular media, the cell culture 
media was replaced in all wells with fresh cell culture media (with or without 5 µg/ml BFA, as 
appropriate) and returned to 37°C.  The extracellular media was collected and centrifuged at 
8000 rpm for 4 mins in an airtight fixed angle FA-45-24-11 rotor for the 5424 bench-top 
centrifuge to pellet any cellular debris, which was then discarded.  The cleared supernatant 
was either stored at -80°C or used immediately for gaussia luciferase quantification as 
follows.  In triplicate, 20 µl of each sample was transferred to a Röhren tube (Sarstedt).  The 
enzyme substrate coelenterazine (Prolume Ltd., AZ, USA, see appendix) was used at 1 
µg/ml in PBS as the input liquid and the chemiluminescence was ascertained using an 
Autolumat Plus LB953 luminometer (Berthold Technologies, Bad Wildbad, Germany).  
Relative light units (RLU) chemiluminesence/well was normalised to protein 
concentration/well (ascertained as described in section 2.7.1) 
2.7.3 TRANSFERRIN UPTAKE ASSAY 
One-day old cells seeded on 13 mm cover slips or two to three-day old transfected cells on 
13 mm cover slips were washed with DMEM without serum once prior to the addition of 2.5 
µg/ml Texas Red® conjugated transferrin (Invitrogen) in DMEM without serum.  Cells were 
incubated at 37°C for 30 mins, washed once with PBS and fixed with 4% paraformaldehyde 
and mounted onto microscope slides (as described in section 2.8.1).  Transferrin uptake was 
assessed by microscopy.  
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2.8 MICROSCOPY 
2.8.1 FIXING AND MOUNTING 
Cells for analysis by microscopy were seeded on 13 mm cover slips (as described in section 
2.1.3) and transfected (section 2.3) or infected (section 2.2.6) as indicated.  To fix samples, 
cover slips were washed 2 times in 500 µl PBS followed by incubation in 200 µl 4% w/v 
paraformaldehyde (PFA) (Sigma-Aldrich) for 20 mins at room temperature.  Cover slips were 
then washed a further 2 times in PBS and stored in 500 µl PBS at 4°C until processed.  
Cover slips were permeabilised in 0.5% v/v Triton® in PBS for 10 mins and washed in 
reverse-osmosis water before mounting in Vectashield mounting medium with 4’, 6 
diamidino-2-phenylindole (DAPI) (Vector Laboratories Inc., CA, USA) on SuperFrost® WHITE 
microscope slides (VWR).  Slides were stored at 4°C in the absence of light until cells were 
visualised. 
Images were captured using a Zeiss Axiovert S100 TV inverted fluorescence microscope 
(Carl Zeiss Ltd., Oberkochen, Germany) in combination with Image-Pro Plus 7.0 software 
(Media Cybernetics Inc., Bethesda, MD, USA).  Where indicated, images were captured on a 
confocal Zeiss LSM510 META inverted laser-scanning microscope with LSM Image Browser 
4.2 software (both Carl Zeiss Ltd.).  Unless specified all images were captured at 63X 
magnification under a drop of Immersol® 518N mineral oil (Carl Zeiss Ltd.). 
2.8.2 IMMUNOFLUORESCENCE STAINING 
After permeabilisation of fixed cells by incubation at room temperature for 10 mins in 0.5% 
v/v Triton® in PBS, cover slips were incubated in block solution (10% v/v NCS in PBS) for a 
further 20 minutes.  Antibodies were diluted in blocking solution at the concentrations 
indicated in tables 2.4 and 2.5.  Cover slips were incubated in 25 µl primary antibody in 
blocking solution for 20 mins, washed for at least 10 mins in PBS and incubated with the 
appropriate fluorescent secondary antibody in blocking solution for a further 10 mins.  After a 
second PBS-wash for 10 mins cover slips were briefly submerged in reverse-osmosis water
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Table 2.6: Summary of sense- and anti-sense sequences of primers used for qRT-PCR. 
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Table 2.6 
Primer Name Sense sequence Anti-sense sequence 
Nectin-1 ctgcaaagctgatgctaacc gatgggtcccttgaagaaga 
Rab6 acttggaggatcgaacaatcaggct cagctgcagcagaatcacgga 
RPLP0 actctgcattctcgcttcct ggactcgtttgtacccgttg 
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before mounting as described in section 2.8.1.  All incubations took place at room 
temperature in the absence of light. 
2.8.3 ELECTRON MICROSCOPY PROCESSING 
Cells were processed for electron microscopy as described previously (107).  Briefly, cells 
were fixed in 0.5% glutaraldehyde (TAAB Laboratories, Berkshire, UK) in 200 mM sodium 
cacodylate buffer (TAAB Laboratories), pH 7.2, for 30 mins.  Cells were then washed in 
buffer and secondarily fixed in reduced 1% osmium tetroxide (Sigma), 1.5% potassium 
ferricyanide (Sigma) for 60 mins.  The samples were washed in distilled water and stained 
overnight at 4°C in 0.5% magnesium uranyl acetate (Agar Scientific, Essex, UK), washed in 
distilled water and dehydrated in graded ethanol.  The samples were then embedded in Epon 
resin (Serva Electrophoresis GmbH, Heidelberg, Germany) in a flat dish.  Resin filled stubs 
were placed on embedded cell monolayers and polymerised. Ultrathin sections (typically 50–
70 nm) were cut 90° to the dish base and examined in a FEI Tecnai electron microscope 
(FEI, OR, USA) with CCD camera image acquisition (Olympus) using analySIS software 
version 3.2 (Olympus). 
2.9 STATISTICAL ANALYSIS 
All data were analysed by Student’s t test using Microsoft® Excel 2011 for Mac.  The 
direction of change was always unknown, therefore two-tailed analysis was performed.  
Student’s t test assumes that data follow a normal distribution (174), which was not explicitly 
tested here.  However the robustness of the t test in the face of non-normal data has been 
verified, even for small sample sizes (227). 
2.10 SOFTWARE 
All digital images and figures were prepared using Adobe® PhotoShop® CS3 (Adobe 
Systems, San Jose, CA USA).  Image manipulation was limited to adjustment of brightness 
and contrast for microscopy images.  Graphs and statistical analysis were prepared using 
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Microsoft® Excel 2011 (Microsoft Corporation).  The manuscript was written using Microsoft® 
Word 2011.  All software was for AppleTM Mac. 
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Human Keratinocyte Cell Lines are 
Permissive to HSV-1 Infection and 
Support a more Enhanced Infection 
than Vero Cells
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3.1 CHAPTER INTRODUCTION 
Considering the substantial body of publications on HSV-1, there are relatively few studies 
on this virus in the physiologically relevant host cell, the keratinocyte.  As discussed in 
section 1.3, organotypic skin raft models were used initially, with success, in the study of 
HPV (150, 156) and this model system has now also been adopted for the characterisation of 
HSV-1 infection.  An organotypic skin raft system has been set up using an immortalised 
human keratinocyte cell line (nTERT) for further study of HSV-1 replication in the skin.  
These cells are more tractable and less limited in supply than primary keratinocytes, and are 
able to form a partial thickness epidermis, as indicated by involucrin and keratin 10 staining, 
both markers of epidermal differentiation (figure 3.1A, unpublished data, Breuer Group, 
University College London).  Prior to this work, the permissive state of nTERTs to HSV-1 
infection was undefined, but staining for the viral proteins ICP4 and gD indicates that 
nTERTs are able to, at least, sustain viral protein expression (figure 3.1B, unpublished data, 
Breuer Group, University College London).  Further utilisation of this model for HSV-1 
infection requires that first, infection of the nTERT keratinocyte cell line be more fully 
characterised in a simpler setting; cell culture monolayer.  This chapter characterises HSV-1 
infection of keratinocytes, namely nTERT cells, and seeks to draw comparisons with the 
routinely used Vero cell line. 
3.2 CHARACTERISATION OF HSV-1 INFECTION OF nTERT AND HaCaT CELLS 
HSV-1 is known to replicate in HaCaTs (154) and our collaborators have shown that it is able 
to at least infect and produce early and late viral proteins in nTERT cells (figure 3.1B), 
however it is unknown whether nTERTs are permissive to a complete cycle of replication and 
spread of virus.  To establish their permissive state and the kinetics of replication in these 
cells, they were infected with wild type HSV-1 strain 17+ for up to 24 hours at a multiplicity of 
two virus particles per cell (MOI) measured in plaque forming units (PFU) per ml.  The 
supernatant was collected one hour after infection and is considered to be representative of 
the initial inoculum (indicated as 0).  Virus was detected in both the extracellular and cell-
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associated virus portions of “zero” hour samples (the initial inoculum) for both cell types to 
similar extents, indicating that the wild type virus is able to attach to these cells (figure 3.2A).  
Very little virus was detectable in either the extracellular or cell-associated virus samples (~1 
x 103 PFU/ml) at 2 hours post-infection, this is likely to be some proportion of the initial 
inoculum which was not removed after one hour, rather than newly produced viral particles 
(figure 3.2A).  The extracellular virus detected at 6 hours from infected HaCaT cells was 
considerably higher than the level of cell-associated virus, however it is probable that it is 
some remaining inoculum (~1 x 105 PFU/ml at both “0” and 2 hours post-infection), rather 
than detectable new extracellular virus (figure 3.2A).  The first detectable increase in virus 
production is at 6 hours post-infection, suggesting that the production of infectious viral 
particles requires between 2 and 6 hours to be detected (figure 3.2A).  Between 6 and 16 
hours post-infection, virus production increased steadily until it plateaued at ~1 x 107 PFU/ml 
from 16 to 24 hours.  One round of replication appeared to be completed by 16 hours post-
infection in both cell types (figure 3.2A).  Extracellular and cell-associated virus levels were 
similar in nTERT cells, although the extracellular titre in infected HaCaTs was moderately 
higher than the cell-associated virus produced (figure 3.2A).  These findings show that 
nTERT and HaCaT keratinocytes can be used for HSV-1 studies of infection as the virus can 
enter and maintain a productive infection for 16 hours or more, reaching titres of up to ~1 x 
107 pfu/ml. 
The virus titre of all stock viruses in the Elliott Group (Imperial College, London) are 
quantified by titration onto Vero cells to give a value of PFU/ml, which is used for subsequent 
infections.  Vero cells are used because HSV-1 infection of these cells produces clustered 
areas of cytopathic effects which are termed plaques.  Monolayers of cells can be fixed and 
stained with crystal violet to produce a purple-colour field of stained cells.  Areas of cells 
which have been productively infected are not stained and so result in circles of 
translucency, or plaques, which are visible by the eye and can be quantified.  It was unknown 
whether plaques can form on HaCaT or nTERT cell monolayers, as occurs in Vero cells, so 
wild type HSV-1 strain 17+ was titrated onto each of these cells and fixed and stained to 
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Figure 3.1: Keratinocyte nTERT cells are able to form organotypic skin rafts which are 
permissive to HSV-1 infection.  (A) Organotypic skin rafts formed from nTERT cells were 
fixed, thin section cut and immunofluorescence staining performed for keratin 10 (red) and 
involucrin (green), accompanied by nuclei staining (DAPI, blue).  The epidermal layer is 
labeled E and the dermal layer is labeled D.  (B) Organotypic skin rafts were infected with 
1000 PFU of wild type HSV-1 strain 17+ per raft for 42 hours.  Rafts were then fixed, thin 
section cut and immunofluorescence staining performed for ICP4 (red) and gD (green), 
accompanied by nuceli staining with DAPI (blue).  Experiments were performed by the 
Breuer Group, University College London.  Images were captured on a Zeiss Axiovert S100 
TV inverted fluorescence microscope, Imperial College London. 
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Figure 3.1
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Figure 3.2: The keratinocyte cell lines HaCaT and nTERT are permissive to HSV-1 infection.  
(A) Confluent nTERT or HaCaT cell monolayers were infected with wild type HSV-1 strain 
17+ at a multiplicity of two.  Intracellular and extracellular virus was harvested at the times 
indicated and titrated onto Vero cells.  A representative of three independent experiments is 
shown as the mean and ± standard error of the data.  (B) Working stocks of wild type HSV-1 
strain 17+ virus were titrated onto confluent layers of Vero, nTERT or HaCaT cells.  After two 
days of infection, cells were fixed with formal saline solution and stained with crystal violet, 
examples of which are shown to illustrate plaque morphology.  In order to quantify the virus 
titre on each of these cells resultant plaques were counted.  Values given are mean values ± 
standard error, taken from three independent experiments (C).  (D) Examples of infected 
nTERT and HaCaT cell monolayers 2 or 3 days post infection with wild type HSV-1 strain 
17+, which were fixed with formal saline solution and stained with crystal violet. 
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Figure 3.2
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identify any resultant plaques and view their morphology (figure 3.2B).  Transparent, 
uniformly circular plaques of fairly consistent diameter formed on the Vero cells and were 
visible by eye from two days post-infection.  At this time, plaques were also detectable in 
nTERT and HaCaT cells, however they were less uniformly circular and less transparent in 
the nTERTs and seemed to be opaque in the HaCaT cells (figure 3.2B, HaCaT and nTERT).  
A translucent ‘halo’ was also seen around infected HaCaT plaques, possibly a result of an 
aggregation of infected cells pulling away from the surrounding areas (figure 3.2B, HaCaT).  
Figure 3.2B indicates that plaques can form and are quantifiable in HaCaT and nTERT cells.  
Therefore, it is possible to establish whether the titre obtained on Vero cells can be applied to 
stock viruses when infecting the nTERT and HaCaT cells.  Wild type HSV-1 strain 17+ was 
titrated onto each of these cells and compared to the titre ascertained on Vero cells (figure 
3.2C).  Although there did seem to be a tendency for the titre to be up to two-fold higher 
when titrated on nTERT cells, no statistically significant difference was detected in virus titre 
(PFU/ml) upon titration on Vero, nTERT or HaCaT cells (figure 3.2C).  Therefore the titres 
previously determined for all stock viruses on Vero cells are still applicable in the infection of 
nTERT and HaCaT cells.  These data indicate that nTERT and HaCaT cells are permissive 
to HSV-1 infection and that HSV-1 can replicate productively in these cells. 
3.3 HSV-1 INFECTION OF nTERT AND HaCaT CELLS PRODUCES COMET TAIL 
FORMATION UNDER CERTAIN CONDITIONS 
During these experiments the plaques formed on infected nTERT and HaCaT cells seemed 
to elongate when left for longer periods of time (figure 3.2D).  These apparent uni-directional 
trails of cytopathology, usually emanating from the central plaque towards the side of well, 
have been termed ‘comet tails’ in previous literature.  Comet tails have been described in a 
number of different virus infections including vaccinia virus, vesicular stomatitis virus and 
HSV-1 itself, but usually in the absence of anti-viral antibodies in the media (195, 209, 257).  
Comet tails had not been observed previously in Vero cells but were forming in the 
keratinocytes in the presence of human serum.  Human serum is used to inhibit secondary 
plaque formation during titrations as it contains anti-HSV-1 neutralising antibodies.  As the 
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comet tails still formed in the presence of human serum (1%), we hypothesised that a higher 
concentration of human serum might be needed to prevent formation in the keratinocytes.  
To charcterise the contribution of human serum concentration on the formation of this 
phenomenon Vero, nTERT and HaCaT cells were infected at a low multiplicity with wild type 
HSV-1 strain s17+ with increasing concentrations of human serum and fixed two, three or 
four days post-infection (DPI).  As expected, in Vero cells, small plaques were visible at 2 
DPI, increasing in diameter with time (figure 3.3, Vero).  The increasing concentrations of 
human serum (1-10%) seemed to have no effect on the plaque formation, however comet 
tails were seen to form in the absence of human serum.  These comet tails were only visible 
from 3 DPI and were still not extensive even after four days.  Conversely, comet tails were 
visible from two DPI in the nTERT cells and were seen both in the absence and presence of 
human serum (figure 3.3, nTERT).  The comet tails became more extensive over time, 
ultimately covering the whole monolayer of cells in extreme cases (no human serum, four 
DPI).  Increasing concentrations of human serum led to a reduction in the extent of the comet 
tails, suggesting an inverse relationship of human serum to comet tail formation.  However, 
the efficacy of the human serum was still reduced over time, with comet tails increasing in 
size in all conditions.  In HaCaT cells similar characteristics were evident; comet tails 
increased in size over time but were inhibited by higher levels of human serum (figure 3.3, 
HaCaT).  It must be noted that the comet tail formation in these cells appears to be less 
extensive and more gradual than in the nTERT cells, however, comet tail formation is still far 
more prevalent in both keratinocyte cells types compared to Vero cells (figure 3.3).   
It is known that in vaccinia virus antibodies directed towards the extracellular enveloped virus 
inhibit comet tails (31, 135, 180).  In this case we wanted to establish whether the limitation 
of comet tail formation were attributable to neutralising antibodies in the human serum and 
not another factor, such as complement.  A monoclonal neutralising antibody to the viral 
glycoprotein gD (LP14) which is known to inhibit entry of HSV-1 (84), was applied during low 
multiplicity infections of monolayers of nTERT cells to see if it had the same effect as human 
serum on comet tails.  Comet tail formation in the nTERT cells was also limited by LP14 in a 
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Figure 3.3: Comet tail formation is inhibited by increasing concentrations of human serum.  
Confluent monolayers of Vero, nTERT or HaCaT cells were infected with varying amounts of 
wild type HSV-1 strain 17+ to produce an equal number of plaques per well.  After one hour 
the inoculum was removed and replaced with fresh media containing the indicated levels of 
human serum (HS).  Infection was allowed to progress for one, two or three days post-
infection before fixing with formal saline solution and staining with crystal violet. 
Figure 3.3
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Figure 3.3 continued
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Figure 3.4: Comet tail formation is inhibited by monoclonal anti-gD antibodies and physical 
barriers.  (A) Confluent monolayers of nTERT cells were infected for one hour with wild type 
HSV-1 strain 17+ to produce 100 plaques per well.  The inoculum was then replaced with 
reduced-serum media containing (A) human serum (HS) or LP14 antibody (specific for gD) 
as indicated or mock treated media.  (B) Cells were overlayed with reduced-serum media 
containing 5% v/v human serum, sea plaque agarose (2% w/v) or mock treated media as 
indicated.  Infection was allowed to progress for two days (A) or three or four days (B) before 
fixing with formal saline solution and staining with crystal violet.
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Figure 3.4
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similar fashion to human serum (figure 3.4A).  It is therefore likely a neutralising antibody 
component of human serum is responsible for the inhibition of comet tail formation.   
It has been published that comet tails do not form under agarose overlay (135), as according 
to the movement of liquid hypothesis, the extracellular virus should not be able to spread 
without the convection currents in the overlay.  Wild type HSV-1 strain 17+ was used to infect 
nTERT cells in the presence of 5% human serum, under an agarose overlay or were mock 
treated in a liquid overlay (figure 3.4B).  As expected comet tails were highly extensive in the 
absence of human serum under a liquid overlay.  These increased in extent from the third to 
the fourth day but their progression was curtailed by the addition of human serum.  Contrary 
to expectations comet tails were visible under agarose overlay and they increased in size 
over time (figure 3.4B).  These comet tails, however, were less extensive than those under 
human serum, therefore the agarose overlay limited the comet tails to a greater extent than 
the human serum, but not completely. 
It is known that, in vaccinia virus, better replicating strains result in more prominent comet 
tails (31, 180).  Taken together with these results, it appears that keratinocyte infection may 
be more productive, or release more virus particles than Vero cell infection, as infection of 
keratinocyte cells produces more extensive comet tails than Vero cells.  We hypothesise that 
the lack of effect of human serum is due to higher levels of virus in the extracellular media of 
the keratinocytes which are able to bind and expend the neutralising antibody pool, of which 
there is only a finite supply.  This then allows subsequently released virus progeny to spread 
extracellularly and form comet tails. 
3.4 HSV-1 REPLICATES MORE EFFICIENTLY IN nTERT CELLS THAN VERO CELLS 
To test the hypothesis that keratinocytes produce more virus than Vero cells, growth curves 
were obtained to compare total virus growth kinetics.  One of the keratinocyte cell types, the 
nTERTs, was chosen as representative of both cell types to compare to Vero cells.  One- 
and multi-step growth curves of wild type HSV-1 strain 17+ were obtained in Vero and 
nTERT cells, measuring total infectious progeny at each time point.  The initial virus inoculum 
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was determined to be similar in all cases at time “0” and therefore a valid comparison can be 
made between the titres produced in both these cell types (figure 3.5A).   
In the one-step growth curve of figure 3.5A newly produced infectious virus progeny was only 
detected from 10 hours post-infection in Vero cells, after which the titre peaked at ~1 x 106 
PFU/ml by 16 hours post-infection and plateaued, indicating a single round of infection had 
occurred in these cells.  The growth kinetics of the virus from infected nTERT cells differed in 
both the onset of new virus production, which was detected from 6 hours post-infection rather 
than 10, and the overall titre reached by 16 hours post-infection, which plateaued at a ten-
fold higher titre. These results were maintained when normalised to cell number (PFU/ml per 
1000 cells).  When a more detailed study of the early onset of virus production in a one-step 
growth curve was carried out (figure 3.5B), detectable virus production was shown to begin 
between 5 and 6 hours post-infection in the nTERT cells; about two hours in advance of virus 
production in the Vero cells. The kinetics of multi-step virus growth showed similar results, 
with a ten-fold higher titre being reached overall in infected nTERT cells than Vero (figure 
3.5C).  However, it is unclear from the time points chosen whether the initiation of virus 
production occurs earlier in the nTERT cells (figure 3.5C).  These findings show that the 
HSV-1 infectious cycle is, for undefined reasons, more efficient in nTERT cells than Vero 
cells, both at the initiation of virus production and the overall titre reached in infected cells. 
The results from the comet tail assays (figure 3.3 and 3.4) suggest that more infectious virus 
was present in the extracellular media of the nTERT cells than the Vero cells.  Figure 3.5 
indicated that virus production is more efficient overall in nTERT cells, however the results of 
the comet tail assay could also be attributed to a higher level of virus release.  To investigate 
whether virus release is higher in nTERT cells than Vero cells wild type HSV-1 strain 17+ 
was used to infect both these cells at a multiplicity of two, and at the indicated times 
extracellular and cell-associated infectious progeny were collected separately.  Virus 
production of cell-associated virus was initiated between 2 and 6 hours post-infection in 
nTERT cells, but later, between 6 and 10 hours post-infection in Vero cells (figure 3.6, cell-
associated virus).  There was a lag in the cell-associated production of virus in the Vero,
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Figure 3.5: Virus replication is enhanced in nTERT cells compared to Vero cells.  Confluent 
Vero or nTERT cells were infected at a multiplicity of 2 (A and B) or 0.02 (C) with wild type 
HSV-1 strain 17+ virus.  After the indicated lengths of time, total infectious progeny was 
harvested and samples were then titrated onto Vero cells.  (A) Virus production is displayed 
as PFU/ml and also normalised to cell count (PFU/ml per 1000 cells).  The mean and ± 
standard error of results performed in triplicate from a representative experiment are shown. 
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Figure 3.5
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Figure 3.6: nTERT keratinocyte cells facilitate greater virus release than Vero cells.  
Confluent Vero or nTERT cells were infected at a multiplicity of two with wild type HSV-1 
strain 17+ virus for the indicated lengths of time, before harvesting intracellular and 
extracellular infectious progeny separately.  Samples were then titrated onto Vero cells and 
the mean and ± standard error of results performed in triplicate in a representative 
experiment are shown. 
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Figure 3.6
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however this matches the nTERT titre by 16 hours post-infection, when both plateau at ~1 x 
107 PFU/ml (figure 3.6, cell-associated virus).  The extracellular portion of infectious progeny 
becomes detectable at 16 hours post-infection in the Veros, displaying a delay compared to 
that of the cell-associated portion, but also a delay from the detection in the extracellular 
portion of virus from infected nTERTs (figure 3.6, extracellular virus).  The overall 
extracellular virus titre is, however, greater in nTERT cells compared to Vero cells (figure 3.6, 
extracellular virus).  These results indicate that there is an initial enhancement in cell-
associated virus production in nTERT cells, which is subsequently overcome later in infection 
in Vero cells.  The extracellular titre of virus in nTERT cells is also higher overall, indicating 
that release of virus is improved in these cells compared to Vero cells.  Overall, this data 
suggests that there is an enhancement in virus replication in these keratinocytes at a single, 
or multiple stages in the replication cycle. 
3.5 CHAPTER DISCUSSION 
This chapter identifies an enhancement in HSV-1 replication in nTERT keratinocytes in 
comparison with Vero cells.  The keratinocyte cell types HaCaT and nTERT were both 
shown to be permissive to infection by wild type HSV-1 strain 17+, with infection of nTERT 
cells by HSV-1 being a novel finding (figure 3.2A).  These cells were also shown to facilitate 
the formation of comet tail-like plaques in the presence of higher concentrations of human 
serum than Vero cells (figure 3.3).  Furthermore, the limitation of comet tail formation by 
higher concentrations of human serum, anti-gD neutralising antibodies and semi-solid 
agarose overlay all indicate that these comet-tails are formed by excess virus in the 
extracellular media, in agreement with published results in vaccinia virus (179) (figure 3.3 
and 3.4).  The novel finding of enhanced overall virus production and extracellular release of 
virus in nTERT keratinocytes compared to Vero cells (figure 3.5) could, therefore, explain this 
discrepancy in comet tail formation.  More rapid detection of initial virus production in the 
nTERT cells as compared to Vero cells also offers an interesting new avenue of study as 
there may be stages of replication which occur in infected nTERT cells which have not been 
identified in previous work, or differ from Vero cell infection.  It is not surprising that cells in 
CHAPTER 3 
 
 105 
which the virus habitually replicates in vivo would provide a better environment for virus 
production. 
3.5.1 THE KERATINOCYTE CELL LINES HaCaT AND nTERT ARE PERMISSIVE TO 
HSV-1 INFECTION 
Although HaCaT cells have been studied with regards to HSV-1 infection, and have been 
previously shown to be permissive to HSV-1, (wild type HSV-1 strain 17+, KOS and strain F) 
(111, 154, 191, 203) nTERT cells had not been identified in the literature as being able to 
sustain HSV-1 infection.  The data from our collaborators (figure 3.1B) indicated that nTERT 
cells are permissive to infection as both early and late viral protein expression is detected by 
immunofluorescence staining, however it was not shown whether infectious virus was 
produced or whether the infection was capable of spreading.  The data from figure 3.2 
confirms that these cells are both permissive to infection and that they are capable of 
producing infectious virus, as detected in the growth curves (A).  The ability of the virus to 
plaque in these cells also confirms the ability of the virus to spread from cell-to-cell and via 
extracellular routes (figure 3.2B and 3.3).  
Whereas our data suggests that the titre of HSV-1 was statistically similar in HaCaT, nTERT 
and Vero cells, Hukkanen et al determined that HaCaT cells were ten times more sensitive to 
HSV-1 than Vero cells (111).  The discrepency here may be attributable to our use of strain 
17+ and the use of strain F in the Hukkanen study, or perhaps that their Vero cells (which are 
described as B-Vero) stem from a different linneage than the Vero cells used in figure. 3.2.  
Nonetheless, for our studies and purposes the titre of strain 17+ from Vero titrations was still 
applicable to infections of nTERT and HaCaT cells.  Our data shows that nTERT cells are 
indeed permissive to HSV-1 strain s17+ infection, and can sustain a similar level of virus 
production as HaCaT cells (figure 3.2A). 
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3.5.2 COMET TAIL FORMATION IN VERO, nTERT AND HaCaT CELLS IS LINKED TO 
THE ABUNDANCE OF EXTRACELLULAR VIRUS 
Comet tails have been commonly documented in a number of viruses, predominantly of the 
orthopox family, with the first incidences of comet tails described in rabbitpox infection (11).  
They have been recognised as primary plaques (which form the ‘head’ of the comet) and 
linked to a ‘tail’ (formed by a series of secondary plaques).  Comet tail formation is 
theoretically attributed to movement of virus via spontaneous flows in the liquid overlay.  In 
fact when plates of vaccinia virus-infected cells were tilted 10° from horizontal all the 
resultant comet tails formed in one direction (135).  This was thought to be due to upward 
convection currents caused by temperature gradients in the media and evaporation inside 
the incubator.   
The production of comet tails in nTERT, Vero and HaCaT cells was surprising given the 
minimal data published on HSV-1 induced comet tails and the fact that these comets were 
forming in the presence of human serum, which is routinely used to prevent secondary 
plaque formation (209).  If the comet tails are indeed formed by secondary plaques then our 
data indicates that virus infection of nTERT and HaCaT cells is able to overcome the 
inhibitory effects of human serum and produce secondary plaques in the form of comet tails. 
The ability of vaccinia virus to produce these plaques has been linked to increased release of 
extracellular enveloped virus particles (EEV) (179, 246).  Their formation has also been 
shown to be restricted by the addition of anti-sera in vaccinia virus infection (31, 135, 180).  
These facts, coupled with data showing that higher levels of human serum are needed to 
restrict comet tails in the keratinocyte cell lines, suggest that more virus is being released 
into the extracellular media compared to infected Vero cells.  Furthermore, the restriction 
imposed by human serum on comet formation is a result of the action of neutralising 
antibodies, as indicated by the inhibition caused by the addition of higher levels of the 
neutralising antibody LP14 in figure 3.4A.  Therefore, we hypothesise that when more virus is 
released into the extracellular media, the limited pool of antibodies available will, over time 
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and increasing virus release, eventually be exhausted and thus allow any subsequent virus 
particles to spread via extracellular routes and produce secondary plaques, which ultimately 
result in comet tails.  
This hypothesis would therefore predict that keratinocytes release more virus particles than 
Vero cells, and that if a solid overlay were applied to these cells, then no comet tails would 
form, as extracellular spread would be prevented.  However, the results from this experiment 
did not fully support this (figure 3.4B agarose comets).  Although the comets were limited to a 
greater extent by the agarose overlay than the human serum, they still formed.  This can only 
be reconciled if a liquid interface still remains between the cells and the agarose overlay, 
which is hard to show, or if the virus is able to spread cell to cell in a directional manner.  
This latter option seems unlikely given the body of evidence in vaccinia virus which supports 
secondary plaque formation as the cause and the experiment tilting cels 10° to the horizontal 
which produced comets all flowing in one direction (135), however it cannot be discounted 
completely. There are instances of directional virus spread, particularly in retroviruses, 
[reviewed in (166)].  These suggest that directional cell-to-cell spread is caused by down-
regulation of viral receptors on infected cells, or through build-up of released virus being 
retained at the surface that can then spread to neighbouring cells which still present 
receptors.  An unbalanced release of antiviral factors, such as interferons, from a population 
of cells could also explain the spread of virus away from these cells, however in a population 
of one cell type one might expect this to only limit the infection from all sides.  A 
concentration of virus receptors at one side of a cell, for example in a polarised cell, could 
also theoretically allow for directional cell to cell spread.  However HaCaT, nTERT and Vero 
cells are unpolarised, therefore it is less likely to be an explanation for directional spread in 
these cells.  Descriptions of directional spread of HSV-1 are usually through a three-
dimensional heterogeneous system or between different cells, preferentially from one cell 
type to another (98).  Our system is a single cell type monolayer, therefore would also 
discount this kind of directionality.  Additionally it is difficult to reconcile the extension of the 
comet tails always in the direction of the extremeties of the well, rather than away from areas 
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of infected cells, with a rational mechanism of virus cell-to-cell spread.  The results from 
figure 3.6 (extracellular titre) indicate that there is indeed more virus released in nTERT cells 
than Vero cells, and so for this, and the previously mentioned reasons, we did not pursue this 
avenue of study further. 
3.5.3 ENHANCED VIRUS PRODUCTION IN nTERT CELLS 
The virus replication kinetics reveal that virus replication begins earlier in nTERT cells, and 
that total virus titres are ten times higher than Vero cells (figure 3.5).  They also confirm that 
extracellular virus release is more efficient in these keratinocytes, however, the cell-
associated virus kinetics indicate that although the virus is being produced earlier in nTERT 
cells, the intracellular production appears to attain comparable levels later during infection 
(figure 3.6).   
3.5.4 CONCLUDING REMARKS 
In this chapter nTERT and HaCaT cells were shown to be permissive to HSV-1 infection.  
The formation of comet tails during plaque formation was demonstrated to be caused by 
higher levels of extracellular virus released from infected nTERT cells and their restriction 
was shown to likely be attributable to the presence of neutralising antibodies in human 
serum.  Two major differences in the infection of these cells have been identified.  Firstly, 
virus production begins more rapidly in nTERTs; and secondly, virus is released more 
efficiently than in Vero cells. 
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4.1 CHAPTER INTRODUCTION 
Chapter 3 provided evidence to suggest that virus production is initiated more rapidly in 
nTERT keratinocytes than in Vero cells.  The continued use of Vero cells for these 
experiments was required as a comparison to locate any differences in the stages of 
infection between the two cell types.  This chapter aims to further characterise infection of 
nTERT keratinocytes and to identify the stage, or stages, in the replication cycle at which this 
rapid virus production is initiated in these cells. 
4.2 COMPARISON OF VIRAL PROTEIN EXPRESSION IN INFECTED nTERT AND VERO 
CELLS 
To attempt to identify the point, or points at which the enhancement of replication is initiated, 
viral protein expression was analysed during infection.  It was hoped that this could identify 
whether the enhancement/s occurred early or late in infection, according to the expression of 
immediate early and late proteins.  A comparative time course study of infection of nTERT 
and Vero cells was carried out with wild type HSV-1 strain 17+ at a multiplicity of infection of 
ten PFU per cell.  Samples were harvested and equalised by either protein quantification or 
α-tubulin and GAPDH blotting and western blotted to allow direct comparison of viral protein 
expression between the two cell types (figure 4.1).  Two different equalisation methods were 
used, as samples harvested for protein quantification were lysed in an NP-40 based buffer, 
which is not as stringent a lysing agent as the SDS loading dye.  It was thought possible that 
not all proteins would be liberated for western blotting with the NP-40 based lysis agent, 
therefore, although less accurate for equalisation, detection of α-tubulin was used as an 
alternative loading control method to corroborate the results.  The western blots indicate that 
the same populations of proteins are available by both methods of lysis as they give the 
same protein expression profile (figure 4.1).  The GAPDH signal in nTERT cells appears to 
run at a slightly higher mobility, under both lysis conditions, indicating that it may be a 
modified form of GAPDH compared to that in Vero cells, however the strength of the signals 
of both GAPDH and α-tubulin are still comparable and supports that protein was loaded 
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equally throughout (figure 4.1, GAPDH).  Therefore, analysis of protein expression was 
equivalent in both methods. 
A selection of viral proteins from various stages of viral gene expression were chosen to 
allow identification of any stages at which protein expression differed between the cells.  
Immediate early proteins such as ICP0 and ICP27 are the first proteins to be detected (figure 
4.1, 2-4 HPI), with the tegument protein VP22 and the capsid protein VP5 following shortly 
behind (figure 4.1, 4-6 HPI), and the glycoprotein gD being the latest viral protein to be 
detected in both Vero and nTERT cells (figure 4.1, 6 HPI).  Generally levels of each protein 
increased over time, or in some cases appeared to plateau (ICP0 and ICP27 in particular), 
however this is probably more evident due to their early onset compared to the other proteins 
detected (figure 4.1).  In Vero cells viral protein expression was detected from 4 hours post-
infection, however both ICP0 and ICP27 are detected at 2 hours post-infection in the infected 
nTERT cells, which shows that viral protein expression was detected two hours earlier than 
in Vero cells (figure 4.1).  VP22 expression is also only evident at 6 hours post-infection in 
Vero cells, while it is detected two hours earlier in nTERT cells (figure 4.1, 4 HPI).  Levels of 
viral protein expression seem overall only slightly enhanced in nTERT cells, particularly by 
VP22 and gD expression.  
A similar time course was carried out for immunofluorescence microscopy with 166v, a 
recombinant HSV-1 tagged with GFP (72).  In this case the tegument protein VP22 was 
fused to GFP and the cells were infected at a multiplicity of infection of two PFU per cell.  
Anti-ICP0 antibody was used to stain for the early viral protein ICP0 and all images were 
taken under the same conditions and settings.  VP22 production became detectable faintly at 
4-6 hours post-infection in the cytoplasm of Vero cells (figure 4.2).  In contrast in the nTERT 
infection VP22 was initially identified at 2 hours post-infection and proceeded to an intense 
signal relatively quickly (figure 4.2).  ICP0 is known to localise to the nucleus early in 
infection before becoming visible in a punctate cytoplasmic localisation (69).  ICP0 was 
detectable only in the nucleus from 2-6 hours post-infection in the Vero cells and became 
apparent in the cytoplasm no earlier than at 8 hours post-infection (figure 4.2).  ICP0 staining 
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Figure 4.1: Viral proteins are produced earlier in infected nTERT cells than Vero cells.  
Confluent monolayers of nTERT or Vero cells were infected or mock infected (M) with wild-
type HSV-1 strain 17+ at a multiplicity of ten.  Cells were harvested into either NP40-based 
lysis buffer or SDS loading dye at the hours post infection (HPI) indicated.  Samples were 
equalised by protein concentration (NP40-based lysis buffer samples) or by the α-tubulin 
loading control (SDS loading dye) and analysed by western blot with antibodies as 
annotated.  Images are representative of three independent experiments. 
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Figure 4.2: ICP0 and VP22 are detectable earlier, and at higher levels, in nTERT cells than 
Vero cells.  Subconfluent monolayers of Vero or nTERT cells were mock infected, or infected 
with the GFP-22 recombinant virus, at a multiplicity of two.  After the indicated hours post 
infection, cells were fixed in 4% paraformaldehyde and immunofluorescence staining 
performed for ICP0, accompanied by nuclei staining (DAPI).  Images were captured on a 
Zeiss Axiovert S100 TV inverted fluorescence microscope and are representative of three 
independent experiments. 
Figure 4.2
CHAPTER 4 
 
 115 
Figure 4.2 continued
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in the nTERTs, however, was apparent in the nucleus and cytoplasm throughout the entire 
infection time course (figure 4.2).  Both figure 4.1 and 4.2 show early expression of IE viral 
proteins in nTERT cells, and figure 4.2 also shows overall enhanced levels of viral protein 
expression compared to Vero cells.  Taken together, this data indicates that the enhanced 
virus replication is initiated early in the replication cycle; upon the expression of immediate 
early viral proteins, or at a stage prior to this. 
4.3 CHARACTERISATION OF PML NUCLEAR BODY DISRUPTION IN KERATINOCYTE 
CELLS 
One early stage of virus replication involves the disruption of promyelocytic leukemia nuclear 
bodies (PML NBs), also known as ND10 domains, by the action of ICP0 (149).  These are 
heterogeneous domains within the nucleus consisting of non-constitutive and constitutive 
proteins including PML and SUMO (168).  They have been linked to a number of different 
cellular pathways, including apoptosis (26), ubiquitination (133, 143) and importantly it is 
thought that these domains are disrupted by ICP0 in an attempt to circumvent the cellular 
anti-viral IFN response (192).  If this response were to be deficient in nTERT cells then the 
infection would proceed without the requirement of disrupting these domains, and therefore 
theoretically could advance more rapidly.  This could explain the enhanced onset of 
replication in the nTERT cells, as Vero cells have been well characterised to contain PML 
NBs. 
To ascertain whether nTERT cells also contain PML NBs, cells were fixed and stained with 
an antibody to PML for analysis by immunofluorescence microscopy.  Small, punctate intra-
nuclear domains were evident in Vero cells, indicating the expected presence of PML NBs in 
uninfected cells (figure 4.3A).  Similar domains were also visible in nTERT cell nuclei, 
showing that these cells do indeed house PML NBs (figure 4.3A).  In order to quantify the 
disruption of these domains during infection, cells were mock infected or infected with wild 
type HSV-1 strain 17+ at a multiplicity of infection of two PFU per cell for the time indicated in 
order to count the number of PML positive domains present in infected cells (figure 4.3B).  
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The cells were stained with an antibody specific for ICP0 to ensure that only infected cells 
would be assessed for PML body quantification.  This also provided data on the proportion of 
cells expressing ICP0 at each time point, thus enabling quantitative comparison of ICP0 
protein expression to corroborate the data in figure 4.1 and 4.2 (figure 4.3C).  Uninfected 
Vero cells contained, on average, ten PML-positive foci per cell nuclei, while uninfected 
nTERT cells had two fewer PML-positive foci per nuclei than Vero cells (n=100).  Over the 
course of the infection, the number of PML-positive foci present diminished at a comparative 
rate in both cell types, with nearly all foci disappearing by 3 hours post-infection.  This 
suggests that nTERT cells contain PML NBs, which are disrupted during infection in a similar 
manner, and to a similar extent, as in infected Vero cells, and therefore is probably not 
accountable for the enhanced replication identified in nTERT cells. 
As the cells for this experiment were stained with an antibody specific for the immediate early 
viral protein ICP0, this enabled the quantification and comparison of expression between the 
Vero and nTERT cells in order to supplement the qualitative data collected in figure 4.1 and 
4.2 (figure 4.3C).  One hundred cells positive for DAPI-staining were scored for their ICP0 
status at each of the times during infection indicated in the PML counting experiment (figure 
4.3B).  Mock infected cells showed no background staining for ICP0, ensuring the ICP0 
staining is only seen in infected cells.  After one hour of infection almost 20% of the Vero 
cells were positive for ICP0 staining, and this increased steadily to 70% by 4 hours post-
infection (figure 4.3C).  In contrast as early as one hour post-infection more than 50% of 
nTERT cells were already positive for ICP0 staining, and this increased only modestly to 
between 70 and 80% by 3 hours post-infection, with Vero levels only drawing equal one hour 
later, at 4 hours post-infection (figure 4.3C).  This quantifiably corroborates the conclusions 
drawn from figures 4.1 and 4.2; namely that ICP0 protein expression is more rapid in nTERT 
cells than Vero cells. 
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Figure 4.3: PML-body disruption is equivalent in Vero and nTERT cells.  (A) Subconfluent 
layers of nTERT or Vero cells were fixed with 4% paraformaldehyde and 
immunofluorescence staining performed for PML-bodies (antibody DB75, green) and 
accompanied by nuclei staining (DAPI, blue).  (B and C) Subconfluent layers of nTERT or 
Vero cells were mock infected (M) or infected with wild type HSV-1 s17+ virus, at a 
multiplicity of two for the times indicated.  Cells were then fixed with 4% paraformaldehyde 
and immunofluorescence staining performed as described above with the addition of an ICP0 
specific antibody.  ICP0-expressing cells (B) or the number of PML-bodies per ICP0-
expressing cell (C) were quantified, with at least 100 cells counted in three independent 
experiments, a representative experiment is given with mean and ± standard error of data; * 
p < 0.05; ns - not significant.  Images were captured using a Zeiss Axiovert S100 TV inverted 
fluorescence microscope. 
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Figure 4.3
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4.4 USE OF A β-GALACTOSIDASE EXPRESSING VIRUS AS A REPORTER FOR 
IMMEDIATE EARLY GENE PROMOTER ACTIVITY 
As has been shown, initiation of enhanced virus replication in nTERTs appears to stem from 
a stage prior to, or upon the expression of immediate early viral proteins.  Therefore, an 
assay was designed to identify whether immediate early viral gene induction was also 
augmented in these cells.  The 110lacZ virus was kindly donated by Stacey Efstathiou 
(Cambridge University, UK) and utilised as a reporter virus for immediate early gene 
initiation.  This is an sc16 background virus containing the bacterial gene lacZ linked to an 
ICP0 promoter, inserted in the non-essential gJ locus (131).  To first establish whether this 
virus had comparable replication kinetics to wild type HSV-1 strain 17+ (which has been 
used for most of the work detailed so far), a one-step growth curve of the 110lacZ virus at a 
multiplicity of ten was carried out in both Vero and nTERT cells.  Total infectious progeny 
was harvested and the resultant growth curves demonstrate that replication of 110lacZ virus 
retains similar features to the kinetics of s17+, namely that virus progeny is detected earlier 
in nTERT cells (at six hours, rather than ten) and that the overall virus titre reached is ten fold 
higher than in the Vero cells (figure 4.4A). 
To confirm that this virus was able to produce detectable β-galactosidase from the inserted 
lacZ gene in our infected cells monolayers of Vero cells were infected with serial dilutions of 
the 110lacZ virus and incubated until plaques were visible by eye.  The cells were fixed and 
β-galactosidase activity was visualised by adding X-gal (an analogue of the enzymes target, 
lactose), which is hydrolysed and forms a blue product.  Plaques are visible as clear areas 
surrounded by a ring of blue stained cells, demonstrating the activity of the β-galactosidase 
in these infected cells and therefore permitting the use of this virus for the next stage of work 
(figure 4.4B).  In order to use this virus to analyse ICP0 promoter activity in a quantifiable and 
higher throughput setting, a β-galactosidase assay was optimised.  The 110lacZ virus was 
titrated onto monolayers of nTERT cells in 96-well plates and incubated for one hour prior to 
removing the inoculum.  After four hours further incubation, cells were lysed and the activity 
of the ICP0 promoter assessed by the addition of the reagent ONPG.  Upon the hydrolysis of 
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ONPG by β-galactosidase a measurable yellow colour with a peak absorbance of 420 nm is 
produced.  Mock infected wells were used to remove any background readings obtained 
through this procedure.  At dilutions of 10-1 and 10-2 the β-galactosidase activity had reached 
its limit, however with further dilution of the virus a more linear relationship between activity 
and virus dilution is seen, with readings becoming minimal from dilutions of 10-5 and more 
(figure 4.4C).  The measured β-galactosidase activity was proportional to virus 
concentration, as expected, thus confirming the assay’s use for comparison of ICP0 
promoter activity. 
Vero and nTERT cells were infected with the 110lacZ virus at a multiplicity of ten PFU per 
cell in 96-well plates for one hour before replacing with fresh media for the times indicated.  
At each time point, cells were lysed and β-galactosidase activity measured.  The activity was 
recorded as β-galactosidase in mU per 105 cells to allow direct comparison between the two 
cell types.  In the Vero cells, activity is only detected from 3 to 4 hours post-infection, in 
comparison to 2 hours post-infection in nTERT cells (figure 4.4D).  By 6 hours post-infection 
levels of β-galactosidase activity are also three times higher in nTERT cells than in Vero 
cells (figure 4.4D).  This suggests that ICP0 promoter activity is induced earlier and to a 
greater extent in nTERT cells than Vero cells. 
4.5 CHAPTER DISCUSSION  
In this chapter enhanced virus replication in nTERT cells has been shown to stem from an 
event prior to, or upon the initiation of, IE viral promoter activity.  In nTERT cells viral 
expression of both immediate early and late proteins is detected prior to their counterparts in 
infected Vero cells (figure 4.1).  This is the case by both western blot and 
immunofluorescence analysis (figure 4.1 and 4.2).  This would suggest that the origin of 
enhanced replication in nTERT cells is upstream of viral protein expression, even the very 
first proteins to be made - the IE proteins.  Further to this we have demonstrated by the use 
of a reporter-promoter assay that the initiation of viral gene transcription is also enhanced 
(figure 4.4), limiting yet again the window in which enhancement could originate.  The 
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Figure 4.4: Immediate early viral promoter activity is initiated earlier and to a greater extent 
in infected nTERT cells than Vero cells.  (A) Confluent nTERT or Vero cell monolayers were 
infected with 110lacZ virus at a multiplicity of two.  Total infectious progeny was harvested at 
the times indicated and titrated onto Vero cells.  (B) 110lacZ virus was titrated onto confluent 
monolayers of Vero cells.  When plaques were visible by eye, cells were fixed with 4% 
paraformaldehyde and X-gal stained.  (C) 110lacZ virus was titrated onto nTERT cells and 
allowed to infect for 4 hours before harvesting the cell lysate and assaying for β-
galactosidase activity.  (D) Vero or nTERT cells were infected with 110lacZ virus at a 
multiplicity of ten for one hour, before replacing the inoculum with fresh reduced serum 
media and incubating for further time points as indicated.  Cells were lysed and assayed for 
β-galactosidase activity (mU per 105 cells).  A representative of three independent 
experiments is shown as the mean and ± standard error of the data (A, C and D). 
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Figure 4.4
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possibility that nTERT cells are deficient in PML NBs, and therefore unable to illicit that 
particular anti-viral immune response to HSV-1 infection, was overturned by confirming that 
nTERT cells both contain PML NBs, and that these are disrupted during infection at a similar 
rate to that observed in Vero cells (figure 4.3).  Given these data, a very early event in virus 
replication is implicated in the enhanced infection of nTERT cells.  This could explain why 
virus replication seems to begin ahead of replication in Vero cells, as opposed to the overall 
higher virus titres (figure 3.5 and 3.6), which could still have a separate cause. 
4.5.1 VIRAL PROTEIN EXPRESSION IS INITIATED MORE RAPIDLY IN KERATINOCYTE 
CELLS 
In chapter 3, nTERT cells were shown to facilitate a more efficient virus infection, with a 
higher overall titre and what appeared to be an earlier onset of replication (figure 3.5).  As 
this was shown to be the case in single-step growth kinetics it can be hypothesised that a 
stage, or stages in a single round of replication are responsible for this phenomenon, and 
that spread of virus is not.  The viral protein expression patterns determined by western blot 
confirmed that virus infection does show an earlier onset in nTERT cells, particularly with the 
advanced expression of the IE proteins ICP0 and ICP27 2 hours prior to their detection in 
Vero cells (figure 4.1).  These findings are corroborated by the immunofluorescence staining 
for ICP0 and the GFP-VP22 signals in figure 4.2.  In these images, VP22 is indeed visible 
from 4 hours post-infection in nTERT cells, whilst only becoming apparent more faintly at 6 
hours post-infection in Vero cells.  ICP0 is seen in the Vero cells at two hours-post infection, 
which is earlier than indicated by western blot, however the levels are much lower per cell 
than in the nTERT cells at this time (figure 4.1 and 4.2).  Additionally, the ICP0 count shows 
that the number of Vero cells expressing ICP0 at this time was less than half the number of 
nTERT cells (figure 4.3C), and taken together, this would suggest that the 
immunofluorescence staining is more sensitive than the western blot, but that both still 
confirm that ICP0 production is more advanced in nTERT cells at early times post-infection.  
The fact that ICP0 is also seen to have already started translocating from the nucleus to the 
cytoplasm at 2 hours post-infection in the infected nTERT cells, a movement previously 
CHAPTER 4 
 
 125 
characterised in the literature (69, 124, 140), also suggests that this early stage of infection is 
far more advanced than in the Vero cells, where this translocation is not evident until 6-8 
hours post-infection (figure 4.2).  These data show that viral proteins are expressed earlier in 
infected nTERT cells than Vero cells, and of particular note, that this extends early in 
infection, to the IE viral proteins.  This suggests that enhanced replication in these 
keratinocytes originates upstream of IE protein synthesis.  
4.5.2 PML NUCLEAR BODY DISRUPTION IS COMPARABLE IN VERO AND nTERT 
CELLS 
As two different cell types were compared in this work, it is important to remember that 
cellular responses to virus infection may differ.  If nTERT cells were lacking in an anti-viral 
reaction then it could explain why HSV-1 is able to replicate more efficiently, as it would not 
have to take the time and resources required to address such a cellular attack.  Alternatively, 
it may be that HSV-1 is able to better overcome such an anti-viral response in nTERT cells 
and this could also explain the enhanced replication.  To complicate matters Vero cells are 
known to be defective in their own IFN-response, being unable to produce IFN (60, 73), 
which means that a barrier to infection is already removed in infected Vero cells.  We have 
noted that ICP0 levels are much higher early in infection in nTERT cells, and one anti-viral 
response known to involve ICP0 is the disruption of PML NBs.  Two potential pathways could 
be foreseen; either that HSV-1 is able to utilise elevated levels of ICP0 in infected nTERT 
cells to more efficiently abolish this anti-viral response, or, that nTERT cells are deficient in 
this response.  We were able to show that uninfected Vero cells contained, on average, ten 
PML-positive foci per cell nuclei, which is concurrent with the average found in published 
reports (13), and that the nTERTs also contained a comparable number of PML positive 
domains, 8 per cell.  One publication had already identified that keratinocytes did contain 
PML NBs and to a very similar level as our data (figure 4.3B and (13)), however this paper 
did not specify which keratinocyte cell type was used, hence the requirement for analysing 
the nTERTs themselves.  Although the overall number of PML-positive foci was slightly lower 
in the early stages of infection, they reached the same levels as in the Vero cells by 3 hours 
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post-infection, and they also started slightly lower in uninfected nTERT cells, thereby the rate 
of disruption was similar in both cell types (figure 4.3B).  The presence of PML NBs (figure 
4.3) therefore eliminates the second hypothesis - that nTERT cells are lacking these 
domains.  PML domain-counts in infected cells over time reduced in both cell types at a 
similar rate, whereby also eliminating the hypothesis that higher levels of ICP0 may be able 
to disrupt these domains more efficiently in nTERT cells (figure 4.3B).  This particular virus-
cell interaction is therefore probably not responsible for enhanced replication in nTERT cells. 
4.5.3 THE ICP0 PROMOTER IS ACTIVATED EARLIER AND TO A GREATER EXTENT IN 
INFECTED nTERT CELLS THAN VERO CELLS 
The ICP0 promoter reporter virus (110lacZ) was used for assessing the levels of virus 
promoter activity in the nTERT and Vero cells.  This virus was confirmed to have the same 
characteristics in growth kinetics as wild type virus (figure 3.5A and 4.4A), to generate a blue 
colour when incubated with X-gal (figure 4.4B) and to produce detectable β-galactosidase 
activity proportional to initial virus inoculum (figure 4.4C).  These features allowed for the use 
of the 110lacZ virus to monitor ICP0 promoter activity in infected nTERT cells in comparison 
with infected Vero cells.  Promoter activity, as measured by the β-galactosidase activity 
produced per cell, indicated that the ICP0 promoter is induced earlier, and to a higher level in 
nTERT cells (figure 4.4D).  This assay does not distinguish between rates of transcription 
and translation, however it suggests that this stage, upstream of protein synthesis, is also 
enhanced in nTERT cells.  The stage immediately prior to this is regulated by VP16 activity.  
VP16 is a viral transactivator which is recruited to the nucleus from the infecting virion to 
activate immediate early promoters.  This stage could be more efficient in nTERT cells and 
account for the higher promoter activity seen in the nTERT cells, as could more rapid capsid 
translocation to the nucleus, and would provide interesting stages to study further. 
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4.5.4 CONCLUDING REMARKS 
Conclusions drawn from the previous chapter (chapter 3) indicated that virus replication was 
enhanced at some stage in infected nTERT cells over Vero cells.  Here, later stages in 
infection have been ruled out by western blot, immunofluorescence and reporter assays to 
indicate an enhancement at an early stage of infection.  Further analysis of steps prior to or 
upon the initiation of ICP0 promoter activity, transcription and translation are necessary to 
fully characterise this enhancement in keratinocyte cells. 
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5.1 CHAPTER INTRODUCTION 
The conclusions drawn so far have led to the hypothesis that the enhancement in virus 
replication in nTERT cells stems from an early stage of infection, probably upstream of 
immediate early viral promoter activity.  Stages prior to this include viral DNA injection into 
the nucleus, trafficking of the capsid from the site of entry to a nuclear pore, and entry itself.  
As entry is the first stage of infection it is a logical stage to begin to characterise in these 
cells.  Entry can be thought of in two steps - the initial binding, or adsorption of the virus to 
the surface of the host cell, and the subsequent penetration into the cell, whether this is by 
plasma membrane fusion or endocytosis (discussed in section 1.5.1).  There are many 
variables which are cell type dependent and could therefore alter the rate of virus entry, for 
example the abundance of viral-entry receptors and the actual method of penetration, which 
appears to vary by cell-type.  This chapter aims to compare HSV-1 entry in nTERT and Vero 
cells. 
5.2 COMPARISON OF VIRUS ADSORPTION RATES IN nTERT AND VERO CELLS 
The rate of virus binding to the cell surface was measured using an adapted form of an 
adsorption assay (151).  Monolayers of nTERT or Vero cells were pre-chilled on ice before 
being infected with 200 PFU per well of wild type HSV-1 strain 17+.  Infections were 
maintained on ice to allow binding of the virus particles in the absence of energy for 
penetration.  The adsorption assay was also undertaken on ice to slow down the overall virus 
binding rate to allow for more detailed characterisation.  After each time point described in 
figure 5.1 the inoculum was removed and any unbound virus was removed by washing away 
before the cells were incubated at 37°C in fresh media containing HS, until plaques were 
observed to have formed.  The cells were fixed and the resultant plaques counted as PFU 
per well (figure 5.1A) or used to compare the overall rate of adsorption by calculating the 
percentage adsorption at each time, where the final plaque count at 180 minutes was 
considered 100% (figure 5.1B).  In this assay each resultant plaque that was counted must 
stem from a single virus particle which had bound to a cell whilst on ice.  The number of 
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PFU/well in both Vero and nTERT cells is similar at 5 mins post-infection, with approximately 
40 PFU/well (figure 5.1A).  The number of PFU/well increased over 3 hours in both cell 
types, however the PFU/well for each cell type began to diverge from about 30 minutes post-
infection, ultimately reaching 200 PFU/well in the Vero samples and a slightly higher value of 
250 PFU/well in nTERT samples (figure 5.1A).  Although the overall number of virus particles 
bound to the nTERTs was slightly higher than for the Vero cells, when calculated as 
percentage adsorption the actual rate of binding is almost indistinguishable between the two 
cell types (figure 5.1B).  The data from this experiment suggests that the rate of virus binding 
to the cell surface is not responsible for the advanced onset of replication in nTERT cells 
compared to Vero cells.  Therefore, a stage downstream of virus adsorption is most likely 
accountable. 
5.3 VIRUS PENETRATION IN VERO AND nTERT CELLS 
Virus penetration can be measured using an assay adapted from Huang and Wagner and 
Highlander et al (103, 109).  This involves using a low pH citrate buffer to inactivate any 
bound or extracellular virus particles (59) allowing only virus that has penetrated the cell to 
be protected from the citrate buffer treatment.  To optimise the conditions under which this 
experiment would be conducted, 6-well dishes of nTERT or Vero cells were pre-chilled on ice 
before being infected with equal units of wild type HSV-1 strain 17+ for one hour, again on 
ice.  After this period of virus binding, cells were mock treated, or treated with pH 3 or 1.5 
citrate buffer for 1, 2, or 5 minutes to inactivate bound and extracellular virus, followed by a 
wash stage to remove the buffer.  Plaques were allowed to form and cells were fixed and 
stained, with representative images shown in figure 5.2A.  Mock treated cells showed signs 
of normal plaque development in both cell types.  Regardless of treatment time, both cell 
types treated with the pH 1.5 citrate buffer showed signs of disruption, with patchy crystal 
violet staining in the nTERT cells, and very faint staining of the Vero cell monolayers, both 
compared to the pH 3 treated cells (figure 5.2A).  This indicated that pH 1.5 treatment was 
toxic to the cells, and therefore not appropriate to use for this purpose.  All the cells, 
however, treated with citrate buffer, were unable to produce plaques (figure 5.2A).  Even at 
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Figure 5.1: The rate of virus adsorption to the plasma membrane of the host cell is similar for 
both Vero and nTERT cells.  Confluent layers of nTERT or Vero cells were infected with 200 
plaques forming units of wild type HSV-1 s17+ per 6-well on ice.  After the indicated minutes 
post infection, the inoculum was removed and replaced with media containing human serum.  
The infection was allowed to develop for two days, when cells were fixed with formal saline 
solution and stained with crystal violet.  (A) Plaques were counted from experiments carried 
out in triplicate.  The mean and ± standard error of the data are given from one 
representative experiment (n=3).  (B) Data is also represented as the percentage adsorption, 
where the final plaque count (at 180 minutes) is taken as 100%. 
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Figure 5.2: HSV-1 is protected from acid washing in infected nTERT cells more rapidly than 
in Vero cells.  Confluent monolayers of nTERT or Vero cells were infected with equal 
numbers of plaque forming units of wild type HSV-1 s17+ per 6-well on ice for one hour.  (A) 
Cells were mock treated or treated with citrate buffer at pH 3 or 1.5 for one, two or five 
minutes, or (B) the inoculum was removed and replaced with media at 37oC and incubated 
for the indicated times, before treatment with pH 3 citrate buffer for 1 minute.  (A and B) After 
treatment, cells were washed and overlaid with media containing human serum.  The 
infection was allowed to continue for two days post infection, when cells were fixed with 
formal saline solution and stained with crystal violet to visualise plaque formation (A) or to 
count plaques (B).  Plaques were counted from experiments carried out in triplicate.  The 
mean and ± standard error of the data are given from one representative experiment (n>3).  
Data is displayed as either the number of plaque forming units counted per well, or as the 
percentage of viral particles protected from acid wash (% Protection) at each time, where the 
final plaque count (at 60 minutes post warming) is taken as 100%. 
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the lowest treatment time of one minute, plaque growth was inhibited and by extension, virus 
particles inactivated in the pH 3 citrate buffer treated cells.  This therefore confirmed that the 
use of pH 3 citrate buffer for one minute successfully inactivated bound virus. 
To measure the virus penetration rate, cells were pre-chilled and infected on ice with wild 
type HSV-1 strain 17+ for 1-2 hours to allow maximal virus binding, but not penetration.  The 
cells were then washed and overlaid with fresh pre-warmed media and warmed to 37°C for 
varying times to allow virus penetration to begin.  At each time point, including a well which 
remained on ice as the “0” minutes post-warming control, the cells were treated with pH 3 
citrate buffer for one minute to inactivate any extracellular virus particles.  The cells were 
incubated at 37°C until plaques large enough to count had formed.  The basis of this assay is 
that each plaque counted should relate to a single virus particle that was protected from 
citrate buffer inactivation, presumably by having penetrated the cell.  The cells were fixed 
and the resultant plaques counted as PFU per well or used to compare the overall rate of 
protection by calculating the percentage protection at each time, where the final plaque count 
at 60 minutes was taken to be 100% (figure 5.2B).  On comparison of the penetration assay 
in Vero and nTERT cells it became apparent that they differ greatly (figure 5.2B).  The control 
well of both cell types did not produce plaques, as expected (figure 5.2B, “0”) as these cells 
had not been warmed and therefore no virus was able to penetrate and be protected from 
citrate buffer inactivation.  In infected Vero cell-wells the number of PFU increased steadily 
until it reached a plateau at 60 PFU, 50 minutes post-warming (figure 5.2B, Vero).  In 
contrast, in nTERT cells the number of PFU/well reached its maximal point, approximately 
140 PFU/well, just 5-10 minutes post-warming and remained at this level for the duration of 
the experiment (figure 5.2B, nTERT).  This is also mirrored in the percentage protection 
rates, whereby nearly 100% protection was reached in the nTERT cells by 5-10 minutes 
post-warming compared to 50 minutes post-warming in the Vero cells (figure 5.2B, % 
protection).  This highlighted two differences - that virus protection in nTERT cells was far 
more rapid (maximal by 5 minutes) than in Vero cells (maximal by 50 minutes), and that the 
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absolute number of virus particles protected from citrate buffer treatment was about two-fold 
higher in nTERT cells (figure 5.2B). 
5.4 VIRUS PENETRATION ASSAYS IN OTHER CELL TYPES 
Although the nTERT cell type is a good model for keratinocyte infection, the rapid protection 
phenomenon shown in section 5.3 was compared only to a monkey kidney epithelial cell line.   
If this phenomenon were a feature of all human cell types, it would indicate that any human 
cell type used would also be permissive to rapid HSV-1 entry, and therefore the nTERT cells 
would not be unique in this feature.  To determine if this is the case, one further example of a 
monkey cell line, BSC1, and one further human cell line, HFFF2, were trialled in a 
penetration assay.  BSC1 cells are another epithelial cell line derived from African green 
money kidney origin, and HFFF2 cells which are primary human foreskin foetal cells.  Vero 
cells were compared to BSC1 cells using the penetration assay described in section 5.3, and 
in a separate experiment Vero and nTERT cells were compared to HFFF2 cells (figure 5.3).  
In both Vero cell infections the citrate buffer protection rate was similar to that seen in figure 
5.2B, with approximately 10% of virus particles being protected at 5 minutes post-warming, 
increasing over time and reaching a plateau after 50 minutes of warming (figure 5.3, Vero).  
The nTERT cells also maintained the same phenotype, peaking very early in the infection 
(figure 5.3, nTERT).  The new monkey cell line, BSC1, showed similar virus protection 
kinetics to the Vero cells.  The percentage protection increased steadily over the course of 
the experiment and also reached a plateau by 50 minutes post warming (figure 5.3, BSC1 
and Vero).  The initial rate was slightly enhanced compared to the Vero cells, with 25% 
protection at 5 minutes as opposed to 10% (figure 5.3, BSC1 and Vero).  The percentage 
virus protection rate in HFFF2 cells was also more comparable to that of Vero cells than 
nTERT cells.  Protection rates in both Vero and HFFF2 cells increased steadily at a similar 
rate and plateaued at around 50 minutes post-warming, although again the initial rate was 
moderately increased, with approximately 22% of virus protected in the HFFF2 cells in 
comparison to 5-10% (Vero) at 5 minutes post-warming (figure 5.3).  These data show that 
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Figure 5.3: Rapid acid protection of virus is a keratinocyte-specific phenotype.  Confluent 
monolayers of Vero, BSC1, nTERT or HFFF2 cells were infected with equal numbers of 
plaque forming units of wild type HSV-1 s17+ per 6-well on ice for one hour.  The inoculum 
was removed and replaced with media at 37oC and incubated for the indicated times, before 
treatment with pH 3 citrate buffer for 1 minute.  After treatment, cells were washed and 
overlaid with media containing human serum.  The infection was allowed to continue for two 
days post infection, when cells were fixed with formal saline solution and stained with crystal 
violet to count plaques.  Plaques were counted from experiments carried out in triplicate.  
The mean and ± standard error of the data are given from one representative experiment 
(n>3).  Data is displayed as the percentage of viral particles protected from acid wash (% 
Protection) at each time, where the final plaque count (at 60 minutes post warming) is taken 
as 100%. 
CHAPTER 5 
 
 139 
Figure 5.3
CHAPTER 5 
 
 140
the virus protection rate in Vero, BSC1 and HFFF2 cells is comparable, however the 
protection rate in nTERT cells was still greatly increased compared to these other cell lines.  
It is therefore likely that the rapid virus protection rate identified in the nTERT cells is unique 
to keratinocyte cells. 
5.5 CITRATE BUFFER PROTECTION AT LOW TEMPERATURE 
The temperature of the skin is not usually 37°C, therefore if HSV-1 enters its host at 
temperatures below 37°C, it would not be evident in penetration assays carried out at 37°C.  
A modified version of the penetration assay, where cells were infected on ice as before, but 
then shifted to a specific temperature for one hour before treatment with the citrate buffer, 
was carried out in a number of different cells.  The number of plaques counted at 37°C was 
taken to be maximal and set as 100%.  Another keratinocyte cell type, HaCaT, was chosen 
to compare in order to confirm that any results found in nTERTs are keratinocyte-specific 
(figure 5.4A, HaCaT).  BSC1 and HFFF2 cells were also used again, to compare with Vero 
and nTERT cells (figure 5.4B and C).  In all cell types tested there was no virus protection 
from citrate buffer treatment seen after incubation for a further hour on ice (0°C), as was 
expected for the control (figure 5.4).  In all three experiments where virus was allowed to 
penetrate Vero cells at 7°C, no virus was protected from citrate buffer treatment.  At 15°C, 
however, 10-20% of virus became protected, and this increased to 20-30% at 21°C (figure 
5.4, Vero).  In contrast, in nTERT and HaCaT cells, virus was protected at temperatures as 
low as 7°C (10-40%), and also to a greater extent at both 15°C (50-80%) and 21°C (70-90%) 
(figure 5.4A, nTERT and HaCaT).  This shows that virus is protected from citrate buffer 
treatment at 7°C in nTERT cells and to a greater extent at 15 and 21°C than in Vero cells.  
BSC1 cells, once again, were similar to Vero cells in the levels of virus protection at 7°C, 
although did show slightly higher percentages of virus protection at higher temperatures 
(figure 5.4B).  These levels were still lower than those in the nTERT cells.  HFFF2 cells too, 
were more comparable to Vero cells than nTERT cells, although at 7°C they did allow virus 
to be protected from citrate buffer treatment to a similar extent as the nTERT cells (figure 
5.4C).  Here it must be noted however, that only 10% of virus was protected at 7°C in nTERT 
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cells in this independent experiment, and that usually this percentage is slightly higher, as 
seen in the other example of nTERT protection (30-40%) (figure 5.4A and C).  The 
percentages of virus protection in these different cell types would suggest that virus can be 
protected from low pH treatment at much lower temperatures and to a greater extent in 
keratinocyte cells than the other cells tested. 
5.6 ANALYSIS OF CITRATE BUFFER-TREATED VIRUS PARTICLES BY ELECTRON 
MICROSCOPY 
The penetration assay relies on virus becoming protected from citrate buffer treatment 
presumably by being internalised into the cell through penetration.  However, given the 
unexpected results of section 5.5 (figure 5.4) it was considered whether this assay was able 
to distinguish between virus which is somehow protected on the surface of the cell and virus 
which has fully penetrated the cell membrane.  Treatment with low pH is known to inactivate 
HSV-1, however little is known about the specific effect on virus particles (109).  To address 
this, nTERT cells were infected on ice at a very high multiplicity of infection with ficoll-
gradient purified wild type HSV-1 sc16 to allow maximal pure virus binding and to 
synchronise entry.  Cells were treated on ice with either citrate buffer, or mock treated and 
then fixed and processed for analysis by electron microscopy.  The first observation from 
these samples was that virus was present in both cases, both with and without citrate buffer 
treatment, therefore indicating that treatment does not cause the virus to be washed away.  It 
became evident that two populations of virus were present in both samples: those with fully 
intact electron dense envelope, an intact capsid and visible nuclear material (figure 5.5A, 
Intact), or those which appeared to have a disrupted envelope (figure 5.5A, Disrupted).  One 
hundred virus particles were counted from each condition and assessed for whether their 
envelope was intact and electron dense material was visible within the capsid (figure 5.5A, 
Intact), whether their envelope looked disrupted (figure 5.5A, Disrupted), or an intermediate 
stage which could not be scored as fully intact or fully disrupted (figure 5.5A, Indistinct).  The 
vertical area required to count one hundred virus particles from each sample was 
comparable, indicating that there were not fewer virus particles overall in either sample.  The 
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Figure 5.4: HSV-1 is protected from acid washing in infected keratinocyte cells at lower 
temperatures compared to Vero, BSC1 and HFFF2 cells.  Confluent monolayers of nTERT, 
HaCaT, Vero, BSC1 or HFFF2 cells were infected with equal numbers of plaque forming 
units of wild type HSV-1 s17+ per 6-well on ice for one hour.  The inoculum was removed 
and replaced with media at the temperature indicated, and incubated at that temperature for 
1 h before treatment with pH 3 citrate buffer for 1 minute.  After treatment, cells were washed 
and overlaid with media containing human serum.  The infection was allowed to continue for 
two days post infection, when cells were fixed with formal saline solution and stained with 
crystal violet to count plaques.  Plaques were counted from experiments carried out in 
triplicate.  The mean and ± standard error of the data are given from one representative 
experiment (n>3).  Data is displayed as the percentage of viral particles protected from acid 
wash (% Protection) at each time, where the final plaque count (at 60 minutes post warming) 
is taken as 100%. 
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Figure 5.5: Viral membranes become disrupted on citrate buffer treatment.  One-day old 
monolayers of nTERT cells seeded in 60 mm dishes were pre-chilled on ice and infected with 
200 PFU per cell ficoll-gradient purified wild type HSV-1 sc16 on ice for one hour.  Cells were 
treated or mock-treated with citrate buffer pH3 for one minute before immediately fixing on 
ice and processing for analysis by electron microscopy.  (A) One hundred virus particles per 
condition were scored for the state of their envelope - intact, disrupted or indistinct.  (B) 
Electron micrograph images from vertical sections are shown with examples of virus particles 
for each status labeled “I”, intact; “D”, disrupted; “?”, indistinct. 
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majority of mock-treated virus particles (~70%) appeared to be intact with a full envelope, 
while only 20% were counted as being disrupted (figure 5.5B, Mock).  Conversely, in citrate 
buffer-treated samples almost 70% of the virus particles counted were disrupted in some 
way, and only approximately 30% were still intact (figure 5.5B, Citrate Buffer).  The 
proportion of indistinct virus particles (~10%) was similar in both samples (figure 5.5B, 
Indistinct).  Citrate buffer-treatment therefore appears to cause virus particle inactivation 
most likely by disrupting the virus envelope.  The particles, however, are still present to a 
similar level as in mock-treated infections, indicating that they are not washed away after 
treatment. 
5.7 ELECTRON MICROSCOPY ANALYSIS OF VIRUS PARTICLE LOCALISATION 
DURING RAPID-, AND LOW TEMPERATURE-ENTRY OF nTERT CELLS 
We have shown that not all virus particles are completely disrupted by low pH treatment 
(figure 5.5), therefore it is still possible that the results from the penetration assays in 
sections 5.3, 5.4 and 5.5 may still be caused by virus which was protected at the surface of 
the cell and not necessarily internalised.  For example, extensive cell membrane protrusions 
are characteristic of these cells (figure 5.6B) and could potentially shield the particles from 
acid washing.  To distinguish whether these particles were able to fully penetrate nTERT 
cells as rapidly as 5 minutes post-warming, and at temperatures as low as 7°C, electron 
microscopy was used to identify the location of the particles under these conditions.  
Monolayers of nTERT cells were infected on ice at a very high multiplicity of infection with 
ficoll-gradient purified wild type HSV-1 sc16, to allow maximal virus binding and to 
synchronise entry.  Cells were then shifted to 37°C for 5 minutes (figure 5.6), or 7°C for one 
hour (figure 5.7) before immediately fixing on ice and processing for analysis by electron 
microscopy. 
Samples infected for 5 minutes at 37°C were prepared either in horizontal or vertical 
sections, as indicated in figure 5.6.  Examination of the sections revealed the presence of 
intact virus particles on the surface of the infected keratinocytes, including two capsids 
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wrapped in a single envelope, illustrating the pleomorphic nature of HSV-1 particles (figure 
5.6A, labelled “ED”).  The vertical sections showed that these keratinocyte cells were highly 
enriched in plasma membrane protrusions and indicate a highly active cell periphery (figure 
5.6 B).  Crucially hexagonal profiles which were the same size as the capsids of external 
virus particles (figure 5.6A, “E”), containing an electron dense granular core (nucleic acid) 
were identified within the cell cytoplasm.  These profiles were most often identified near the 
plasma membrane and were always free in the cytosol, possibly indicating that entry was by 
PM fusion rather than endocytosis, however this cannot be confirmed in this experiment 
(figure 5.6A, arrows).  This provides evidence that viral capsids had penetrated keratinocyte 
cells and were readily observable.   
Infections incubated at 7°C showed evidence of extracellular enveloped virus particles at the 
surface of the keratinocytes (figure 5.7, labelled “E”), as expected.  Surprisingly, although 
less prevalent, profiles of capsids containing nucleic acid were identifiable intracellularly 
(figure 5.7, arrows), suggesting that HSV-1 is able to penetrate keratinocytes at 7°C.  These 
capsids were always observed at the cell periphery and often within a cell surface protrusion, 
which were still evident at this low temperature (figure 5.7). 
These electron micrograph images show that virus particles are able to enter the cytosol of 
keratinocytes, and are not merely protected on the extracellular surface after a 5 minute 
incubation at 37°C or one hour incubation at 7°C.  The fact that only free capsids were 
identified in the cytosol also suggests that virus particles had not been endocytosed, 
however further experiments would be required to confirm this. 
5.8 EFFECT OF TEMPERATURE ON ENDOCYTIC UPTAKE OF TRANSFERRIN 
As capsid profiles were identified within the cytosol of the infected nTERT cells in section 5.7, 
this suggests that virus is indeed entering keratinocytes at lower temperatures than in Vero 
cells.  To further characterise this route of entry Texas Red® transferrin was utilised to 
monitor endocytic uptake of the transferrin receptor by microscopy.  Cells were pre-incubated 
at the temperatures indicated in figure 5.8, before being maintained at the same temperature 
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Figure 5.6: HSV-1 is able to penetrate nTERT keratinocytes rapidly.  One-day old 
monolayers of nTERT cells seeded in 60 mm dishes were pre-chilled on ice and infected with 
200 PFU per cell ficoll-gradient purified wild type HSV-1 sc16 on ice for one hour.  Cells were 
then shifted to 37°C for 5 mins before fixing on ice for electron microscopy processing.  (A) 
Vertical and horizontal sections were analysed and representative images are shown.  
Arrows indicate internal viral capsids, “E” label external virus particles, “ED” label double 
enveloped capsids.  (B) A low magnification example of the complexity of the keratinocytes, 
with basal and apical sides labeled. 
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Figure 5.7: Virus particles are able to penetrate nTERT keratinocytes at 7°C.  One-day old 
monolayers of nTERT cells seeded in 60 mm dishes were pre-chilled on ice and infected with 
200 PFU per cell ficoll-gradient purified wild type HSV-1 sc16 on ice for one hour.  Cells were 
then shifted to 7°C for 60 mins before fixing on ice for electron microscopy processing.  
Vertical sections were analysed and representative images are shown with arrows identifying 
intracellular capsids.  Arrows indicate internal viral capsids, “E” label external virus particles. 
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Figure 5.8: Receptor mediated endocytosis of transferrin is inhibited at low temperatures.  
Monolayers of Vero and nTERT cells were incubated at various temperatures for 10 mins 
before the media was replaced with cell culture media containing Texas Red® conjugated 
transferrin (2.5 µg/ml) at the appropriate temperature for a further 30 mins.  Cells were then 
fixed in 4% paraformaldehyde and used the stain DAPI to label nuclei in blue.  Images were 
captured on a confocal Zeiss LSM510 META inverted laser-scanning microscope. 
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for a further 30 minute incubation period in the presence of media containing Texas Red® 
transferrin.  Cells were then washed of surface bound Texas Red® transferrin, and fixed for 
analysis by fluorescence microscopy.  At 37°C, as expected, a robust Texas Red® signal 
was detected in the cytoplasm of both nTERT and Vero cells as scattered punctate domains 
(figure 5.8, 37°C).  At 21°C this signal was reduced somewhat but still seen in the cytoplasm 
of nTERT and Vero cells as punctate domains, however at 15°C only very few punctate 
domains could be identified (figure 5.8, 21°C and 15°C).  The Texas Red® signal was almost 
completely absent at temperature of 7°C and below in both cell types (figure 5.8, 7°C and 
0°C), indicating loss of the ability of the cell to endocytose Texas Red® transferrin at these 
low temperatures. 
5.9 DEPLETION OF NECTIN-1 DURING INFECTION OF nTERT AND HeLa CELLS 
As the entry of HSV-1 has been shown to differ between keratinocyte and other cells, it is 
possible that a different entry mechanism is employed in these cells.  In particular, the virus 
entry receptors used on keratinocyte cells may vary from the well-characterised receptors 
such as nectin-1 and HVEM.  To begin to address whether this could be the case, siRNA 
transfection of four sets of duplexes was used to deplete nectin-1 (or a negative control 
siRNA) in nTERT and HeLa cells.  HeLa cells were used as a control as nectin-1 was 
originally identified from HeLa cell cDNA.  The nectin-1 depleted cells were then infected on 
ice with the 110lacZ virus for 1 hour to allow virus binding, followed by transfer to 37°C in 
fresh pre-warmed reduced serum infection media for a further 4 hours.  The cells were then 
harvested for quantification of β-galactosidase activity (in mU per well), which was used to 
give a measure of virus entry (figure 5.9A).  In nTERT cells transfected with nectin-1 siRNA 
the β-galactosidase activity was comparable to the control transfected cells, indicating that 
virus entry had not been affected (figure 5.9A, nTERT).  In contrast, transfection of HeLa 
cells with nectin-1 siRNA resulted in a reduction of virus entry by over 60% compared to the 
negative siRNA transfected cells (figure 5.9A, HeLa).  Attempts to quantify nectin-1 levels in 
both HeLa and nTERT cells proved difficult.  Eight different antibodies were acquired for 
analysis by western blot or immunofluorescence, however we were unable to successfully 
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detect nectin-1 with any under various conditions (data not shown).  Quantitation by qRT-
PCR has also proven problematic in nTERT cells, however nectin-1 levels during siRNA 
transfection of HeLa cells have been ascertained, which indicate a 99.8% reduction in nectin-
1 mRNA transcripts (figure 5.9B).  These results show that virus entry is partially inhibited in 
the absence of nectin-1 in HeLa cells and that nectin-1 appears to be dispensable for virus 
entry of nTERT cells.  This conclusion must be given with the caveat that the knock down is 
yet to be confirmed by nectin-1 quantification in nTERT cells. 
5.10 CHAPTER DISCUSSION 
Entry of HSV-1 into keratinocyte cells has been shown to differ greatly in both its rapidity and 
its permissive temperature in comparison to other cell types.  The rate of virus binding to 
both Vero and nTERT cells was shown to be equivalent (figure 5.1B), however it must be 
noted that the overall levels of virus binding were two-fold higher in nTERT keratinocytes 
(figure 5.1A).  Virus protection assays revealed that virus was rapidly protected from 
inactivation in nTERT cells compared to Vero, HFFF2 and BSC1 cells, suggesting that this is 
a keratinocyte specific phenomenon (figure 5.2 and 5.3).  Electron microscopy data also 
confirmed that citrate buffer treatment causes the disruption of extracellular virus particles, 
rendering them unable to enter and infect cells despite being in close proximity to the plasma 
membrane (figure 5.5).  The electron microscopy data also validated the results of the 
penetration assays as virus particles incubated at 7°C for one hour, or 37°C for 5 minutes 
were protected from citrate buffer inactivation because they had physically penetrated the 
plasma membrane and become internalised (figure 5.6 and 5.7).  The inhibition of Texas 
Red® transferrin into cells at low temperatures suggests that the method by which HSV-1 is 
able to enter nTERT, and possibly Vero cells, at these low temperatures is independent of 
this endocytic pathway.  The entry receptor nectin-1 also seems to be dispensable for virus 
entry in nTERT cells but not HeLa cells, suggesting a difference in reliance of virus entry 
receptors in keratinocyte cells.  These findings provide a new insight into the entry of HSV-1 
into human keratinocytes at temperatures below body temperature and also a potential 
source for the early onset of infection in nTERT cells compared to Vero cells. 
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Figure 5.9: Transfection of nTERT cells with siRNA to nectin-1 does not effect virus entry.  
nTERT or HeLa cells were reverse transfected with 100 nM/well nectin-1 siRNA (a pool of 
four duplexes, see table 2.2) or control (-) siRNA 72 hours prior to trypsinising and 
transferring to 96-well plates for infection (A) or harvesting the HeLa cells for mRNA 
extraction (B) 24 hours later.  (A) Cells were infected on ice with 110lacZ virus at a 
multiplicity of two PFU per cell for 1 hour prior to replacing the inoculum with fresh reduced 
serum media at 37°C and incubating for a further 4 hours.  Cells were lysed and assayed for 
β-galactosidase activity (mU per well).  (B) Cellular mRNA was then used to quantify the 
nectin-1 mRNA levels in the nectin-1 siRNA treated cells by qRT-PCR relative to (-) negative 
siRNA treated cells.  A representative of three independent experiments is shown as the 
mean and ± standard error of the data.  
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Figure 5.9
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5.10.1 THE RATE OF VIRUS ADSORPTION IS COMPARABLE IN nTERT AND VERO 
CELLS 
Virus adsorption assays can be used to measure the rate of virus binding to the cell surface 
(17, 151).  It can be carried out at temperatures between 4°C and 37°C, however higher 
temperatures result in faster completion due to higher energy movement of the virus particles 
in the liquid.  For this reason the assay described here was carried out on ice, to slow the 
process and thus enable a more detailed characterisation, over an extended time, of virus 
binding.  The rates of virus binding in both Vero and nTERT cells were very similar indicating 
no difference in the kinetics of virus adsorption, however overall levels of virus binding was 
two-fold higher in nTERT cells (figure 5.1).  Interestingly, this difference is consistent with the 
two-fold increase of virus titre in nTERT cells compared to Vero cells seen in figure 3.2C.  
This was found to be statistically insignificant at the start of this work and therefore not taken 
into consideration when titrating virus stocks, which were all titrated in Vero cells.  However, 
the results from the adsorption assay therefore suggest this increase to be valid and 
together, these data indicate that twice as many virus particles are able to bind to nTERT 
cells than Vero cells in the same period of time.  This could be due to higher levels of 
receptors on the surface of the keratinocytes, or perhaps improved access to the receptors.   
The adsorption assay is not a direct reading of binding as it relies on all the later replication 
stages to produce a plaque.  Therefore, it is possible that similar numbers of virus bind to 
both cell types, but that a downstream stage is inhibitory or absent in Vero cells thus 
impairing completion of the lytic stage of infection.  Alone, this two-fold increase in binding (or 
a later stage causing this) cannot explain the early onset of infection in nTERT cells, or the 
overall ten-fold enhancement in replication compared to Vero cells (figure 3.5).  It is likely 
that it plays a role only in combination with other factors downstream. 
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5.10.2 VIRUS IS PROTECTED FROM CITRATE BUFFER INACTIVATION RAPIDLY IN 
KERATINOCYTE CELLS 
As the rate of virus binding to the nTERTs was similar to Vero cells, the next stage of entry 
was investigated using a penetration assay.  This assay was successfully optimised in 
nTERT and Vero cells to allow inactivation of bound virus on ice using a pH 3 citrate buffer 
(figure 5.2A) (59).  The initial findings of the penetration assay showed that virus became 
maximally protected from acid-inactivation as early as 5 minutes post-warming in the nTERT 
cells, suggesting that all the virus is protected considerably more rapidly compared to Vero 
cells (figure 5.2B).  The overall levels of virus penetration were twice as high in nTERT cells 
and this is consistent with results discussed in section 5.10.1.  A two-fold increase in virus 
binding of nTERT cells would presumably equate to a protection rate of half that in Vero 
cells, however it became maximal after only 5-10 minutes of warming; five to ten times faster 
than the 50 minutes required in infected Vero cells (figure 5.2B).  The two-fold increase in 
virus numbers bound to nTERT cells seen in the adsorption assay (figure 5.1), cannot on 
their own explain the exceptionally rapid virus protection seen in nTERT cells (figure 5.2B).  
This rapid virus protection from acid-wash is remarkable and could potentially explain the 
early onset of virus replication in nTERT keratinocytes. 
5.10.3 HSV-1 IS PROTECTED FROM LOW pH TREATMENT AT TEMPERATURES AS 
LOW AS 7°C IN nTERT KERATINOCYTES 
Virus penetration assays were carried out at 37°C as this is generally considered to be 
human body temperature.  However, this is the core temperature and the site of HSV-1 
infection, the skin or lips, have the potential to be at quite different temperatures.  In fact, 
measurements of the skin can vary greatly depending on the external environment (in one 
study measurements from 14-33°C were found from one subject) and are not uniform across 
the different areas of the surface of the skin (temperatures across different areas of the body 
can vary by up to 10°C or more in normal situations) (24, 25).  For this reason the effect of 
temperature on virus penetration was investigated.  These results indicated that 37°C was 
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still the most efficient temperature for virus protection from acid-wash, however temperatures 
below 37°C did not completely inhibit virus protection (figure 5.4).   Although the skin may be 
at temperatures lower than 37°C, sites of HSV-1 infection are thought to require abrasion or 
damage for access to nucleated keratinocyte cells below the cornified layer (203).  
Consequently these areas are likely to be subject to inflammation and therefore suffer from 
raised temperatures, perhaps explaining why virus-protection was still most efficient at 37°C 
(figure 5.4). 
Interestingly, virus was still protected from citrate buffer treatment at temperatures lower than 
37°C, indicating that HSV-1 may still be able to enter the skin under less optimal conditions.  
Results from this experiment showed that percentages of protected virus decreased with 
decreasing temperature in both Vero and nTERT cells, as might be expected, however the 
levels were always higher in nTERT cells (figure 5.4).  Strikingly, at 7°C, when no virus was 
protected in Vero cells, almost 40% of virus particles were still protected from citrate buffer 
treatment in the nTERT cells (figure 5.4), demonstrating a potentially different mechanism of 
penetration in nTERT keratinocytes at low temperatures. 
5.10.4 RAPID VIRUS PROTECTION AND PROTECTION AT 7°C IS SPECIFIC TO 
KERATINOCYTE CELLS 
In order to prove that the virus protection seen in nTERTs at very early times post-warming 
and at low temperatures, is specific to keratinocyte cells and not an artefact of the two 
particular cell types studied, other cell types were also applied to these experiments.  The 
levels of virus protection were very similar in both keratinocyte cell types (figure 5.4, HaCaT 
and nTERT), confirming that entry at low temperatures was not simply due to a peculiarity of 
the nTERT cells.  Virus was not protected as efficiently at low temperatures in BSC1 cells 
and only a third of virus was protected at 5 minutes post-warming, indicating that the 
phenomenon seen in nTERT cells is species specific (figure 5.3 and 5.4, BSC1 and Vero).  
The use of HFFF2 cells was two-fold; not only did it provide another human cell type to 
compare, but these fibroblasts are another example of cells found in the skin.  The 
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comparison of the keratinocytes to these fibroblast cells showed that the fibroblasts behaved 
more like the Vero cells in both the assays (figure 5.3 and 5.4).  These comparisons come 
together to confirm that rapid and low-temperature virus protection among the cells tested, is 
not just specific to human skin, but is also the exclusive behaviour of keratinocyte cells.  This 
lends further support to the use of nTERT keratinocytes as a model cell type for the study of 
HSV-1 infection. 
5.10.5 CITRATE BUFFER INACTIVATION RESULTS IN VIRAL ENVELOPE DISRUPTION 
The penetration assays used in this thesis make the assumption that all external virus 
particles are inactivated by low pH treatment therefore any virus which survives this 
treatment must have penetrated the cell membrane.  Although penetration assays are used 
routinely and acid treatment is a common method for inactivating viruses, the affects of low 
pH treatment on virus particles are not well characterised.  Inactivation of HSV-1 with pH 3 
treatment, results in 99.8% reduction in infectivity (109), and this is thought to be due to 
conformational changes of viral proteins caused by the acidic conditions, however it is 
unknown whether this reverses virus binding or if it is a permanent effect.  If citrate buffer 
inactivation is not effective on all external virus particles of nTERT cells for some reason, this 
could mean that the penetration assay was no longer valid for distinguishing between virus 
protection at the surface and virus penetration.  Electron microscopy analysis of virus 
particles at the surface of nTERT cells showed that under normal conditions approximately 
70% of virus appeared to have a fully intact envelope and nucleic acid within the capsid 
(figure 5.5B).  After pH 3 citrate buffer treatment, the number of virus particles within the 
same surface area was maintained, therefore virus particles were not being washed away by 
treatment.  The proportion of intact particles was reduced to 25% after treatment and a large 
population of virus particles with disrupted envelopes and occasionally genomic material 
released from the capsid was identified (~65%, figure 5.5B).  A small proportion of particles 
were unable to be scored as intact or disrupted (<10% in both samples), this is probably due 
to profiles of some particles being off centre in the section, and therefore having less finely 
distinguished characteristics.  These data provided evidence that low pH treatment causes 
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virus particle envelopes to become ruptured or disrupted, presumably reducing the stability of 
the particle, resulting in the loss of a stable envelope and ultimately causing the particle to 
become non-infectious.  After citrate buffer treatment a small proportion of virus particles 
were scored as intact (~30%, figure 5.5B).  This population could potentially be responsible 
for the ‘penetration rate’ seen at 7°C in nTERT cells (figure 5.4).  Alternatively it is also 
possible that this proportion could be even slighter as it is difficult to fully evaluate the state of 
a single virus particle (120-300 nm in diameter) in one thin section by electron microscopy, 
as a thin section is usually 50-70 nm.  Optimally the profile would be through the centre of 
the particle but this is not always the case and given that the section does not span the 
whole diameter of the particle, some particles may have been disrupted in an area beyond 
the field of vision.  The complete reduction in plaque formation after citrate buffer treatment 
of infections on ice, and the published reduction in infectivity by 99.8% (109) would also 
suggest that acid-washing does almost completely inactivate all virus particles.  These 
results suggest that HSV-1 is inactivated by citrate buffer treatment through disruption of the 
virus particle, however this does not seem to reverse virus binding. 
5.10.6 VIRUS IS ABLE TO PENETRATE nTERT CELLS RAPIDLY AND AT LOW 
TEMPERATURES 
The penetration assay indicated that 40% of virus is still protected from acid-wash, and by 
extension able to penetrate nTERT cells at 7°C (figure 5.4).  This seems an unlikely scenario 
at such a low temperature.  Given that virus particles are not washed away after citrate buffer 
treatment and that a proportion of particles were scored as intact, it is possible that instead of 
fully penetrating the nTERT cells the virus is protected by structures on the surface of the cell 
(perhaps the extensive membrane protrusions identified in figure 5.6B), or perhaps at an 
intermediate stage of penetration.  Electron microscopy was used to analyse the localisation 
of virus particles in nTERT cells infected on ice for one hour, then either for one further hour 
at 7°C or 5 minutes at 37°C.  This allowed the results of both penetration assays to be 
validated as actual penetration, or an intermediate protection stage.  For this analysis, a high 
PFU-to-cell ratio was required to give a suitable number of virus particles to analyse in thin 
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sections.  Due to difficulties isolating large enough quantities of purified wild type HSV-1 
sc16, this assay was only carried out in nTERT cells, however this was considered adequate 
as keratinocytes were the focus of this work. 
In both the 7°C and the 5 minute conditions, virus capsids were identified free in the cytosol 
(figure 5.6 and 5.7), confirming that definite penetration of HSV-1 is able to occur at 7°C and 
after only 5 minutes in keratinocyte cells.  At 7°C the capsids were always found at the cell 
periphery, probably because the microtubule network would be unable to function to 
transport the capsid away from the periphery at such a low temperature, therefore providing 
an accumulation of capsids in the cytosol near the cell surface.  It is possible to conclude, 
upon the basis of both the penetration assay and the electron microscopy results, that HSV-1 
is able to penetrate nTERT cells at 7°C, and following external acid washing and warming to 
37°C, is able to complete a successful infection resulting in plaque formation. 
Virus capsids were seldom identified near the cell periphery at 37°C, however this is most 
likely because the entry and translocation process is highly dynamic, therefore the window of 
opportunity for capturing a recently entered capsid is small by electron microscopy.  This 
would mean that many virus particles which had successfully entered the nTERT cells were 
probably missed during this analysis. 
All the examples of internal capsids shown (figure 15 and 16) were of free cytosolic capsids.  
Although it is possible that release from endocytic vesicles was too rapid to identify the 
intermediate-enveloped stage, it is unlikely that both endocytosis and a further fusion stage 
would be more rapid that a single fusogenic step.  It is therefore more likely that PM fusion is 
the method of HSV-1 entry in nTERT cells at both 37°C and 7°C. 
5.10.7 LOW TEMPERATURE VIRUS PLASMA MEMBRANE FUSION IN nTERT CELLS 
HSV-1 is thought to be able to enter cells via different methods, the best characterised routes 
being endocytosis and plasma membrane fusion (discussed in section 1.5.1).  The 
penetration of HSV-1 into keratinocyte cells at 7°C is intriguing as such a low temperature 
would presumably reduce the efficiency of an endocytic entry mechanism which intrinsically 
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requires energy.  This assumption was validated by the inhibition of endocytic uptake of 
Texas Red® transferrin in both nTERT and Vero cells at temperatures below 15°C (figure 
17).  This is highly suggestive that the endocytic pathway used by the transferrin receptor is 
not responsible for the entry of HSV-1 seen in nTERT cells at 7°C and supports our 
hypothesis that PM fusion is the likely entry method in keratinocytes. 
5.10.8 NECTIN-1 IS DISPENSABLE FOR HSV-1 INFECTION OF nTERT CELLS 
Preliminary work on the roles of cellular receptors required for HSV-1 entry into keratinocytes 
has been presented in section 5.9.  Keratinocytes have been shown to facilitate rapid virus 
entry and allow entry at low temperatures, in contrast with other non-keratinocyte cells 
routinely used for HSV-1 study (section 5.3-5.7).  This would suggest a different method of 
entry may be employed into keratinocyte cells, and it is possible that this could involve the 
use of different entry receptors.  Past conjecture over the necessity of the entry receptor 
nectin-1 for virus entry of keratinocytes has been raised, when anti-nectin-1 antibody was 
unable to fully inhibit virus entry into HaCaT cells (110) and when nectin-1 did not colocalise 
to sites of virus entry in primary keratinocytes (203).  The requirement for nectin-1 in HSV-1 
entry was demonstrated to be partially necessary in HeLa cells (the cDNA of which was used 
to identify nectin-1 originally (242)) in figure 5.9, however it seemed to be completely 
indispensible in nTERT cells.  This could be because it is redundant and HVEM or another 
virus entry-receptor is able to compensate, however it could also be the case that another 
receptor, or coreceptor exists for entry into keratinocyte cells.  Although confirmation of 
nectin-1 depletion in the nTERTs was not achieved by any of the various methods rigorously 
trialled (Western blotting, immunofluorescence with eight different commercial/non-
commercial antibodies or qRT-PCR), the data shows that the nectin-1 siRNA were able to 
reduce nectin-1 transcripts by 99.8% in HeLa cells under the same conditions (figure 5.9B).  
These conditions have also been used previously in nTERT cells to successfully deplete 
specific Rab proteins (chapter 6) and this therefore increases the confidence that the 
transfection is successful in the nTERT cells.  If nectin-1 is unnecessary for HSV-1 infection 
of nTERT cells, this leads to the possibility that one of the other characterised receptors 
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could be the main entry-point for HSV-1, or alternatively that an as yet uncharacterised 
receptor may be used by HSV-1 to enter keratinocyte cells. 
5.10.9 CONCLUDING REMARKS  
Chapter 2 narrowed down the window of origin of enhanced replication in nTERTs to be an 
early stage of infection prior to, or upon the induction of IE promoter activity.  This chapter 
provides evidence that early onset infection in nTERT cells may stem from rapid penetration 
of the virus into the host cell, most likely via plasma membrane fusion.  There may be other, 
as yet unidentified stages downstream of entry which could also add to the enhanced 
infection of keratinocytes and therefore would necessitate further investigation.  These data 
also suggest that HSV-1 is able to enter keratinocytes at lower temperatures than Vero cells, 
probably through a plasma-membrane fusion type event and likely in a nectin-1 independent 
manner.  It is likely, therefore, that a different mechanism of entry is engaged in keratinocytes 
and further work will be required to fully characterise this. 
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The Role of Rab GTPases in HSV-1 
Infection of nTERT Keratinocytes 
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6.1 CHAPTER INTRODUCTION 
As a group with a strong interest in assembly there has been a focus on the role of Rab 
GTPases (as modulators of the secretory system) in infection in our work.  These proteins 
are required for regulating vesicle trafficking and so are of interest to our group as tools to 
study the maturation of HSV-1 in relation to cellular membrane trafficking and identity (96, 
122, 224).  To date there have been several reports of Rab proteins being involved in the 
infection processes of other viruses, including HIV and FMDV entry (Rab6 (33); Rab5 (117), 
Influenza A budding (Rab11 (36)), HCMV intracellular localisation (Rab6 (115)) and 
ebolavirus particle formation (Rab1, (249)).  Recent work has also identified a role for Rab1 
and Rab43 in HSV-1 infection (254).  We have also confirmed the role of Rab1 in HSV-1 
infection and further shown an involvement of Rab5, 6 and 11 in infection of HeLa cells 
(107)(unpublished data, Elliott Group, Imperial College, London).  Rab proteins have also 
been identified within mature virions (141)(unpublished data from the Elliott Group, Imperial 
College, London).  Early work in infected cells has identified several Rab proteins which, 
when depleted, result in a deficiency in virus maturation (unpublished data, Elliott Group, 
Imperial College, London).  This work was carried out in HeLa cells as the siRNA library 
used, targeting 60 human Rabs, had been validated in these cells previously.  Depletion of 
Rabs 1, 5, 6 and 11 individually using siRNA had the greatest effect on virus titre in infected 
HeLa cells (Rab6 depletion reduced virus yield to <1% of the negative control treated cells, 
Rab1 depletion to <2% and Rab5 and 11 depletion to <10%) and indicated that a specific set 
of Rabs were required by the virus for replication in HeLa cells (unpublished data, Elliott 
Group, Imperial College, London).  Given our interest in keratinocytes as the more 
physiologically relevant cell type for HSV-1 infection, we set out to ascertain whether this 
same set of Rabs would be required for infection of nTERT cells, or whether different Rab 
proteins play a role in keratinocytes.  As such, the same library of siRNA directed towards 60 
individual Rab proteins was also used in infected nTERT cells to identify a population of 
Rabs important for infection.  This chapter describes the optimisation of the RNAi technique 
in nTERT cells prior to the screening of Rab proteins in infected keratinocytes and the 
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subsequent identification and basic characterisation of the Rab proteins that had the greatest 
effect on HSV-1 infection. 
6.2 ESTABLISHING TRANSFECTION TECHNIQUES IN nTERT CELLS 
In order to screen 60 human Rab proteins with the siRNA library, transfection procedures for 
RNAi required optimisation.  There are a number of different transfection techniques and 
reagents for delivering siRNA into a cell.  LipofectamineTM 2000 was used successfully when 
screening in HeLa cells and so was considered suitable to use when optimising the 
technique in nTERT cells.  Initially, optimal cell density upon infection was established by 
seeding varying numbers of cells one day prior to transfection with an siRNA against Importin 
β .  This siRNA was employed because it had been used with success in HeLa cells and a 
suitable antibody was available for confirming the knockdown by western blot.  A commercial 
siRNA with no homology to any sequence in the human genome was used as a negative 
control in these experiments.  An efficient reduction in Importin β  was obtained only with 
transfection of the lowest cell density (2.5 x 104 cells per well), whilst no reduction in protein 
detection by western blot was evident at higher cell densities (figure 6.1A).  This indicated 
that a much lower density was required for successful transfection of nTERT cells using 
LipofectamineTM 2000 than the protocol recommended, however this lower density was used 
in all future experiments.  The amount of transfection reagent and siRNA were also tested, 
this time using Rab6 siRNA as this siRNA would be used in the future screen and would 
allow the opportunity to begin to optimise Rab protein western blotting protocols for nTERT 
cell lysates.  The volume of LipofectamineTM 2000 used per well seemed to have no tangible 
effect on the depletion of Rab6 as detected by western blot (figure 6.1B).  Rab6 protein was 
reduced with both 5 and 20 nM siRNA, however the higher concentration seemed to have a 
slightly greater effect (figure 6.1B).  The cells in these experiments were harvested 48 hours 
post-transfection, however in the event that Rab6 protein has a long half-life in the cell, the 
transfection was allowed to progress for 72 hours to ascertain the ideal harvesting time.  
Both times post-transfection resulted in an efficient reduction in the detection of Rab6 
protein, although there was a faint band at 72 hours post-transfection with 2µl  
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Figure 6.1: Reduction of target protein expression by siRNA transfection is possible in 
nTERT cells.  (A) One day prior to transfection nTERT cells were seeded at the indicated 
densities per 24-well.  Cells were transfected with 5 nM/well siRNA targeting Importin-β (Iβ).  
Cells were harvested 72 hours post-transfection and an antibody targeting Iβ was used for 
analysis by western blotting.  (B) nTERT cells were seeded at 2.5 x 104 per well one day 
prior to transfection with 1 or 2 µl Lipofectamine and 5 or 20 nM per well siRNA, targeting 
Rab6.  Cells were harvested 72 hours post-transfection and an antibody targeting Rab6 was 
used for analysis by western blotting.  (C) One day after seeding nTERT cells were 
transfected with 1 or 2 µl Lipofectamine and with 10 nM per well Rab6 siRNA.  Cells were 
harvested 48 or 72 hours post-transfection and an antibody targeting Rab6 was used for 
analysis by western blotting.  (D) Cells were either seeded one day prior to transfection 
(Forward method) or transfected at the time of seeding (Reverse method) with siRNA 
targeting Rab6.  Cells were harvested for western blot analysis 72 hours post-transfection 
and probed for Rab6.  Cell were transfected with negative siRNA as a control (-) and an 
antibody to α-tubulin was used as a loading control by western blot in all cases. 
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Figure 6.2: HSV-1 infection is not restricted in nTERT cells by siRNA transfection.  nTERT 
cells were seeded and transfected simultaneously (Reverse transfected) in 24-well plates 
with either negative siRNA (-), no siRNA (Lipofectamine) or no transfection reagents (Mock).  
Cells were then infected 72 hours post-transfection with HSV-1 wild type s17+ virus at a 
multiplicity of two.  Extracellular or cell-associated viral progeny was collected at the 
indicated time points and titrated onto Vero cells.  A representative of three independent 
experiments is shown, with the mean and ± standard error of the data given. 
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LipofectamineTM 2000 indicating that the knockdown may have begun to become less 
efficient (figure 6.1C).  Therefore the lower level of LipofectamineTM 2000 was chosen as it 
was likely to produce less cytotoxicity in cells (figure 6.1C).  All these methods had been 
carried out using forward transfection, whereby cells are seeded 24 hours prior to 
transfecting, however it is also possible to transfect and seed cells simultaneously (known as 
reverse transfection) and this would theoretically avoid some problems which had become 
apparent with cell clumping before transfection.  These methods were directly compared at 
72 hours post-transfection (forward transfection samples had therefore been growing 24 
hours longer and thus had a slightly higher α-tubulin content overall) and resulted in a more 
efficient Rab6 knockdown by the reverse method than the forward method as indicated by 
the fainter Rab6 band in the reverse sample with Rab6 siRNA (figure 6.1D).  Reverse 
transfection for 72 hours would therefore allow for a simpler experimental set up and more 
efficient depletion of the specifically targeted protein in keratinocyte cells and provide the 
conditions required to carry out the siRNA screen in these cells. 
It was important to establish whether transfection of nTERT cells would affect infection 
efficiency as it is possible that the cellular responses could be primed by siRNA transfection 
to deal with infection and so create an environment in which virus infection would be resisted 
by host immune mechanisms such as induction of the anti-viral cytokine Interferon (21).  Wild 
type HSV-1 strain 17+ was used at a multiplicity of two to infect nTERT cells either mock 
transfected, transfected with only LipofectamineTM 2000, or in addition with negative siRNA.  
Extracellular or cell-associated virus was harvested at various times post-infection and 
titrated onto Vero cells.  For all conditions tested, virus growth kinetics were almost 
indistinguishable, following a pattern of initial lag at 4 hours post-infection in cell-associated 
virus, and still at 6 hours post-infection in extracellular virus, then a logarithmic phase of virus 
production resulting in final overall titres of 1 x 106 to 1 x 107 PFU/ml in both intra- and extra-
cellular virus titres (figure 6.2).  These patterns of virus production are also in agreement with 
results from one-step growth curves in (figure 3.2).  The growth curves of both 
LipofectamineTM 2000 treated cells and cells transfected with negative control siRNA were 
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almost exactly identical to the mock transfected curve, indicating that neither the transfection 
procedure nor the negative control siRNA is able to inhibit or create a refractory environment 
to infection by HSV-1 and is therefore a suitable reagent and protocol to use to target specific 
Rab proteins for depletion with siRNA (figure 6.2). 
6.3 IDENTIFICATION OF RAB GTPASES INVOLVED IN HSV-1 INFECTION OF 
KERATINOCYTES 
The optimisation of transfection procedures in nTERT cells to specifically target a single Rab 
protein for depletion made possible the screening of an siRNA library targeting 60 human 
Rab proteins.  Each siRNA has a set of two siRNA duplexes designed to target different 
regions within the desired Rab mRNA.  Where a Rab protein had multiple isoforms their 
corresponding siRNAs were pooled, for example Rab1 has two isoforms - Rab1A and 1B.  
One negative control siRNA and 43 sets of siRNA targeting Rab proteins were reverse 
transfected into nTERT cells and subsequently infected 72 hours later with wild type HSV-1 
strain 17+ at a multiplicity of two for 18 hours.  Extracellular virus progeny was harvested and 
titrated onto Vero cells.  The titres were shown as a proportion of the negative control (cells 
transfected with negative siRNA), which was set to 1 (figure 6.3).  The data has been 
rearranged in order of greatest effect on virus infection.  The majority of Rab depletions had 
no statistically significant effect on released virus progeny, however several did significantly 
reduce virus titre.  Rab6 depletion produced the greatest effect, with up to a ten-fold 
reduction in virus yield, with other targets Rab10, 11, 1, 22, 5, 36, 38, 12, 33 and 23, also 
significantly reducing virus titre (figure 6.3).  To have a more manageable set of Rab proteins 
only six were chosen to study further.  The Rabs with the greatest effect chosen for this study 
were Rab6, 10, 11, 1, 22 and 5.  Although it must be noted that most of the siRNA have not 
been validated for their efficiency in nTERT cells, the majority of Rab proteins had no 
statistically significant affect on virus titre.  Therefore, this data suggests that a limited set of 
Rab proteins play a specific role in HSV-1 infection in nTERT cells and provides several 
targets for further investigation. 
CHAPTER 6 
 
 176
Figure 6.3: Specific Rab proteins are required for HSV-1 replication in nTERT keratinocytes.  
A library of siRNA targeting 60 human Rab proteins was used to reverse transfect nTERT 
cells.  Individual isoforms were pooled, e.g. Rab6A, B and C were all used together to have 
10 nM siRNA/well.  Cells were infected 72 hours post-transfection with wild type HSV-1 s17+ 
at a multiplicity of two.  The infection was allowed to progress for 18 hours before 
extracellular viral progeny was harvested and titrated onto Vero cells.  Samples are shown 
relative to cells transfected with negative siRNA (-) which were set to 1.  The mean and ± 
standard error of four independent experiments is shown.  Student T-test was used to 
calculate significance, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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6.4 VALIDATION AND OPTIMISATION OF SPECIFIC RAB PROTEIN DEPLETIONS BY 
RNAi 
The Rab depletion screen in nTERT cells was carried using the concentration of siRNA (10 
nM per well) known to optimally deplete Rab6 protein with Rab6 siRNA, as it would be 
impractical to optimise all 43 sets of siRNA (figure 6.3).  It was, however, necessary to 
validate these siRNAs and to optimise each individually for future study.  To this end, 
antibodies to the Rabs which had greatest effect on virus titre (Rabs 1, 5, 6, 10, 11 and 22) 
were sourced along with an antibody to a Rab that did not seem to have any effect (Rab7).  
This antibody was used to test whether other Rab proteins were actually being depleted and 
still not having any effect on virus titre.  Varying concentrations of siRNA were assessed by 
western blotting for their ability to reduce Rab protein levels, as compared to negative control 
samples.  Rab1 siRNA was able to reduce levels of Rab1 at all concentrations indicated, 
however seemed to be most efficient at 5 and 10 nM per well.  Rab6 and Rab7 levels were 
reduced to a level comparable with Rab1 and the reduction was efficient even at the lowest 
concentration of 5 nM per well.  The depletion of Rab5 and particularly Rab10 were not as 
efficient.  Bands were still detected with all three concentrations of siRNA and again, 5 and 
10 nM of siRNA seemed to deliver a better depletion than 20 nM per well.  We were unable 
to optimise the antibodies to Rab11 and Rab22 for western blot analysis and so could not 
determine the extent of their depletion during siRNA transfection.  From this experience we 
found that Rab antibodies are difficult to use for western blotting and that this method is not 
suitable for validating all of the knockdowns.  However, this data does confirm that protein 
levels of Rab1, 5, 6, 7 and 10 are depleted (5 and 10 less so than the others) during 
transfection and so confirming these depletions from the screen (figure 6.3) and allowing 
more optimised conditions to be used in the future. 
Although we have already confirmed that the transfection process itself does not affect the 
cells permissibility to infection we also wanted to establish whether depletion of a specific 
Rab protein would have any effect on cell growth.  To this end, we transfected or mock 
transfected nTERT cells with negative, Rab1, 5, 6, 10, 11 and 22 siRNA and after 72 hours 
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counted the number of dead and live cells per well.  Cells in mock, negative and 
Lipofectamine TM 2000 transfected wells all grew to a similar density of ~8 x 104 cells per well, 
with less than 10% of cells counted as dead (according to Trypan Blue staining) (figure 6.B).  
Most other transfected samples were similar, with number of cells per well counted being ~8 
x 104 and ~10% of the population of cells staining blue with Trypan Blue (figure 6.4B).  Rab1 
depletion had perhaps the most effect as growth seemed to be slightly reduced (6.8 x 104 
cells per well) in these cells, however the proportion of dead cells was similar to controls 
(figure 6.B).  These results indicate that there is no great effect on cell growth during the 
depletion of Rabs 1, 5, 6, 10, 11 or 22 and so this cannot be the cause for reduced virus titre 
during infection. 
The slight alteration in the growth of cells transfected with Rab1 siRNA noted in figure 6.4B 
was noticeable by eye during the course of these experiments.  Figure 6.5, shows phase 
images of nTERT cells transfected with negative siRNA and Rab1 siRNA on 24-well plates, 
which have been fixed after 72 hours.  These keratinocytes usually grow in islets, clumping 
together from early on in seeding and forming areas of high density surrounded by areas with 
no cell growth (figure 6.5, (-)).  This growth pattern illustrates the importance of cell-cell 
contacts in keratinocyte growth.  In contrast, nTERT cells transfected with Rab1 siRNA grow 
in a more dispersed manner, with few or no ‘islets’ forming (figure 6.5, Rab1).  These images 
indicate that depletion of Rab1 protein alters nTERT growth in some way in tissue culture 
monolayer. 
6.5 VIRAL PROTEIN EXPRESSION IN RAB DEPLETED CELLS 
We have identified a specific set of Rab proteins to be important for virus replication in 
infected nTERT cells (figure 6.3), however it is unknown at which point during infection they 
are required.  To begin to pinpoint when they play a role in replication we infected cells 
transfected with each set of siRNAs with wild type strain 17+ virus at a multiplicity of two for 
16 hours.  At this time cell lysates were harvested for western blot analysis using antibodies 
specific for viral proteins expressed at different stages of replication.  For example, ICP0 is 
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Figure 6.4: Optimisation of Rab knockdown in nTERT cells.  nTERT cells were mock or 
reverse transfected with pooled isoforms targeting Rab1, 5, 6, 7, 11, 22 or negative siRNA as 
a control (-).  (A) Cells were harvested 72 hours post-transfection and antibodies to the 
appropriate Rab protein used for western blotting.  (B) Dead cells were stained with trypan 
blue and calculated as a proportion of total cells/well.  The mean and ± standard error of the 
data are given from one representative experiment (n=3). 
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Figure 6.5: Cells present with an abnormal, dispersed growth pattern, when Rab1 protein 
expression is reduced.  Rab1 or negative (-) siRNA (5 nM/well) was reverse transfected into 
nTERT cells in 24-well plates, 72 hours prior to fixing with 4% paraformaldehyde.  Brightfield 
images were captured using a Zeiss Axiovert S100 TV inverted fluorescence microscope 
(10x lens). 
CHAPTER 6 
 
 183 
Figure 6.5
CHAPTER 6 
 
 184
Figure 6.6: HSV-1 viral protein expression is largely unchanged by depletion of Rab 
proteins, with the exception of Rab1.  nTERT cells were reverse transfected with Rab siRNA 
or control (-) siRNA for 72 hours.  Cells were then infected with wild type HSV-1 s17+ virus at 
a multiplicity of two for 16 hours.  Cells were harvested for western blot analysis and probed 
for the proteins indicated with specific antibodies. 
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an immediate early protein, whereas the glycoproteins gD and gE are expressed later on in 
infection.  In the negative control sample a band is visible with each of the antibodies tested 
indicating successful expression and detection of ICP0, VP22, gD and gE at 16 hours post-
infection (figure 6.6).  The detection of ICP0 and VP22 was also similar in all Rab depleted 
samples, with the exception, perhaps, of Rab1 depletion, which appears to induce a very 
slight reduction in ICP0 and VP22 expression (figure 6.6).  Antibodies to the glycoproteins 
both pick up one smaller, immature band and multiple slightly larger bands that are 
recognised as post-translationally modified forms of the proteins that are glycosylated in the 
Golgi (171).  The immature form of gD and gE seem to be unaltered in all the samples, as 
compared to the negative control.  The glycosylated bands are also present in all samples 
exhausted of Rab proteins to a similar degree, however Rab1 depletion causes a reduction 
in the glycosylated forms of gD and particularly gE (figure 6.6).  This result is consistent with 
published roles of Rab1 in ER to Golgi transport and suggests that Rab1 depletion prevents 
normal transport of viral glycoproteins from the ER to the Golgi where post translational 
modifications would usually occur (185, 232).  These results indicate that viral protein 
expression is able to occur virtually unhindered during depletion of all the Rab proteins, with 
the exception of Rab1 depletion, which appears to inhibit the post translational modification 
of gD and gE. 
6.6 RAB1 DEPLETION ALTERS GOLGI MORPHOLOGY IN KERATINOCYTE CELLS 
As viral protein expression is largely unaltered in Rab depleted cells it is likely that these Rab 
proteins play a role in infection downstream of viral protein expression.  Rab1 is known to 
regulate ER to Golgi trafficking and so could be affecting trafficking of viral proteins to their 
target destinations after they are expressed (185, 232).  To ascertain whether the Golgi is 
disrupted in the absence of the target Rab proteins we transfected nTERT cells with Rab1, 5, 
6, 10, 11 or 22 siRNA, fixed then 72 hours later stained with an antibody which marks the 
Golgi complex.  In negative control transfected cells the antibody-staining indicates that the 
Golgi complex is located in a perinuclear region, either in a tight aggregate or as distinct 
domains speckled around the nucleus (figure 6.7).  The appearance of the Golgi complex 
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remains unchanged during transfection of Rab5, 10, 11 and 22 siRNA, with staining still in a 
perinuclear localisation (figure 6.7).  Rab1 siRNA transfection, however, had a dramatic 
affect on Golgi staining.  Two example fields are given to illustrate the two different Golgi 
morphologies identified.  Example 1 shows a predominantly dispersed, speckled staining 
pattern throughout the cytoplasm (figure 6.7).  Example 2 (figure 6.7) contains images of 
cells with speckled staining, and also cells with staining completely diffuse throughout the 
cytoplasm.  The punctate, fragmented staining pattern seen in example 1 is similar to the 
pattern we usually see in Rab1 depletion by siRNA transfection of HeLa cells (unpublished 
data, Elliott Group, Imperial College London), however both punctate and diffuse staining has 
been reported by others in HeLa cells transfected with an inactive form of Rab1b (N121l) (5).  
These immunofluorescence microscopy images indicate that there is no effect on Golgi 
integrity when Rabs 5, 6, 10, 11 and 22 are depleted, whereas Rab1 depletion, as expected, 
does cause Golgi disruption. 
6.7 CHARACTERISATION OF GAUSSIA LUCIFERASE SECRETION AND 
TRANSFERRIN UPTAKE IN RAB DEPLETED CELLS 
As some Rab proteins are responsible for regulating the secretory pathway it was 
hypothesised that depletion of individual Rabs may lead to overall levels of secretion in the 
cell being reduced and therefore the Rab playing a non-specific role in HSV-1 replication.  To 
test this theory gaussia luciferase was transfected into Rab-depleted cells for 4 hours.  This 
reporter protein is secreted into the extracellular media and upon the addition of its substrate, 
emits light as a result of its ability to catalyse the oxidation of this substrate.  Cells were also 
treated with Brefeldin A, a fungal anti-viral antibiotic (230) known to inhibit cellular secretion 
by redistributing Golgi proteins into the ER (126, 161, 182) as a positive control.  Levels of 
gaussia luciferase activity were normalised to protein levels.  One hour prior to harvesting, 
the extracellular media was refreshed so that the gaussia luciferase detected was secreted 
over the course of a one hour period.  Treatment of nTERT cells with the positive control 
Brefeldin A reduced gaussia luciferase secretion by almost 100-fold, as expected (figure 
6.8A).  Rab1 was the only Rab to also reduce secretion by approximately half, although here 
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Figure 6.7: Depletion of Rab1 causes disruption of the golgi complex.  nTERT cells were 
reverse transfected with the Rab siRNA specified or (-) siRNA.  Cells were fixed 72 hours 
later, using 4% paraformaldehyde, and immunofluorescence staining performed for giantin 
accompanied by nuclei staining with DAPI.  Images were captured using a Zeiss Axiovert 
S100 TV inverted fluorescence microscope.  Giantin, red; DAPI, blue. 
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Figure 6.8: Depletion of Rab proteins alters secretion of gaussia luciferase in nTERT cells 
but does not greatly affect transferrin uptake.  (A) nTERT cells were reverse transfected with 
10 nM/well Rab or (-) siRNA and 72 hours later transfected again with 400 ng/well pCMV-
Gluc-1.  One day later cells were mock treated or treated with Brefeldin A for four hours.  
One hour prior to harvesting the cell culture media was changed.  The cell supernatant was 
harvested for gaussia luciferase quantification and normalised to protein concentration 
(RLU/ng).  The mean and ± standard error from one experiment of three in total is shown; * p 
< 0.05, *** p < 0.001.  (B) nTERT cells were reverse transfected with 10 nM/well Rab or (-) 
siRNA.  Forty-eight hours later cells were treated with fresh media (with no serum) containing 
Texas Red® transferrin (2.5 µM/ml) for 30 mins before fixing with 4% paraformaldehyde, and 
accompanied by staining for nuclei (DAPI).  Representative images captured using a 
confocal Zeiss LSM510 META inverted laser-scanning microscope are shown.  Texas Red® 
transferrin, red; DAPI, blue. 
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this difference is not statistically significant (figure 6.8A).  Rabs 6, 10 and 11 appear to have 
very little affect on secretion, however Rab5 and particularly Rab22, significantly increase the 
secretion of gaussia luciferase by about two fold (figure 6.8A).  If secretion, or exocytosis, 
can be effected by Rabs, these Rabs may also play a role in endocytosis.  Although it is 
unlikely that they are able to prevent initial entry, as we have demonstrated that normal viral 
protein expression still occurs (figure 6.6), endocytosis may still be necessary for the 
internalisation of membranes, and their associated proteins, required for virus maturation 
(107).  As such, we decided to assess Rab depleted cells using a marker for endocytosis, 
Texas Red® transferrin.  Transferrin is a serum glycoprotein that binds to the transferrin 
receptor, which is then internalised by endocytosis.  Detection of the internalised conjugate is 
then possible by microscopy.  Rab proteins were depleted by reverse transfection of nTERT 
cells with the appropriate siRNA.  Forty-eight hours later nTERT cells were treated with 
Texas Red® transferrin for 30 mins and fixed for microscopy.  In negative control transfected 
cells the transferrin was visible throughout the cytoplasm as small speckled punctate 
domains, these were sometimes seen to coalesce or be more prominent in a perinuclear 
localisation (figure 6.8B).  Rab1 depleted cells were more dispersed than the control cells, in 
accordance with results from figure 6.5, however their nuclei also appeared to be somewhat 
reduced in size with a stronger signal, indicating that the contents were more compact.  The 
transferrin signal is also visible in speckled puncta throughout the cytoplasm and to similar 
levels as the control in the Rab1, 5, 6, 10 and 11 depleted cells, indicating no failure in this 
particular pathway of endocytic uptake.  These results indicate that nTERT cells exhausted 
of these Rab proteins are intact in endocytic (transferrin-mediated) and secretory (gaussia 
luciferase) pathways. 
6.8 RAB6 PLAYS A ROLE IN THE INFECTION OF KERATINOCYTES 
To characterise the role of Rabs in HSV-1 replication in more detail we decided to focus in on 
the Rab identified in the screen that had the greatest effect, Rab6 (figure 6.3).  Rab6 also 
had the most significant effect on virus titre when depleted in HeLa cells by other members of 
our group (Claudia Gonzalez-Lopez and Helen Johns, unpublished data, Elliott Group, 
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Imperial College, London).  After additional characterisation in these cells it was found that 
Rab6 was required for viral glycoproteins to be correctly trafficked prior to virus envelopment.  
To add further evidence that Rab6 is required in the physiologically relevant setting, this role 
of Rab6 in infected nTERT keratinocytes was confirmed. 
Initially the Rab6 depletion itself was further confirmed by quantifying Rab6 mRNA transcripts 
in Rab6 knockdown nTERT cells compared to negative control siRNA transfected cells.  
Seventy-two hours post-transfection cells were harvested and the mRNA extracted and 
quantified by quantitative real time PCR.  Rab6 siRNA transfection reduced the Rab6 mRNA 
transcripts by almost ten-fold compared to the negative control (figure 6.9), corroborating the 
protein depletion identified by western blot (figure 6.1).  Rab6 has three isoforms, Rab6A, B 
and C and although all these siRNAs have been used in combination, Rab6A and C 
sequences differ by only three amino acids, and so it is likely that the siRNAs may cross 
target these isoforms (65).  We used each of the Rab6 isoform siRNA separately to transfect 
nTERT cells and identify whether there was any difference in levels of protein by western blot 
after 72 hours.  All three isoforms in combination produced the greatest reduction in 
detectable Rab6 protein, as used in experiments from figures 6.1 and 6.4, with Rab6A and C 
individually resulting in similar reductions in detectable protein levels compared to negative 
siRNA transfected control lysates (figure 6.9B).  Transfection with Rab6B siRNA did not 
reduce levels of Rab6 protein detection (figure 6.9B).  The antibody (C-19, Santa Cruz) can 
detect all three isoforms of Rab6, however Rab6B is thought to be mainly found in neuronal 
tissue, therefore it is likely there is very little, if any to depleted by the Rab6B siRNA and the 
band probably represents Rab6A and 6C which have not been depleted under these 
conditions (figure 6.9B, (175)). 
The reduction in virus titre seen in Rab6 depleted HeLa cells is more pronounced than in the 
nTERT keratinocytes, with up to 200 fold reduction in HeLa as compared to a ten-fold 
reduction in nTERT cells.  To address whether levels of Rab6 differ in these cells and could 
address the disparities apparent between HeLa and nTERT cells, and also to compare to 
other routinely used cell types, we detected Rab6 by western blotting lysates of HeLa, 
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Figure 6.9: Optimised knockdown of Rab6 protein expression leads to a reduction in HSV-1 
replication in keratinocyte cells.  nTERT cells were reverse transfected with 10 nM/well Rab6 
(A, B, C or pool) or control (-) siRNA 72 hours prior to harvesting for (A) mRNA extraction or 
(B) western blot analysis.  (B) Antibodies specific for Rab6 or α-tubulin were used for this 
analysis.  (A) Rab6A mRNA was quantified by qRT-PCR and is shown relative to (-) control 
sample.  The mean and ± standard error of three independent experiments is shown; ** p < 
0.01.  (C) Confluent monolayers of HeLa, HFFF, HaCaT, nTERT or Vero cells were 
harvested for western blot analysis with antibodies specific for Rab6 or α-tubulin.  In (D and 
E) cells were reverse transfected with siRNA targeting Rab6A, B and C.  (D) Cells were 
infected 72 hours post-transfection with wild type HSV-1 s17+ at a multiplicity of two.  The 
infection was allowed to progress for 8 or 16 hours before total viral progeny was harvested 
and titrated onto Vero cells.  The mean and ± standard error from one experiment of three in 
total is shown; * p < 0.05, ** p < 0.01.  (E) Cells were harvested and analysed by western blot 
analysis with Rab6 or α-tubulin-specific antibodies. 
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HFFF2, nTERT and Vero cells.  Equal loading of lysates was established by detection of α-
tubulin as a loading control, which allowed direct comparison of Rab6 protein levels as 
detected by the Rab6 antibody (figure 6.9C).  The cells seemed to fall into two categories; 
low levels of Rab6 protein, and higher levels, with HeLa and Vero cells falling into the former 
category and HFFF2, nTERT and HaCaT cells falling into the latter, indicating that Rab6 
protein expression is not uniform across all these cells, but varies by cell type (figure 6.9C). 
As we are using nTERT cells as a prototypic keratinocyte cell type we also wanted to confirm 
that depletion of Rab6 in other keratinocytes also resulted in a reduction in virus titre after 
infection.  HaCaT cells were chosen as another immortalised human keratinocyte cell type 
(30) that also seemed to have similar levels of Rab6 as nTERTs.  HaCaT or nTERT cells 
were transfected with Rab6 siRNA 72 hours prior to infecting with wild type HSV-1 strain 17+ 
at a multiplicity of two.  Infections were allowed to progress for 8 or 16 hours to characterise 
the earlier times in infection (as initial identification of Rab6 was at 18 hours post-infection in 
the Rab screen, figure 6.3).  Total virus titres harvested from infected nTERT cells reach 1 x 
105 PFU/ml by 8 hours post-infection in negative control transfected cells, and increase to 
1.5 x 106 PFU/ml by 16 hours post-infection (figure 6.9D, nTERT, (-)).  In contrast, Rab6 
depleted infected nTERT cells produced over ten-fold less virus at both 8 and 16 hours post-
infection (figure 6.9D, nTERT, Rab6).  Infected HaCaT cells produced slightly higher titres in 
the negative siRNA transfected cells at both time points, although the difference between the 
control and Rab6 knockdown cells was again around ten-fold, if a little more modest than in 
the nTERT cells (figure 6.9D, HaCaT).  The Rab6 depletion from this experiment was also 
confirmed by western blotting to be sure that an optimal knockdown had been achieved 
before infection was initiated (figure 6.9E). 
The quantitative real time PCR and western blot data confirm that an efficient depletion of 
Rab6 can be achieved in nTERT and HaCaT cells (figure 6.9A,B,D).  It also adds further 
evidence that keratinocytes in general (not just nTERT cells) require Rab6 for proper 
replication as virus titres were reduced in both nTERT and HaCaT keratinocytes lacking 
Rab6 (figure 6.9D). 
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6.9 RAB6-GFP CO-LOCALISES WITH VIRAL GLYCOPROTEIN D IN INFECTED nTERT 
CELLS 
To further characterise the role of Rab6 in HSV-1 infection it was necessary to visualise the 
localisation of Rab6.  Although the Rab6 antibody could be used for detecting Rab6 protein 
by western blotting, we could not optimise the conditions for successful detection by 
immunofluorescence microscopy.  A plasmid encoding Rab6 tagged with GFP (GFP-Rab6A 
gifted by Casper Hoogenraad, Universiteit Utrecht, The Netherlands, (200)) was obtained for 
transfection and subsequent detection of exogenous Rab6 protein by microscopy.  Rab6 is 
known to localise to the Golgi compartment in many cell types, including HeLa cells (147), 
therefore initially it was important to establish whether its localisation would be the same in 
nTERT cells.  In order to do this nTERT cells were transfected with the GFP-Rab6A plasmid 
for 4 hours before being fixed and immunofluorescence staining performed for giantin.  
Giantin is an integral Golgi membrane protein (138) and therefore colocalisation of the GFP 
signal and giantin marker would indicate the presence of the exogenously expressed Rab6 
protein in the Golgi complex.  As shown also in figure 6.7, giantin staining in mock 
transfected cells indicates a perinuclear localisation for the Golgi in nTERT cells, often 
spread over multiple tight domains (figure 6.10, Mock).  Transfection of the GFP-Rab6A 
plasmid did not alter the staining pattern of the giantin indicating that it had no effect on the 
morphology of the Golgi (figure 6.10 GFP-Rab6A).  Few cells showed successful GFP-
Rab6A transfection (figure 6.10) and some of those that were transfected were over-
expressing to the extent that the whole cell was strongly positive in its GFP signal, so only 
cells not over-expressing were considered to show appropriate localisation (not shown).  
Although the GFP signal was sometimes visible at very low levels throughout the cell the 
most concentrated signal was found in elongated puncta around the nucleus which 
colocalised with the giantin staining (figure 6.10).  This confirmed that the Rab6 expressed 
from the GFP-Rab6A plasmid was properly localised to the Golgi complex in nTERT cells 
(figure 6.10). 
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Figure 6.10: GFP-Rab6 co-localises with the Golgi marker giantin in nTERT cells.  Sub-
confluent monolayers of nTERT cells were mock transfected or transfected with 400 ng/well 
of the plasmid GFP-Rab6A for four hours.  Cells were then fixed with 4% paraformaldehyde, 
and immunofluorescence staining performed for giantin and staining for nuclei (DAPI).  
Images were captured using a Zeiss Axiovert S100 TV inverted fluorescence microscope.  
GFP-Rab6a, green; giantin, red; DAPI, blue. 
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Figure 6.11: GFP-Rab6a co-localises with gD during infection.  Sub-confluent monolayers of 
nTERT cells were transfected with 400 ng/well of the plasmid GFP-Rab6a and one hour later 
infected with wild type HSV-1 s17+ at a multiplicity of two.  Cells were fixed seven hours 
later, with 4% paraformaldehyde, and immunofluorescence staining performed for gD (LP14) 
and staining for nuclei using DAPI.  Analysis was carried out on a confocal Zeiss LSM510 
META inverted laser-scanning microscope.  GFP-Rab6a, green; LP14, red; DAPI, blue. 
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In HeLa cells Rab6 was found to colocalise with viral glycoproteins in infected cells, 
indicating that Rab6 is associated with trafficking vesicles that contain viral membrane 
proteins (unpublished data, Elliott Group, Imperial College, London).  The GFP-Rab6A 
plasmid was used to confirm whether this was also the case in nTERT cells.  The GFP-
Rab6A plasmid was transfected into nTERT cells one hour prior to infecting or mock infecting 
with wild type HSV-1 strain 17+ at a multiplicity of two for seven hours.  Infected cells were 
fixed and processed for immunofluorescence staining of gD.  The GFP signal in mock-
infected cells was consistent with data from figure 6.11 indicating a perinuclear, most likely 
Golgi associated, localisation of the exogenous Rab6 (figure 6.11, Mock).  Rab6 localisation 
changed drastically after infection; losing its tight association with the nucleus, the puncta 
appearing more dispersed and spread throughout the cytoplasm and often coalescing at 
sites close to the plasma membrane (figure 6.11, GFP-Rab6).  The gD staining also 
appeared as uneven puncta throughout the cytoplasm (figure 6.11, gD).  When gD and GFP-
Rab6 signals were compared, although not all populations colocalised, a sub-population of 
gD and GFP-Rab6 did colocalise, often at cell peripheries (figure 6.11, Example 2).  
Together these data indicate that in uninfected cells Rab6 localises to the Golgi and upon 
infection it is relocalised into punctate domains throughout the cell, some of which colocalise 
with the viral glycoprotein gD, indicating a potential role for Rab6 in gD trafficking. 
6.10 CHAPTER DISCUSSION 
A transfection technique used previously (unpublished data, Elliott Group, Imperial College, 
London) in HeLa cells to deliver siRNA to target specific Rab proteins has been optimised to 
deplete particular targets in nTERT cells without causing an anti-viral environment to be set 
up in these cells by the transfection procedure (figure 6.1 and 6.2).  Following execution of 
the screen of 43 groups of Rab proteins, a subset of Rabs has been identified as causing a 
reduction in virus titre when depleted in nTERT cells (figure 6.3), which are similar to the set 
identified previously in HeLa cells (unpublished data, Elliott Group, Imperial College, 
London).  Normal cellular growth, intact viral protein expression, Golgi integrity and endocytic 
uptake levels were all confirmed in Rab depleted cells (5, 6, 10, 11, 22), with the exception of 
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Rab1.  Secretion of gaussia luciferase was altered in some of the Rab depleted cells (figure 
6.8A). 
Rab6 depletion by siRNA was further confirmed by quantitative real-time PCR and levels of 
protein shown to vary in a cell type dependent manner, with keratinocytes expressing the 
highest levels of Rab6 (figure 6.9C).  The importance of Rab6 in keratinocyte infection was 
further corroborated by showing that infected HaCaT cells transfected with Rab6 siRNA 
produce ten-fold less virus than control cells (figure 6.9D).  A GFP-Rab6A expressing 
plasmid was then utilised to confirm that, as in HeLa cells (unpublished data, Elliott Group, 
Imperial College, London) a sub-population of the viral glycoprotein gD colocalised with 
exogenous Rab6 in infected nTERT cells (figure 6.11).  These data provide good evidence to 
support work already carried out in HeLa cells and to confirm that this data is relevant to 
HSV-1 infection of the skin.  
6.10.1 TRANSFECTION OF nTERT CELLS CAN BE OPTIMISED FOR TARGETED 
DEPLETION OF CELLULAR PROTEINS WITHOUT ALTERING THE ANTI-VIRAL 
IMMUNE RESPONSE 
To identify Rabs of importance to virus replication in nTERT cells optimisation of the RNAi 
technique in these cells was necessary in order to be able to carry out the screening of the 
Rab siRNA library.  Rab6 was chosen as a single siRNA to use for optimisation prior to 
screening the 43 groups of human Rab proteins, as it is routinely used in the lab and an 
antibody was available for confirming the depletion by western blotting.  Although the 
transfection conditions identified in figure 6.1 are suitable for Rab6, it is possible that they are 
not exact for all the other Rab siRNA, however it was not possible to optimise the conditions 
for each individually and it was hoped that, as in the HeLa screen (unpublished data, Elliott 
Group, Imperial College, London), the approximate conditions would work sufficiently for all 
the Rab proteins, and that further validation could be carried out on potential targets at a later 
stage.  This RNAi technique has been used here successfully to knockdown specific target 
proteins in the nTERT cells, and thus provides the experimental conditions for an siRNA 
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screen.  However, RNAi involves the delivery of small duplexes of RNA into a cell, and as a 
consequence it is possible that innate immune cellular defenses are primed by the intrusion 
of these potential viral RNAs, reviewed in (21).  Keratinocytes are an immunologically ‘active’ 
cell, surveying the local environment in order to initiate inflammation by release of potent 
cytokines and chemokines such as interleukin-1 and tumour necrosis factor α, reviewed in 
(228). Given this information it is possible that the cellular responses would be primed, by 
siRNA transfection, to deal with infection and so create an environment in which virus 
infection would be resisted by host immune mechanisms such as induction of the anti-viral 
cytokine Interferon (21).  It has been confirmed that treatment with the lipid reagent 
LipofectamineTM 2000 does not affect the growth of nTERT cells and transfection with either 
the lipid reagent or negative control siRNA does not cause the cell to be refractory to 
infection (figure 6.2), therefore would not interfere with further transfection-infection studies.   
6.10.2 SPECIFIC RAB GTPASES PLAY A ROLE IN HSV-1 INFECTION OF nTERT CELLS 
Having optimised the transfection conditions sufficiently to allow targeted depletion of a 
specific cellular protein, 43 sets of human Rab proteins were screened for their requirement 
in HSV-1 infection of nTERT cells.  This provides information on a vast number of different 
cellular pathways as regards to HSV-1 infection, as vesicle trafficking is involved in many 
different cellular processes (96, 122, 224).  The depletion of several Rab proteins resulted in 
a statistically significant reduction in extracellular virus titre, three proteins produced greater 
than a two-fold decrease (Rab10, 11 and 1) and Rab6 depletion caused the virus titre to drop 
ten-fold.  There were also some Rab proteins which caused a modest increase in virus titre 
(Rab 14 and 15), however these were not statistically significant increases and therefore of 
less interest than the Rabs which caused a reduction in virus titre.  There were many other 
Rabs that did not lead to any changes, which means that the effect is not a general one 
caused by knocking down any Rab protein in the cell.   
The Rab targets which were chosen for initial characterisation were Rab6, 10, 11, 1, 22 and 
5.  Complete inhibition of virus was not expected from depletion of Rab proteins due to their 
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overlapping functions and sequence similarity, for example the absence of all four Rab3 
isoforms in mice only produces a 30% reduction in the probability of Ca2+-triggered 
neurotransmitter release (204).  Past studies on RNAi screens to identify cellular 
components involved in virus infection have often used two-fold reductions as cut-offs, 
including screens in enterovirus and HIV infection (33, 51).  A more recent HSV-1 screen of 
dominant negative Rab GAP proteins used a more stringent threshold of a five-fold reduction 
in titre (254).  This could be applied to the nTERT screen to give just two hits; Rab6 and 10, 
however Rab11, 1, 22 and 5 were thought to still be of interest from the nTERT screen as 
they were also identified in the HeLa screen (unpublished data, Elliott Group, Imperial 
College, London) and with the exception of Rab5 and 22 (which were close), all fell inside the 
two-fold cut-off.  Rab5 and 22 are also classified in the same subfamily of Rabs (183) and 
both associate with early endosomes (37, 194).  Given the recent publication linking 
endosomal tubules to Rab5 and Rab11 in HSV-1 envelopment (107), these Rabs are of 
further interest to this study.  This broad choice of Rabs for further characterisation was to 
allow validation of many of the hits from the HeLa screen in the keratinocyte cells.   
It appeared that the overall reductions in titre caused by Rab depletions in infected nTERT 
cells were not as extreme as the reductions seen in HeLa cells, for example Rab6 depletion 
produced a ten-fold reduction in nTERT cells but more than 100-fold reduction in HeLa cells.  
Although these screens are not directly comparable as they are separate experiments, the 
experimental conditions were similar.  This could be due to overall levels of Rab proteins or 
efficiencies of pathways differing between the cells or differential reliance on certain 
pathways.  It could also stem from better transfection rates in HeLa cells than nTERTs, all of 
which should be taken into consideration. 
Some of these Rabs have already been implicated in virus infections, for example Rab6 is 
linked to HCMV infection and HIV entry (33, 115), Rab1 depletion impairs HSV-1 replication 
(107, 254) and Rab11 is known to be involved in both Influenza A genome transport to the 
plasma membrane and, along with Rab5, for the endocytic retrieval of viral glycoproteins 
from the plasma membrane in HSV-1 infected HeLa cells (6, 36, 107, 236).  Therefore it is 
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not unexpected that these Rabs should be required for HSV-1 infection of its physiologically 
relevant host cell.  
However, it must not be overlooked that this screen has some limitations.  The Rab protein 
depletions were not fully validated, and therefore it is possible that there are false negatives 
among this population of data and that some potential factors were missed.  It is also 
possible that, due to the inherent redundancy of Rab GTPases, with 75-95% sequence 
identity frequent in this family of proteins and the fact that they are often products of gene 
duplication (27), depletion of one Rab may be compensated for by another Rab protein.  This 
was perhaps partially addressed by grouping all isoforms to give 43 sets of targets for 
depletion, however further characterisation of the effect of depleting groups of Rabs might 
also be revealing. 
6.10.3 OPTIMISATION AND DETECTION OF RAB GTPASES 
Antibodies for detection of Rab proteins are notoriously often difficult to optimise, probably 
because Rab proteins are small and share much sequence similarity.  Usually any 
commercially available antibody will be tested on cells over-expressing the target Rab, rather 
than endogenous expression and prior to this study none of the antibodies used in this thesis 
were characterised in nTERT cells.  Consequently we were unable to obtain a full 
complement of antibodies to all the Rab targets, in particular Rab11 and Rab22 for western 
blotting and none of the Rab antibodies gave a specific signal by immunofluorescence 
staining in nTERT cells.  This meant we were unable to validate the knock down of Rab11 
and 22 by western blot and therefore must be taken into account when analysing any further 
results involving these Rab proteins.  The target Rabs 1, 5, 6, 7 and 10 were all validated 
and optimised by western blot (figure 6.4).  Rab7 when depleted caused no effect on virus 
titre and so was used as a partial control for false negatives (figure 6.3). 
One important factor to take into account from the western blot data is that Rab10 and 5 
protein levels did not appear to be reduced to the same extent as Rab1 and 6, indicating that 
only partial depletion of Rab10 was still enough to reduce virus titre by nearly ten-fold.  
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Rab10 is thought to play a role in the basolateral recycling of endosomes (15, 44) and in 
post-Golgi trafficking (45, 157, 198, 241).  If these post-Golgi trafficking routes are not 
efficiently inhibited by Rab10 depletion then if protein levels could be further reduced, the 
effect on virus titre could be even more pronounced.  The efficiency of siRNA transfection will 
also depend on the specificity of the siRNAs used, the half-life or stability of the mRNA and 
protein and the overall levels present in the cell.  These could also be reasons why the 
depletion of Rab10 and 5 were not very efficient compared to Rab1, 6 and 7 (figure 6.4). 
6.10.4 RAB1 DEPLETION CAUSES GOLGI DISORGANISATION, INHIBITS SECRETION 
AND PREVENTS NORMAL GLYCOSYLATION OF VIRAL PROTEINS 
Expression of a dominant negative form of Rab1 (Rab1/N121I) causes Golgi disruption in 
vivo, whereby giantin is redistributed to the ER and other Golgi markers localise in punctate 
fragmented structures (5, 32), similar to what is seen frequently in Rab1 siRNA transfected 
HeLa cells (unpublished data, Elliott Group, Imperial College London).  This is consistent 
with the data in figure 6.7 where the Golgi is disrupted in Rab1 knock down cells, however it 
was unexpected that there would be a diffuse staining pattern throughout the cytoplasm.  
This phenotype, however, has also been reported by others in HeLa cells transfected with 
N121l, an inactive form of Rab1b (5).  The authors speculate that these cells were producing 
higher levels of the inactive form for longer periods of time, than the cells presenting with 
punctate giantin staining.  These phenotypes could therefore represent early and late stages 
in the disruption of the Golgi by Rab1 depletion, with variable levels of Rab1 depletion in 
each cell. 
This effect on the ER and Golgi when Rab1 is depleted also helps to explain why most viral 
proteins were still produced to a similar level in infected Rab1 knock down cells, while viral 
glycoproteins were not fully glycosylated due to their requirement for transport through a 
functioning Golgi complex (171).  This effect has also been noted in HeLa cells (unpublished 
data, Elliott Group, Imperial College, London; (254)) and supports the theory that this is the 
main cause of reduced virus yield in Rab1 knock down cells. 
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Another consequence of abolishing ER to Golgi transport due to Rab1 depletion is that 
cellular secretion of gaussia luciferase is inhibited (figure 6.8).  It might have been expected 
that secretion would be impaired to a similar level as the control, BFA, given the similarity in 
its mechanism of action and the effect of Rab1 depletion.  However, there is probably still a 
proportion of Rab1 protein functioning in these cells, or alternatively, another protein must be 
compensating, as the Rab1 knock down cells were still viable (figure 6.4) (126, 161, 182).   
The unusual dispersed growth morphology of the Rab1 knockdown cells, compared to the 
islet-growing control cells (figure 6.5), could also perhaps be explained by this inhibition of 
secretion (figure 6.8).  The growth of keratinocytes in these discrete islets has been 
attributed to cell-cell contacts such as tight junctions, adhesion junctions and desmosomes 
(reviewed in (22)).  These are often formed from transmembrane proteins such as claudins 
(85) and when disrupted, such as in blistering diseases where desmoglein-dependent cell 
adhesion is targeted by autoantibodies, results in the loss of cell-cell adhesion in 
keratinocytes (10).  It is known that Rab1 is responsible for the anterograde trafficking of 
transmembrane proteins such as cystic fibrosis transmembrane conductance regulator, 
vesicular stomatitis glycoprotein and human calcium sensing receptor (55, 251, 258).  As 
such, it is possible that transmembrane molecules required for cell-cell contacts are unable 
to reach the cell surface due to the loss of Rab1 function and that this would explain the 
dispersed growth of Rab1 knock down nTERT cells.  
Viral protein expression was unaffected by the depletion of the other Rab targets, including 
Rab5, 6, 10, 11 or 22 (figure 6.6).  This precludes the possibility that these Rabs play a role 
upstream of viral protein expression and therefore suggests a role in virus maturation or 
egress.  In support of this, transferrin uptake was comparable in all Rab depletions (figure 
6.8B), suggesting that virus entry is probably not affected by Rab depletion.  This is 
particularly interesting because endocytosis has been reported as a method of virus entry in 
keratinocytes (169, 191) and is regulated by Rab GTPases, including Rab5 (reviewed in (1)).  
It is therefore surprising that in the Rab5 knock down cells transferrin uptake appeared 
relatively unchanged (figure 6.8B), as Rab5 promotes early endosome fusion and 
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transfection of HeLa cells with a Rab5 mutant that has a preferential affinity to GDP results in 
the inhibition of transferrin by clathrin-mediated endocytosis (223).  An explanation could be 
that the partial depletion of Rab5 is sufficient to reduce endocytosis to a limited extent, which 
reduces virus yield, but that this distinction cannot be made by immunofluorescence 
microscopy as the effect is too slight to detect by this method.  Alternatively, 20 Rab proteins 
have defined functions in endocytosis and related processes, including Rab5, therefore it is 
possible that other Rab proteins are compensating for the loss of Rab5 function (reviewed in 
(1)) 
The Golgi remained intact through depletion of all these Rabs (figure 6.7, Rabs 5, 6,10, 11 
and 22), and that, coupled with the normal glycosylation patterns of viral glycoproteins under 
these conditions confirms that they do not act in the same way as Rab1 and that complete 
viral protein expression and Golgi processing occurs as normal in these cells. 
An interesting observation made in figure 6.8A was that secretion of gaussia luciferase was 
unchanged in Rabs 6, 10 and to a certain extent 11, however was augmented in Rab5 and 
22 by around two-fold.  This means that depletion of these Rabs is not restricting virus 
replication through the general effect of limiting secretion.  It is of note that these two Rabs 
are of the same subfamily, that Rab22 interacts with EEA1 and Rabenosyn-5, both Rab5 
effector proteins and that both associate with early endosomes, however this result is almost 
counterintuitive to what is known about these Rab proteins (37, 123, 160, 183, 194).  Rab5 is 
well characterised as a regulator of clathrin-mediated endocytosis and Rab22 works with 
Rab5 through Rabex-5 to regulate endosomal dynamics (256).  One could speculate that the 
balance of membrane trafficking and secretion is disturbed by the depletion of these Rabs 
and that somehow this causes there to be more vesicles available for secretion.  It must also 
be remembered that this is one specific secretory pathway and this may not be the case for 
others. 
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6.10.5 RAB6 IS INVOLVED IN THE EXOCYTOSIS OF VIRAL TRANSMEMBRANE 
PROTEINS  
Initial work on quantifying Rab6 levels during Rab6 siRNA transfection confirmed that Rab6 
mRNA transcripts are maximally reduced (figure 6.9A) under these conditions and that 
depletion of Rab6 in other keratinocyte cells has the same affect on virus yield as in nTERT 
cells, indicating that this is not an nTERT-specific phenomenon.  We have also shown that 
Rab6 levels appear to be increased in two keratinocyte cell lines and HFFF2 cells (all found 
in the skin), and this may explain why depletion of Rab6 in infected keratinocytes (figure 6.3 
and 9D) has a lesser effect than in HeLa cells (unpublished data, Elliott Group, Imperial 
College, London). The colocalisation of GFP-Rab6 with giantin in figure 6.10 indicates that 
Rab6 is found at the Golgi in nTERT cells and this is in line with its known localisation to the 
TGN cisternae in other cells (9). 
Many roles for Rab6 have been identified, including regulation of intra Golgi trafficking (147), 
COP-1 independent anterograde Golgi to ER transport (90, 243), retrograde movement from 
early and recycling endosomes to the TGN (143) and more recently the regulation of vesicle 
migration from the Golgi to the plasma membrane (94, 95, 159).  Some of these roles are 
isoform dependent, for example Rab6A and C are both involved in Golgi to ER transport, 
however only 6C is responsible for early and recycling endosome to Golgi trafficking (58).  
The experiments described in this thesis target all three isoforms of Rab6 for depletion, even 
the neuronally localised form 6B (175), in order to optimally reduce protein levels of these 
Rabs and therefore all these pathways are considered to be affected in these knock out cells. 
Crucial work carried out prior to this study on the role of Rab6 in infected HeLa cells has 
found that Rab6 depletion leads to the specific inhibition of viral glycoprotein transport from 
the TGN to the plasma membrane and that Rab6 positive vesicles are redistributed and 
colocalise with these viral glycoproteins during infection (unpublished data, Elliott Group, 
Imperial College, London).  The previously mentioned role of Rab6 in vesicle migration to the 
plasma membrane would support that this is a function Rab6 could fulfil in HSV-1 infection 
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(94, 95, 159).  This, along with a recent publication from our group has led to the 
development of a model whereby Rab6 is required for the correct trafficking of viral 
glycoproteins from the Golgi to the plasma membrane, where they are re-internalised on 
vesicles which ultimately envelope capsids in the cytoplasm to form mature virions (107).  As 
the role of Rab6 has therefore begun to become clear in HeLa cells, confirmation of this 
same role in nTERTs was achieved by the staining of a viral glycoprotein gD in GFP-Rab6 
expressing infected cells (figure 6.11). This data not only shows that Rab6 is redistributed in 
HSV-1 infection (as was shown for HeLa cells), but also that a population of Rab6 
colocalises with gD, supporting the theory that Rab6 acts to transport these viral 
transmembrane proteins to the cell periphery.  Not all gD and GFP-Rab6 signals colocalised 
and this could be partially because Rab6 is expressed from a plasmid in these cells and is 
therefore likely to be over-expressed.  Also, gD is most likely produced in excess during 
infection, and so only a small population of protein would actually progress to its required site 
for virus maturation.  These data support a role for Rab6 in the exocytosis of viral 
glycoproteins and show that this occurs in keratinocyte cells. 
6.10.6 CONCLUDING REMARKS 
An interest in Rabs as regulators of the secretory system led to the identification of several 
Rab proteins required for the infection of HeLa cells (unpublished data, Elliott Group, Imperial 
College, London: (107)).  It has been extrapolated that if Rabs are needed for infection of 
HeLa cells then they may also be necessary for infection of other cells, and by extension 
keratinocytes.  By optimising and employing a comparable screen of Rab siRNAs in infected 
nTERT cells, this chapter has identified a similar set of Rabs which play a role in HSV-1 
infection of keratinocyte cells.  Our findings that Rab1, 5, 6, 11 and 22 depletion all reduce 
virus titre in nTERT cells are in line with the previous work in HeLa cells (unpublished data, 
Elliott Group, Imperial College, London and (107, 254)), however the effect of Rab10 
depletion on virus yield is a novel finding in the field of virology.  Here we have shown that 
HSV-1 relies on a particular set of host cellular proteins in keratinocyte cells and these data 
lend support to the work carried out in HeLa cells, highlighting the importance of Rab 
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proteins in HSV-1 infection of the skin. 
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7.1 ENHANCED HSV-1 REPLICATION IN KERATINOCYTE CELLS 
This thesis of work has endevoured to characterise more fully, the relationship between 
HSV-1 and its physiologically relevent host cell type, the human keratinocyte.  Historically, 
cell lines such as Vero have been used for HSV-1 study and there has been little attention 
given in the literature to any differences of keratinocytes to these other cell lines that might 
be pertinent to HSV-1 infeciton.  Hukkanen and coworkers noted that HaCaT cells were ten 
times more sensitive to HSV-1 infection than Vero cells, however they did not speculate as to 
the significance of this discrepency (111).  Another group found that HaCaT cells were able 
to produce a similar titre of wild type HSV-1 strain F to Vero cells, however the numbers of 
cells per plaque were five to ten times higher in HaCaT cells than the other cells, indicating 
more efficient spread in the keratinocytes (110).  These are among the few papers in which 
attention has been drawn to discrepencies between findings in keratinocytes and other cell 
lines.  Here we show that there is an important difference in HSV-1 infection of keratinocytes 
compared to Vero cells, and that this indicates the existence of potential infectious processes 
which have previously been overlooked by studying HSV-1 infection in cells other than 
keratinocytes. 
It is unsurprising that we have identified earlier onset of infection and a higher yield of virus 
production in keratinocytes compared to other cells tested (chapter 3), given that these are 
the cells which the virus first infects in the host.  Herpesviruses infect a wide range of 
vertebrates and interspecies transmission is rare, therefore their high degree of species 
specificity suggests that they evolved in close association with their host (152, 153).  This 
could explain how HSV-1 has developed specific mechanisms to infect and replicate 
efficiently in these specialised cells. 
Although HSV-1 entry has been identified as a stage which is enhanced in keratinocyte cells 
(chapter 5) and can at least partially explain the early onset of infection in these cells, it is 
likely that other stages of infection will also prove to be more efficient and contribute to the 
overall higher virus yield seen in infected keratinocytes.  Steps downstream of virus 
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penetration include translocation to the nucleus, viral genome injection and VP16 activity 
leading to immediate early promoter activation.  It is also feasible that even later stages may 
occur more optimally, for example egress of enveloped virions could be more efficient in 
these cells if their cytoskeletal trafficking system is more active or they could produce an 
abundance of membranes suitable for greater numbers of capsid wrapping.  It is also 
possible that the relationship between HSV-1 and the keratinocyte is so well tuned at every 
stage that it is a matter of less waste in these cells compared to others.  For example, 
perhaps a higher proportion of light-particles are produced in error in Vero cells than nTERT 
cells, thereby exhausting viral and cellular resources on non-productive vehicles for infection. 
The two-fold increase in virus titre when titrated onto nTERT cells in comparison with Vero 
cells is most likely responsible for the two-fold increase in virus binding seen in chapter 3 and 
5, however it is unknown why double the number of virus particles are able to plaque on 
nTERT cells.  It may be that the same number of virus particles are able to enter both cell 
types, however that a stage downstream fails to lead to a productive infection in half of those 
in the Vero cells. 
7.2 HSV-1 ENTRY MECHANISM IN nTERT CELLS 
The rapid entry phenotype identified in keratinocytes (chapter 5), whereby almost all bound 
virus had penetrated the nTERT cells by 5 minutes post-warming, was initially surprising 
compared to the much slower rate in Vero cells.  However, rapid entry of virus particles is not 
undocumented, for example membrane fluorescence dequenching studies of HIV entry into 
target cells showed that most of the membranes were mixed within 5 minutes of incubation at 
37°C (212) and in fact a later study suggested that this fusion usually occurred within 1-3 
minutes (93).  This suggests that the virus envelope is able to fuse as rapidly as 5 minutes at 
37°C and supports our findings that HSV-1 can penetrate keratinocyte cells fully after 5 
minutes post-warming.  All the penetrated capsids observed were free in the cytosol (figure 
15), suggesting that they had lost their viral envelope, however we were unable to confirm 
whether this was by fusion with the plasma membrane, or with an endocytic membrane via 
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which the virus particle had just entered.  Nevertheless, no double-enveloped particles were 
identified inside the cells suggesting that PM fusion represents a more likely candidate, or 
alternatively, that virus release from endocytic vesicles is extremely rapid in these cells.  
Direct PM fusion does seem the most probable method for rapid virus entry as it only 
requires a single stage, whereas endocytosis relies on a further fusion stage to release the 
virus from the vesicle, and would presumably take longer to occur.  The ability of HSV-1 to 
rapidly enter its target cell, the keratinocyte, seems logical as it is in the interest of the virus 
to access the cell as quickly as possible to avoid the risk of becoming inactivated outside the 
host. 
Virus penetration at 7°C in the keratinocytes is challenging to explain.  The lower the 
temperature in the cell, the more rigid the membranes and the lower the availability of 
energy.  However, nearly half of the virus was able to penetrate nTERT cells at this low 
temperature after one hour (figure 15).  Such low temperatures would seem to be irrelevant 
to true infectious processes, as virus would not routinely infect skin at 7°C, however the fact 
that HSV-1 enters keratinocytes and not Vero cells at these temperatures could be telling of 
an innate difference in the mechanism of entry used in these cells.   
Entry at lower temperatures in nTERT cells and not in Vero cells could be due to differences 
in the membrane structure or the viral entry receptors used.  Although some viruses are 
known to be able to enter over a limited temperature range, for example Sendai virus (105) 
and Rous sarcoma virus can only enter above 20°C (89), there is evidence to support that 
fusion is able to occur at temperatures as low as 0°C.  In an influenza virus study, membrane 
fusion was shown to occur at 0°C, but in this case it was 40 times slower than at 37°C (221).  
Energy is needed for membrane fusion and the amount of energy required depends on the 
molecular structures involved, for example membranes which are less flexible and harder to 
deform will have a much higher activation energy (187).  Perhaps the membrane of 
keratinocyte cells differs due to its structure, possibly even evidenced by the enrichment of 
membrane protrusions seen in figure 14 which are not usually seen in Vero cells (data not 
shown), and it requires a lower energy for entry.  This could explain why virus is able to enter 
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more rapidly at 37°C in these cells, and also shed some light on the ability of keratinocytes to 
allow more efficient virus entry at lower temperatures than Vero cells.  Alternatively, viral 
entry receptors undergo conformational changes which will be more or less efficient under 
certain conditions, depending on the particular receptor.  For example, influenza virus 
Hemagglutinin undergoes a conformational change when exposed to the low pH within an 
endosome, which is thought to allow fusion between the endosomal and viral membranes 
(214).  Murine Coronavirus also relies on a conformational change in its spike glycoprotein 
(S) for fusion, however in this case the conformation change is temperature dependent (253).  
If the receptors utilised on the surface of the keratinocytes were able to undergo 
conformational changes at lower temperatures than those employed on Vero cells, this could 
also explain virus entry at 7°C in keratinocyte cells. 
If HSV-1 did employ different receptors for entry in keratinocytes, then the already 
characterised virus entry-receptors would not be required for normal entry.  The depletion of 
nectin-1 in nTERT cells is a preliminary indication that nectin-1 is unnecessary for HSV-1 
entry, however this has yet to be confirmed by nectin-1 quantification.  Although nectin-1 
levels have been shown to be ten times higher in HaCaT keratinocytes than HeLa cells, the 
same paper found that antibodies to nectin-1 are unable to fully inhibit entry into HaCaT 
cells, supporting the theory that keratinocytes are not dependent on nectin-1 for entry (110).  
Also in support of this, evidence from the Knebel-Morsdorf group found that nectin-1 
distribution did not correlate to sites of HSV-1 entry in primary keratinocytes (203).  As much 
of the initial work identifying entry receptors used a cDNA library from HeLa cells, it is 
feasible that keratinocyte cells encode a further virus entry receptor, or coreceptor, not found 
in the original screen (164, 242).  This provides an interesting avenue of study, as knowledge 
of the true mechanism of entry in the physiologically relevant cell type will be informative to 
both vaccine development and the study of therapeutic treatments. 
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7.3 RAB PROTEINS ARE REQUIRED FOR OPTIMAL HSV-1 REPLICATION IN 
KERATINOCYTES 
In this study we have carried out a screen of 60 human Rab GTPases in HSV-1 infection and 
identified several targets which significantly reduced virus yield (figure 6.3).  Rab1, 5 and 11 
have already been published to play a role in HSV-1 infection of HeLa cells by our group and 
others (107, 254).  Rab6 has also been characterised in relation to HSV-1 infection of HeLa 
cells by our group and therefore the majority of the Rab GTPases identified in this screen in 
infected keratinocyte cells mirrored the previous results from infected HeLa cells (figure 6.3 
and unpublished data, Elliott Group, Imperial College, London).  This work in keratinocyte 
cells therefore validates the role of these Rab proteins identified in HeLa cells as being 
physiologically relevant to HSV-1 infection.  No evidence was found that any of the Rab 
proteins had an effect on viral gene expression (figure 6.6) or entry (figure 6.8B), indicating 
that their roles lie downstream of viral protein synthesis, most likely in virus assembly or 
egress pathways.  Nevertheless, the many other Rab GTPase depletions carried out in figure 
6.3, which were not validated by western blot analysis or qRT-PCR and could therefore have 
not been efficiently exhausted, could still potentially play a role in entry, viral gene expression 
or later stages of HSV-1 infection.   
Rab GTPases are conserved from yeast to humans, and as such have probably evolved 
alongside HSV-1 infection.  This has doubtless allowed the virus to find means of subverting 
useful cellular pathways by interacting with this family of proteins, and this work has begun to 
characterise these interactions.  There are a limited number of publications on keratinocytes 
and Rab proteins and only one has addressed a role for a Rab GTPase in relation to an 
infectious disease; the Rab5-dependent trafficking of human papillomavirus type 31 (216).  
This thesis of work provides the first characterisation of Rab proteins in HSV-1 infected 
keratinocytes. 
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7.3.1 RAB1 DEPLETION INHIBITS VIRAL GLYCOPROTEIN EXIT AND TRANSPORT 
FROM THE ER 
The fact that suppression of Rab1 expression by siRNA causes a restriction in HSV-1 
replication is only a novel finding in keratinocyte cells and is not surprising given its role in 
ER to Golgi trafficking (107, 254).  Viral glycoproteins must be trafficked from their site of 
production in the ER through the Golgi and on towards the plasma membrane (171).  The 
effect of Rab1 is therefore most likely due to viral glycoproteins becoming stalled in the ER 
due to their reliance on Rab1 to regulate their movement to the Golgi.  One interesting 
finding was the loss of islet-like growth in Rab1 depleted keratinocytes.  This could be a 
result of the loss of cell-cell contacts due to a lack of adhesion molecules reaching the cell 
surface.  Transmembrane proteins such as integrins, claudins and cadherins are required to 
form tight junctions, adherens junctions and desmosomes which facilitate cell adhesion.  
Therefore, if these proteins follow a Rab1-dependent trafficking pathway to the plasma 
membrane, this could explain the growth phenotype in Rab1 depleted keratinocytes.  
Although this was not investigated in this thesis, it could provide further insight into the 
mechanism of cell-cell contact formation in nTERT cells, and suggests a role for Rab1-
dependent processes in such a mechanism.  
7.3.2 A ROLE FOR RAB6 IN TRAFFICKING VIRAL GLYCOPROTEINS FROM THE 
GOLGI TO THE PLASMA MEMBRANE 
The involvement of Rab6 in HSV-1 infection has also been previously characterised by our 
group in HeLa cells (unpublished data, Elliott Group, Imperial College, London).  In HeLa 
cells Rab6 is required to transport viral glycoproteins from the Golgi to the plasma membrane 
(unpublished data, Elliott Group, Imperial College, London) in line with one of its 
characterised regulatory roles in the cell (94, 95, 159).  Here we show that Rab6 depletion 
results in a ten-fold reduction of virus titre in both keratinocyte cell types nTERT and HaCaT 
(figure 6.9D), that it does not disrupt the Golgi complex (figure 6.7) and that crucially Rab6-
GFP re-locates from the Golgi to colocalise with gD positive domains close to the cell 
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periphery during infection (figure 6.11).  Although Rab6 depletion was found to have no effect 
on secretion of gaussia luciferase (figure 6.8A), it may regulate the transport of specific 
groups of proteins to the plasma membrane.  These results are in line with findings in HeLa 
cells and the data presented here supports a similar role for this Rab protein in infected 
keratinocytes.  It is likely that the normal function of Rab6 is therefore being hijacked by the 
virus in order to provide efficient transport of the viral glycoproteins to the cell surface.  The 
mechanism is as yet unknown, however it is likely that a viral protein, or viral proteins, may 
recruit Rab6 or its effectors to sites abundant in viral glycoproteins.  It is also possible that 
HSV-1 could encode a protein able to mimic the function of a Rab6 effector or that the fact 
that Rab6 is found in the envelope of mature virions is not a coincidence but a means of 
delivering more Rab6 into the cell (141) and unpublished data from the Elliott group).  
Effector proteins of Rab6 are numerous, including members of the golgin family and motor 
proteins Rabkinesin6 and myosin IIA (38, 64, 159).  HSV-1 could, therefore, be 
commandeering the motor proteins through an interaction with Rab6, and modulating the 
normal function of these proteins so as to increase the trafficking of viral glycoprotein-rich 
vesicles to the cell surface. 
7.3.3 POTENTIAL ROLES FOR OTHER RAB GTPASES IN HSV-1 REPLICATION 
Although this work has only begun to characterise the role of the other Rabs in nTERT 
infection, roles for Rab5 and Rab11 have already been identified for HSV-1 infection of HeLa 
cells (107).  These Rabs are required for regulating a process of endocytosis responsible for 
retrieving viral glycoproteins from the plasma membrane on endocytic vesicles required for 
final wrapping of capsids in the cytosol (107).  As Rab6 in keratinocytes appeared to 
maintain the same role as in HeLa cells during infection, this would support that Rab5 and 11 
could also play similar roles in keratinocytes, however this would need to be confirmed by 
further study.  Rab22, a Rab known to be of the same subfamily as Rab5, to also associate 
with endosomes and to work with Rab5 in regulating endosomal dynamics through the same 
effector protein Rabex-5 (37, 123, 160, 183, 194, 256), may therefore work in a cooperative 
mechanism with Rab5 during infection.  A simultaneous depletion of Rab22 and Rab5 during 
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infection could perhaps address whether these Rabs are involved in the same pathways 
during infection. 
Rab10, the second most effective target identified by the Rab screen in keratinocytes, is a 
lesser-characterised Rab, however it is known to localise to the TGN and is known to play a 
part in the basolateral recycling of endosomes (15, 44).  A number of studies have identified 
a role for Rab10 in post-Golgi trafficking, including regulating the transport of toll like receptor 
4 to the plasma membrane (241) and in Caenorhabditis.elegans facilitating von Willebrand 
factor secretion (157).  Interestingly, Rab10 was shown to interact with Myosin-Va, which is 
an actin motor protein, and together mediate trafficking of GLUT4 storage vesicles to the 
plasma membrane in mammalian adipocytes (45, 198).  Given these published roles it is 
likely that Rab10 may also be involved in a similar fashion as Rab6 in HSV-1 infection.  
Perhaps Rab10 regulates viral protein transport from the Golgi to the plasma membrane and 
recruits Myosin-Va as a means of movement along the microtubule network.  It would be 
interesting to see if the effect on infection was cooperative if both Rab6 and Rab10 were 
simultaneously depleted.  This does not explain why it should only be identified in the 
keratinocyte siRNA screen and not the HeLa screen.  As Rab10 depletion was not validated 
in HeLa cells it is possible that it does also play a role in these cells or Rab6 may be able to 
functionally compensate in HeLa cells but not keratinocyte cells.  It is also possible that 
Rab10 has an entirely different function in keratinocytes, and further study of this possibility 
could provide new information on not only HSV-1 infection, but also Rab10 itself. 
7.4 FUTURE DIRECTIONS 
7.4.1 FURTHER DEVELOPMENT OF A MODEL FOR HSV-1 nTERT INFECTION 
Virions are known to contain cellular components, and the selection of components are 
thought to be cell type-dependent (141).  As virus stocks for work in this thesis have all been 
prepared in Vero cells, it would therefore be interesting to grow virus in nTERT cells and 
compare the viral and cellular components of the virions grown in both these cellular 
backgrounds.  It is possible that subsequent infection of Vero, or nTERT cells, with the 
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nTERT-derived virus could result in an even more efficient virus infection due to the 
incorporation, or higher levels of a particular component in the nTERT-derived virions.   
Another possibility is that the virus particle to PFU ratio differs in virus produced in nTERT 
cells.  If it were shown that the PFU:particle ratio produced in the nTERT infection were 
higher than from infected Vero cells, this could account for the increased infectious virus 
yield obtained in the HSV-1 infection of keratinocytes. 
Entry has been identified as a stage which is enhanced in nTERT cells compared to Vero 
cells, however, other stages could also be contributing to the early onset of infection and 
higher virus yield produced in infected nTERT cells.  Stages to investigate downstream of 
entry are translocation to the nucleus, injection of viral DNA into the nucleus and activation of 
immediate early gene promoters.  The viral transactivator VP16, would be an interesting 
protein to study in nTERT infection as it interacts with cellular proteins Oct-1 and HCF in 
order to reach the nucleus (41, 188, 244).  It is feasible that this process could be more 
efficient in nTERT cells, either due to higher levels or other factors playing a role to bring 
VP16 more rapidly to the nucleus and therefore provides an interesting area of study for 
future work.  Preliminary ultrastrucutal data from infected nTERT cells indicates that these 
cells are greatly enriched in endocytic vesicles and that wrapping events are highly abundant 
compared to other cells types (data not shown).  Therefore, later events in replication, such 
as virus wrapping and egress from the cells should also be considered for further 
investigation, as multiple elements in the replication cycle may be causing the overall higher 
virus yield in keratinocyte cells 
Although there are two studies of entry in keratinocytes: one that identifies endocytosis, and 
one that identifies both endocytosis and PM fusion as methods of HSV-1 entry (169, 191), 
the data here could not absolutely confirm either method of entry in nTERT cells.  However, 
given the fact that only cytosolic capsids and no enveloped virus particles were identified 
within the cell at 7°C or 37°C, and also endocytic events were inhibited at 7°C, these data 
are overwhelmingly indicative of PM fusion as a route of HSV-1 entry into nTERT cells. 
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While entry of HSV-1 has been shown to be more efficient in keratinocyte cells in this thesis 
of work, the mechanism of this enhancement has not been found.  Preliminary work has 
begun to address the entry receptor used in nTERT cells using nectin-1 siRNA (figure 5.), 
and this provides a first suggestion that nectin-1 may be unnecessary for HSV-1 infection in 
keratinocytes.  Primarily, this data must be confirmed by quantifying the nectin-1 levels in 
nTERTs, as although qRT-PCR was able to quantify nectin-1 mRNA in HeLa cells, efforts to 
date using both western blot, immunofluorescence and in nTERT qRT-PCR, have been 
unsuccessful.  Detection of nectin-1 levels by flow cytometric analysis would be the next 
logical method to attempt, as this has been used successfully in previous publications (2, 3, 
110).  However, if nectin-1 is confirmed to be dispensable for HSV-1 entry of keratinocytes, 
there is further work to be done in this field as nectin-1 is not the only HSV-1 entry receptor 
characterised.  Both HVEM and 3-OS HS would also both need to be characterised using 
this technique for their requirement for HSV-1 entry of keratinocyte cells, both individually 
and together with nectin-1.  If none of these HSV-1 entry receptors were required for HSV-1 
entry, a search for a potentially novel receptor could be undertaken.  The screening of a 
cDNA library for entry of HSV-1 into non-permissive CHO cells originally used to identify 
HVEM could be employed in a similar manner (164).  However, instead of using a HeLa 
derived cDNA library, and therefore potentially missing any keratinocyte specific cDNA, a 
cDNA library derived from keratinocyte cells would be used.  It is also possible that 
keratinocytes may encode a co-receptor which enhances the gD-HSV-1 entry receptor 
interaction, analogous to HIVs reliance on a co-receptor for CD4-gp120 dependent entry 
(reviewed in (91)).  The availability of a virus deficient in gD could also prove useful in 
determining if the interaction between HSV-1 and keratinocytes is gD-dependent, or can be 
compensated for by another glycoprotein-cellular protein interaction. 
Ultimately, it will be important to confirm any working model for HSV-1 infection developed 
during this work in primary keratinocytes and eventually move on to further characterise 
HSV-1 infection in organotypic skin rafts.  This work would aim to further address the initial 
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stage of entry in context of the epidermal skin layers, and also the virus spread within these 
layers. 
7.4.2 FURTHER STUDY ON RAB PROTEINS 
This project has identified a group of Rab GTPases important for efficient virus replication of 
keratinocyte cells and all, with the exception of Rab10, have confirmed their initial 
identification in infected HeLa cells to be valid in HSV-1 infection of the skin.  Study of these 
Rabs is on-going in HeLa cells and has already provided more data on the roles of these 
Rabs in HeLa cells (107), unpublished data, Elliott Group, Imperial College, London).  It 
would therefore be useful to confirm that the model presented for Rab5 and Rab11 (107) 
also conform in keratinocyte cells.  However, this should be done by pursuing only select 
experiments already successfully set up in HeLa cells, as this data will only confirm a model 
already characterised and not provide novel information further than confirming it in a 
physiologically relevant cell type.  Rab10, the only unique Rab to be identified in the 
keratinocyte and not the HeLa screen, therefore provides an exciting Rab GTPase for further 
characterisation.  As Rab10 may be playing a similar role to Rab6 in HSV-1 infection it would 
be worthwhile assessing the localisation of viral proteins during the infection of Rab10 
depleted keratinocytes to see if viral glycoproteins are inhibited in their translocation to the 
cell periphery. 
7.5 CONCLUDING REMARKS 
This thesis has characterised HSV-1 infection in nTERT cells and offers a new keratinocyte 
HSV-1 infection model for future study.  A novel enhancement of virus replication has been 
identified in these cells compared to routinely used cell lines used for HSV-1 study.  Entry of 
HSV-1 into keratinocytes has been revealed to be more efficient as it is both more rapid and 
able to occur at lower temperatures than in Vero cells.  Preliminary work has been set up to 
further address the method of virus entry in human keratinocyte cells.  Importantly this work 
demonstrates the requirement of studying HSV-1 replication in its physiologically relevant cell 
type, namely the human keratinocyte. 
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APPENDIX 
A1.1 VIROLOGY METHODS 
A1.1.1 2X FORMAL SALINE SOLUTION 
Formaldehyde (8% v/v) (Sigma), NaCl (0.291 M) (Sigma-Aldrich). 
A1.1.2 0.1% CRYSTAL VIOLET SOLUTION 
Crystal violet (2.45 mM) (Sigma-Aldrich), ethanol (15% v/v) (VWR). 
A1.1.3 pH 3 CITRATE BUFFER 
Citric acid (40 mM) (Sigma), KCl (10 mM) (Sigma), NaCl (135 mM), adjusted to pH 3. 
A1.1.4 X-GAL DETERGENT SOLUTION 
MgCl2 (2 mM), PBS, sodium deoxycholate (240 mM) (Sigma), Nonidet P40 (NP40) substitute 
(0.01% v/v) (Amresco Inc. OH, USA). 
A1.1.5 X-GAL SOLUTION  
Potassium ferrocyanide (5 mM) (Sigma), Potassium ferricyanide (5 mM) (Sigma), X-gal (5-
bromo-4-chloro-3-indolyl-β-D-galactoside) (1 mg/ml) (Sigma-Aldrich) in X-Gal detergent 
solution. 
A1.2 PROTEIN ANALYSIS 
A1.2.1 2X SDS-PAGE LOADING DYE 
Tris-HCl (100 mM) (pH 7.0), SDS (4% w/v), beta-mercaptoethanol (10% v/v), glycerol (20% 
w/v), bromophenol blue (0.2% w/v) (all reagents Sigma-Aldrich). 
A1.2.2 LYSIS BUFFER 
Tris pH 7.5 (50 mM), NaCl (200 mM), MgCl2  (2 mM), 1% v/v NP40 substitute, 1X Complete® 
Mini Protease Inhibitors (Roche, Penzberg, Germany). 
A1.2.3 POLYACRYLAMIDE RESOLVING GEL 
Acrylamide/bis-acrylamide (37.5:1) (10% / 12% / 15% w/v) (Bio-Rad Laboratories), tris-HCl 
(0.375 M) (pH 8.8) (Bio-Rad Laboratories), SDS (0.1% w/v), N,N,N’,N’-
tetramethylethylenediamine (0.05% v/v) (Sigma-Aldrich), ammonium persulphate (0.1% w/v) 
(Sigma-Aldrich). 
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A1.2.4 SDS-PAGE STACKING GEL 
Acrylamide/bis-acrylamide (37.5:1) (4% w/v), tris-HCl (0.13 M) (pH 6.8) (Bio-Rad 
Laboratories), SDS (0.1% w/v), N,N,N’,N’-tetramethylethylenediamine (0.1% v/v), ammonium 
persulphate (0.1% w/v). 
A1.2.5 SDS-PAGE RUNNING BUFFER 
Glycine (192 mM), tris base (25 mM), SDS (1% w/v) (all reagents Sigma-Aldrich). 
A1.2.6 SDS-PAGE GEL TRANSFER BUFFER 
Glycine (192 mM), tris base (25 mM), methanol (20% v/v) (VWR). 
A1.3 ASSAY REAGENTS 
A1.3.1 GAUSSIA LUCIFERASE SUBSTRATE 
Coelenterazine (LUX Innovate, Edinburgh, UK) stock was dissolved at 1 mg/ml concentration 
in 100% ethanol and stored at -20˚C. Coelenterazine stock was diluted to 1 µg/ml in room 
temperature PBS before use. 
A1.4 GENERAL LABORATORY SOLUTIONS 
A1.4.1 PBS (pH 7.2) 
NaCl (8.77 g/L), Na2HPO4•12H2O (19.2 g/L), NaH2PO4•2H2O (6.55 g/L). (VWR) 
